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1 
EPSTEIN-BARR VIRUS 
 
Epstein-Barr virus (EBV) was first discovered in a Burkitt lymphoma (BL)-derived cell 
line by Michael Epstein, Yvonne Barr and Bert Achong in 1964 by electron microscopy 
(1). EBV or human herpesvirus 4 (HHV4), is a double-stranded DNA virus that belongs 
to the Herpesviridae family and Gammaherpesvirinae subfamily. The latter one includes 
another important human gammaherpesvirus such as human herpesvirus 8 (HHV8) also 
known as Kaposi’s sarcoma-associated herpes virus. These two viruses are 
characterized by establishing latent infection in lymphocytes, restricted host range for 
infection in cell culture, episome persistence in dividing cells and oncogenic 
associations (2).  
 
EPIDEMIOLOGY 
Although herpes viruses are ubiquitous in nature, humans serve as the only natural host 
for EBV. EBV is a ubiquitous γ-herpes virus with tropism for B lymphocytes that 
infects at least 90% of the population worldwide in which establishes a life-long 
asymptomatic infection (3). Two EBV types circulate within the population, EBV-1 and 
EBV-2 (also named types A and B) and are different in geographic distributions and in 
the organization of the genes encoding EBV nuclear antigen (EBNA). EBV-1 is more 
prevalent in most populations and type 1 EBV isolates are more efficient in trans-
forming infected-B cells in vitro than type 2 isolates, although differences in EBV types 
have not correlated with human diseases and both types co-exist in all populations that 
have been studied. EBV-2 is detected frequently in New Guinea, equatorial Africa, and 
Alaska (2,4). Infection is most common among children of 2 and 4 years of age and 
young adults of 15 years of age. Primary infection with EBV in infants and young 
children is usually symptomatic or results in non-specific symptoms. In developing 
countries, infants and young children are infected with EBV and infectious 
mononucleosis (IM) is much less common. For example, in areas of Africa where BL is 
common, 50% of children are infected with EBV before 1 year of age. Whereas, in 
developed countries, about 50% of adolescents and young adults are EBV seronegative, 
and about 25% of these seronegative persons who become infected with EBV develop 
Part I 
_______________ 
2 
 
IM. EBV is usually spread by infected saliva and some observations suggest that the 
virus may be spread by sexual intercourse. In fact, EBV was detected in both male and 
female genital secretions, but the level of EBV in genital secretions is lower than in 
saliva. Finally, EBV can be acquired from blood transfusions or from receipt of 
allogeneic donor stem cells or tissue (5).  
 
VIRUS AND GENOME STRUCTURE 
EBV has a toroid-shaped DNA core in a nucleocapsid with 162 capsomeres, an outer 
envelope with external glycoprotein spikes, and a protein tegument between the 
nucleocapsid and envelope (Figure 1a). Among the viral glycoproteins, gp350, gH, gB, 
gp42, gp220 and gL are those important for binding and subsequent fusion of the virion 
envelope with cellular membranes (2). The EBV genome is a linear, double-stranded 
DNA of approximately 172 kb, encoding approximately 100 viral proteins (4). It 
contains five unique sequence elements (U1 to U5) interspersed with one major internal 
repeat (IR1) and three smaller internal repeats (IR2 to IR4). The major internal repeat 
element contains six to twelve tandem repeats of 3 kb, depending on the virus strain. 
There are three replication origins: two of these (Ori-lyt, lytic origin of replication) are 
used during productive infection and one (Ori-P, origin of plasmid replication) is used 
during latent infection. At both termini of the linear genome, there are variable numbers 
of 0.5-kb tandem repeats; EBV DNA circularizes upon entering the cell via a terminal 
repeats (TR) sequence (6). The Figure 1b depicts the linear EBV genome. 
 
 
 
 
 
 
 
 
 
 Figure 1: Schematic depiction
arrangement with the unique short (US) and unique long (UL) regions shown
from Fields. Virology. 6
 
   a)                                                                           
 
 
 
EBV  LIFE CYCLE
Almost all EBV
an EBV-naïve 
entry point for EBV via the immunoglobulin (Ig) A
the epithelium, and active viral replication 
spreads out from the infected cell
enveloping of gp350 to the B 
virus requires i
and human leukocyte antigen
Indirectly, the infected epithel
infected B cells in the lymphoid tissues and blood undergo lytic infection or 
cell blasts, which
(NK) cells and cytotoxic T 
viral proteins unless they divide; if 
3
s of the: a) 
th Edition) 
 
-seropositive hosts shed virus in the saliva, a
person is exposed to EBV-rich saliva
s and directly infects nearby B 
lymphocyte surface molecule CD21. Penetration of the 
nteraction between viral gp42, 
 - antigen D Related
ium can transmit the virus to B 
 are controlled in immunocompetent individuals 
cells. Latently infected resting memory B cells express no 
they reactivate, they are controlled by cytotoxic T 
_______________
 
EBV virion and b) overall EBV genome
b)    
 
nd infection occurs when 
. Oropharyngeal epithelium is an 
-EBV complex to IgA receptors on 
- lytic infection - occurs there. The virus 
lymphocytes via vira
which makes a complex with gH and gL
 (HLA-DR) on B lymphocytes. 
lymphocytes 
by N
Part I 
 
 
. (Adapted 
l 
, 
(7). EBV-
become B 
atural Killer 
 cells. Some latently infected cells traffic to the orop
replication and release 
 
Figure 2: Representation of EBV life cycle. 
 
 
 
 
LATENT EBV INFECTION
Only a handful of genes are expressed during latent 
(EBNA-1, -2, 
(LMP-1, -2A and 
polymerase III 
DNA and maintain its episomal 
responsible for transcriptional activation of viral LMP genes and a
4
the virus (Figure 2) (2)
 
-3A, -3B, -3C and -LP leader protein
-2B) and two small, untranslated RNAs that are transcribed by RNA 
(EBV encoded small RNA (EBER)
form (7
_______________
 
harynx where they undergo lytic 
. 
(From Fields. Virology. 6th Edition)
infection: six EBV nuclear antig
), three latent membrane proteins 
-1 and -2). EBNA-1 bind
). EBNA-2 and EBNA-LP together are 
 number of cellular 
Part I 
 
  
 
ens 
s to viral 
Part I 
_______________ 
5 
 
genes. One of the major target cellular genes activated is c-myc, which in turn activates 
many other cellular genes and can lead to unchecked cellular growth and division. Three 
different isoforms exist in EBNA-3, and they inhibit EBNA-2-mediated upregulation of 
LMP-1 (7). LMP1 acts like a constitutively activated cellular receptor (i.e. CD40). 
Signaling by CD40 triggers a cascade of events leading to the activation of the 
important cellular transcription factor, such as nuclear factor kappa B (NF-kB). This is 
one of the steps that leads to B lymphocyte proliferation during an immune response. 
LMP-2A also acts like a constitutively activated cellular receptor, the B cell receptor 
(BCR), which when paired with LMP-1 can drive resting B lymphocytes to proliferate 
and differentiate into memory B cells. LMP-2A binds to the cellular tyrosine kinases 
Lyn and Syk, as does an activated BCR. These kinases are activated when the BCR 
binds to an antigen, leading to a cascade of events that eventually generates plasma 
cells. LMP-2A has been shown to block signaling through the BCR, perhaps by 
sequestering Lyn and Syk and therefore preventing their activation; one result is 
blockage of the activation of EBV virus lytic replication. LMP-2A also shows an anti-
apopototic activity (6). Several studies have suggested that LMP-2B can enhance LMP-
1 signaling and negatively regulate the function of LMP-2A (2). EBERs may also 
provide a survival function during latent infection by acting on cellular proteins 
involved in protein synthesis (e.g. ribosomal protein L22), thereby enhancing cell 
growth and division. Furthermore, a number of microRNAs (miRNAs) are expressed 
during EBV latent infection; EBV was the first virus in which miRNA was found. Two 
independent ebv-miRNAs are known: the ebv-miR-BHRF1 and the EBV-miR-BART 
families. Viral miRNAs can maintain viral latency, evade host immune response and 
inhibit lytic cycle reactivation (7). On the basis of the latent gene expression, four 
different latency patterns are recognized. In type 0 latency, only EBERs are expressed. 
In type I latency, EBERs and EBNA-1 are expressed. In type II latency, LMP-1, LMP-
2A and LMP-2B are additionally expressed. In type III latency, all latent genes are 
expressed (2). EBV infected naïve B cells in the lymphoid tissue of Waldeyer’s ring in 
the oropharynx express the full spectrum of latent gene product (latency III, growth 
program). EBV activates B cells to become proliferating blasts through by the growth 
program. The naïve infected B cells enter the germinal center (GC) where they 
proliferate and undergo clonal expansion. The germinal center infected cells exhibit 
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type II latency (default program). Through the process of the germinal center reaction, 
these infected GC cells differentiate into memory B cells and enter the peripheral 
circulation. The EBV-infected memory B cells in periphery expressing only EBERs 
(latency 0, latency program), thus they are rarely detected by the immune system. 
However, some of them that express EBNA-1 protein (latency I, latency program) 
occasionally divide to maintain the long-term reservoir of EBV, which is referred to 
type III latency (Figure 3) (4). 
 
Figure 3:  EBV latent life cycle (Adapted from Fields. Virology. 6th Edition) 
  
 
 
LYTIC  EBV  INFECTION 
In the viral lytic cycle, all the EBV lytic genes (> 80 genes) are expressed coordinately, 
resulting in amplification of its genome by > 100-fold. Execution of this dynamic cycle 
produces progeny virus particles, and the cells stop growing and are eventually 
eliminated by immunity (8). In most asymptomatic carriers of EBV, the virus is 
periodically replicated and infectious virions can be recovered in oral secretions. 
Activation of the lytic program appears to occur in latently infected memory B cells 
recirculating through the lymphoid tissue associated with the oropharyngeal mucosa (9). 
All herpesviruses encode replication proteins that specifically interact with their origins 
of lytic DNA replication to provide key functions, including polymerases, helicases, 
primases, DNA-binding proteins, and associated factors as well as enzymatic activities 
involved in nucleotide synthesis and phosphorylation (10). Six EBV genes encoding 
essential lytic functions have been identified: BALF5, BALF2, BMRF1, BBLF4, 
BSLF1 and BBLF2/3 (11,12). These EBV genes are under the control of two viral 
 transactivators, BZLF1 and BRLF1, which thus orchestrate transcriptionally the 
expression of EBV’s replication machinery
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2 
IMMUNE RESPONSE TO EBV INFECTION 
 
HUMORAL IMMUNE RESPONSE: ANTIBODY RESPONSE 
Acute EBV infection induces polyclonal B cell activation with elevated levels of IgG, 
IgM, and IgA. Heterophile antibodies are produced, which are not EBV specific. One 
type of heterophile antibody, used for diagnosis of acute infection, measures the dilution 
of serum that agglutinates sheep, horse, or cow erythrocytes after absorption with 
guinea pig kidney. Heterophile antibodies persist for up to 1 year after IM and are often 
absent in children younger than 5 years old or in the elderly (2). In addition to 
heterophile antibody, IgM and IgG antibodies to the viral capsid antigen (VCA) are 
usually present at the onset of symptoms of IM. Later in infection, antibody to EBNA is 
detected and IgM antibody to VCA disappears (Figure 5). IgG antibody to VCA and 
EBNA persists for life (2). Antibodies to EBV early antigens (EAs) are classified as 
either diffuse (EA-D, diffusely in the nucleus and cytoplasm, methanol resistant) or 
restricted (EA-R, restricted to the cytoplasm, methanol sensitive). EA-D antibodies are 
often present 3 to 4 weeks after the onset of IM, especially in patients with severe 
illness, and are frequently detected in patients with nasopharyngeal carcinoma (NPC) or 
chronic active EBV (CAEBV). EA-R antibodies are often detected in CAEBV or 
African BL. IgA antibody to EBV is often elevated in patients with NPC, and IgA 
antibody to EBV EAS is present in patients with IM (2). 
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Figure 5: Pattern of antibodies to EBV during acute infection. (From Fields. Virology. 6th 
Edition). 
 
 
 
 
 
INNATE CELLULAR IMMUNE RESPONSES: NATURAL KILLER CELLS  
While T cells are thought to constitute the principal effector component of the immune 
response to EBV, there is mounting evidence that NK cells also play a role (13). 
Elevated NK cell numbers are associated with lower viral loads in individuals with IM 
(14). Studies in immunodeficient mice reconstituted with human cells indicate that NK 
cells are particularly important in controlling lytic EBV infection (15). A recent study 
suggests that a distinct and stable Interferon (IFN)-γhigh NK cell subpopulation found in 
tonsils of EBV carriers are critical in restricting transformation of B cells (16). NK cells 
also appear to have a role in controlling chronic viral infection. Individuals with 
XMEN, a primary immunodeficiency associated with defects in NK cell function, 
exhibit high levels of EBV and are at increased risk for EBV-related 
lymphoproliferative disorders and life-threatening IM. Control of chronic EBV 
infection in these patients has been linked to the NK cell receptor, NKG2D (17) Other 
rare immunodeficiencies that are NK cell specific have been associated with the 
development of EBV-related malignancies and life-threatening IM (18, 19). 
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ADAPTIVE CELLULAR IMMUNE RESPONSES: CD8+ AND CD4+ T CELLS 
Although information on the T cell responses to EBV in health and disease is available, 
CD4+ T cell responses to EBV proteins have been less well studied than CD8+ T cell 
responses, in particular in IM (2, 13). Initially, CD8+ T cells are directed predominantly 
against EBV lytic antigens; later in infection cytotoxic T cells (CTLs) are directed to 
latent antigens. The level of CTLs to EBV immediate-early (IE) antigens (BZLF1, 
BRLF1) declines rapidly after infection, while the level of CTLs to latency proteins 
declines much more slowly (Figure 6a). Of the lytic antigens, CD8+ T cells recognize 
IE proteins (BZLF1, BRLF1) more often than early (E) proteins (BMRF1 and BMLF1), 
and late (L) proteins least frequently (2). Among the latent proteins, EBNA3A,-3B, -3C, 
and LMP2-A are the predominant proteins recognized by host CD8+ T cells, although 
EBNA-1 and LMP-1-specific T cells have also been identified  (Figure 6b) (13). 
Tetramer studies of peripheral blood mononuclear cells (PBMCs) from healthy, 
seropositive individuals revealed that CD8+ T cells specific for individual 
immunodominant epitopes of lytic or latent cycle proteins can constitute as much as 2% 
of the CD8+ T cell subset indicating a significant proportion of the T cell repertoire is 
devoted to maintaining control of EBV (20). Further, analysis of PBMCs from IM 
patients revealed that a massive expansion (upwards of 50%) of EBV-specific T cells 
occurs, with T cells reactive to lytic cycle proteins more abundant than T cells reactive 
to latent cycle proteins (21). Major histocompatibility complex (MHC) class II 
tetramers have also been utilized to visualize the CD4+ T cell response to EBV in IM 
and healthy blood donors. These studies indicate that both lytic and latent proteins are 
targeted by CD4+ T cells, and while relatively high frequencies of CD4+ T cells can be 
detected during IM, the overall magnitude of the response is diminished compared to 
CD8+ T cells (22) (Figure 6a).   
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Figure 6: a) Levels of EBV in the throat and blood and cellular immunity during the 
course of infection; b) T cell responses to EBV immediate early (IE), early (E), late (L) 
and latent proteins. (From Fields. Virology. 6th Edition). 
 
a) 
  
                                      IM: infectious mononucleosis 
b) 
 
Dotted arrows indicate that CD4+ T cell responses have been observed to these proteins but that their relative 
immunodominance is not yet determined; n.t: not tested. 
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IMMUNE EVASION STRATEGIES 
Like other herpes viruses, EBV utilizes a multitude of strategies to evade detection and 
elimination by the host immune system. Immune evasion strategies of EBV have been 
recently reviewed and can be broadly classified into three categories, those that 
modulate: 1) immune cell function, 2) antigen presentation pathways or 3) apoptotic 
pathways (13). Regarding the modulation of immune cell function, it is recalled the late 
lytic cycle protein BCRF1, also termed viral IL-10, that can suppress the production of 
IFN-γ, IL-2 and IL-6 by anti-viral CD4+ T cells (13). A variety of EBV proteins target 
the processing and presentation of viral antigens thereby promoting immune evasion, 
e.g.  EBNA-1 contains a glycine-alanine repeat that inhibits processing and presentation 
by HLA class I (13). Furthermore, EBV has evolved several tactics to prevent apoptosis 
of the infected cell in order to augment viral persistence. A functional bcl-2 homolog 
encoded by the early lytic cycle protein BHRF1 can inhibit apoptosis induced by a 
range of stimuli at least in part by binding to the pro-apoptotic protein Bim (13).  
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3 
HEMATOPOIETIC STEM CELL TRANSPLANTATION 
 
The term hematopoietic stem cell transplantation (HSCT) includes a series of 
procedures in which the patient is treated with either chemotherapy or radiation therapy  
or both (referred to as the "preparative/conditioning regimen") followed by the infusion 
of hematopoietic stem cells (HSCs). HSCT can be broadly divided into subtypes based 
on the donor and the source of HSCs (23). The hematopoietic stem cell donor may be 
autologous, syngeneic and allogeneic. Specifically: 
• In autologous HSCT (auto-HSCT), the HSCs are collected from the patient prior to 
the administration of high-dose chemotherapy designed to target an underlying 
malignancy. The reinfusion of the patient's HSCs rescues the patient from long-lasting, 
usually irreversible, profound pancytopenia. Auto-HSCT is usually not associated with 
graft-versus-host disease (GvHD). Specifically, an incidence of GvHD post-high dose 
chemotherapy followed by autologous transplant equal to 4-13% has been recently 
estimated (24). 
• In syngeneic HSCT the  HSCs are collected from an identical twin (HLA-identical). 
These patients do not require post-transplant immunosuppression and do not develop 
GvHD. 
• In allogeneic HSCT (allo-HSCT) the HSCs are collected from a related (which can 
be HLA-identical, -haploidentical or -mismatched) or an unrelated donor (volunteer or 
umbilical cord donor) (23). These grafts may be associated with GvHD as well as a 
potentially beneficial graft-versus-tumor/leukemia (GVL) effect. The period of 
pancytopenia immediately following HSCT is longer than for autologous HSCT, and 
immunosuppressive agents are commonly used for prophylaxis against and treatment of 
GvHD. The combination of these two factors results in a higher rate of complications 
than after auto- or syngeneic HSCT, especially infectious complications (23).  
Regarding the source of the HSCs, it may be: peripheral blood (PB), umbilical cord 
blood (UCB) and bone marrow (BM). PB stem cells can be collected using 
hematopoietic growth factors, while BM stem cells are harvested directly from the 
pelvic bones (23). 
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Since the first HSCTs were performed more than 50 years ago, this modality has 
become a well-established therapeutic option for many hematologic malignancies as 
well as for BM failure and inborn errors of metabolism. The hematologic malignancies 
commonly treated with HSCT include acute lymphoblastic leukemia (ALL), acute 
myeloid leukemia (AML), myelodysplasia, myeloproliferative disorders, chronic 
lymphocytic leukemia, chronic myeloid leukemia (CML), multiple myeloma, Hodgkin 
lymphoma (HL) and non-Hodgkin lymphoma (NHL) (25). The nonmalignant disorders 
include hemoglobinopathies (e.g. sickle cell disease and thalassemia); immune 
deficiencies (e.g. severe combined immunodeficiency and Wiskott Aldrich syndrome); 
bone marrow failure syndrome (e.g. aplastic anemia, paroxysmal nocturnal 
hemoglobulinuria, fanconi anemia); neutrophil disorders (e.g. chronic granulomatous 
disease); histiocytic disorders (e.g. hemophagocytic lymphohistiocytosis) and lysosomal 
storage diseases (25).  
 
AUTOLOGOUS TRANSPLANTATION 
Auto-HSCT in which the recipient’s own HSCs are collected then reinfused after high-
dose chemotherapy is used to produce hemopoietic reconstitution after high-dose 
chemotherapy. This approach allows dose intensification in settings where there is a 
correlation between dose and tumor response rate and hematopoietic toxicity is a 
limiting factor for dose intensification. HSCs are harvested and cryopreserved and then 
reinfused after doses of chemotherapy and radiotherapy that would otherwise be lethal 
or require a prolonged period of recovery (25). Currently, the most common indications 
for transplant are myeloma, NHL and HL. It has been shown, in randomized trials or 
concluded in evidence-based reviews that dose intensification and hemopoietic rescue 
result in improved long-term disease-free survival (25). However, data from the Center 
for International Bone Marrow Transplant Research show that the major cause of failure 
after auto-HSCT is relapse of the primary disease; 69% of cases in transplants carried 
out in 2011-2012 (26).  
Figure 7 shows the number of auto-HSCT performed in Italy in the period of 1991 to 
December 2014. 
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Figure 7: Number of auto-HSCT carried out in Italy; period of 1991 - December 2014. 
(From GITMO, Italian Group of Bone Marrow Transplantation).  
 
 
ALLOGENEIC TRANSPLANTATION 
Allo-HSCT uses HSCs collected from someone other than the individual with the 
disorder. Allo-HSCT is increasingly used to treat a variety of hematologic neoplasms, 
nonmalignant marrow disorders (acquired and inherited), and inborn errors of 
metabolism. Eligibility for allo-HSCT varies across countries and institutions and 
decisions regarding transplant eligibility should be made on a case-by-case basis based 
on a risk-benefit assessment,  the needs and wishes of the patient (23). The selection of 
a donor is a critical element contributing to the success of  a transplant and the major 
criteria for choosing an allogeneic donor is the degree of histocompatibility between the 
donor and recipient because the risks of both graft rejection and of GvHD increase with 
the degree of genetic disparity. The most important determinant of alloreactivity is 
matching at loci in the MHC which includes HLA, encoded by class I (HLA-A, HLA-B, 
and HLA-C) and class II (HLA-DR, HLA-DQ, and HLA-DP) genes (25). Other 
determinants include minor histocompatibility antigens, which are peptides derived 
from polymorphic proteins that differ between donor and recipient due to single-
nucleotide polymorphism (27). NK cells may also contribute to alloreactivity, 
particularly in the setting of haploidentical transplantation. There is also increasing 
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evidence that genetic loci outside of the MHC may influence the risk of transplant 
complications such as infection or regimen-related mortality and several groups are 
defining genetic variants that might predict these complications (25). The choice of 
donor for an allo-HSCT depends on several factors including donor choices, the 
urgency of the transplant and the patient’s disease status. The optimal donor is a 
matched sibling sharing HLA class I and HLA class II alleles, but because each child 
inherits one set of paternal and one set of maternal HLA antigens, the likelihood of any 
sibling matching is only 25% (25). When such a donor is not available, a matched 
unrelated donor (MUD) may be sought. Despite the rapid expansion of donor registries 
over the past twenty years, availability of MUDs is limited, especially for patients with 
uncommon HLA genotypes (28). A study evaluated the impact of race and ethnicity on 
the likelihood of finding an HLA-matched or minimally mismatched donor in the U.S. 
registry: whites of European descent are the most likely to find an optimal donor (75-
97%), whereas blacks from Central or South America are the least likely (16-66%) (29). 
If an appropriate unrelated donor cannot be found, alternative donors including HLA-
mismatched unrelated donors, UCB and related haploidentical donors may be 
considered (28). Due to the immaturity of the neonatal immune system, a greater degree 
of HLA mismatching can be allowed for UCBSCs transplantation without excessive 
GvHD risk. However, the limited number of stem cells present in a UCB unit is a major 
drawback which is associated with decreased engraftment and delayed immune 
reconstitution, especially in adult patients, thus limiting the success of UCBSCs 
transplantation (28). A haploidentical donor can be the patient’s parents, siblings, 
children or other relatives and is matched for half of the MHC alleles of the recipient 
(one HLA haplotype). Since half of the alleles are mismatched, specific patient 
treatment and processing of the HSC graft are required in order to avoid severe 
immunological consequences. In fact, HLA disparities are associated with increased 
GvHD, graft rejection and poor immune reconstitution (28). It was observed that among 
patients undergoing unrelated donor BMSC or mobilized PBSC transplant, there is a 
progressive decrease in post-HSCT survival with each HLA allele mismatch. In 
particular, each HLA mismatch may reduce the probability of overall survival at five 
years by approximately 10% (30).  
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The initial results of transplantation from unrelated donors were inferior to those seen 
after matched sibling transplantation because of increased incidences of graft rejection 
and of GvHD caused by the greater genetic disparity (25). Over the past decade, 
however, results have gradually improved in both single-center and multicenter registry 
studies, reflecting better donor-recipient matching and advances in GvHD prophylaxis 
and supportive care. However, one remaining limitation is the time required to identify 
and screen an unrelated donor, which is approximately equal to 3-6 months. Instead, 
cord units can be obtained within 1 week of identifying a suitable matched unit. 
Haploidentical family donors have the greatest genetic disparity but are usually also 
rapidly available (25).  
Figure 8 shows the number of allo-HSCT performed in Italy in the period 1991 to 
December 2014. 
 
Figure 8: Number of allo-HSCT performed in Italy; period 1991 - December 2014. 
(From GITMO, Italian Group of Bone Marrow Transplantation). 
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CONDITIONING / PREPARATIVE REGIMENS 
The conditioning regimen has different roles in autologous and allogeneic transplant 
(25). Patients undergoing an allo-HSCT are prepared with either chemotherapy alone or 
chemotherapy combined with radiotherapy. The aims are to reduce the tumor burden 
(when the disease is neoplastic) and suppress the recipient’s immune system in order to 
allow engraftment of stem cells. Exceptions to this rule are infants with combined 
immune deficiency and patients with severe aplastic anemia (SAA) with an identical 
twin donor, who may be grafted without conditioning (31). In autologous transplant, the 
aim of the conditioning regimen is to intensify doses of chemotherapy agents that would 
be limited by hematopoietic toxicity (25). Conditioning regimens can be defined in 
three categories: 1) myeloablative (MA) regimens; 2) nonmyeloablative (NMA) 
regimens and 3) reduced intensity conditioning (RIC) regimens. Assignment to these 
categories is based on the duration of cytopenia and on the requirement for stem cell 
support (31). Specifically: 
• The term MA refers to the administration of total body irradiation (TBI) and/or 
alkylating agents, at doses which will not allow autologous hematologic recovery. A 
MA regimen consists of a combination of agents expected to produce profound 
pancytopenia and myeloablation within 1-3 weeks from administration; pancytopenia is 
long lasting, usually irreversible and in most instances fatal, unless hematopoiesis is 
restored by hemopoietic stem cell infusion. Examples of MA include TBI ≥ 5 Gy in a 
single dose or ≥ 8 Gy fractionated or busulfan > 8 mg/kg orally.  
• A NMA regimen causes minimal cytopenia and does not require stem cell support. 
Examples of NMA include fludarabine plus cyclophosphamide with or without 
antithymocyte immunoglobulin (ATG) or TBI  ≤ 2 Gy with or without a purine analog.  
• RIC regimens are an intermediate category of regimens that do not fit the definition 
of MA or NMA regimens. RIC regimens differ from NMA since they cause cytopenia, 
which may be prolonged, and require stem cell support. It is possible that autologous 
recovery would eventually occur, although pancytopenia may be prolonged to such a 
degree that is causes significant morbidity and mortality. RIC regimens differ from MA 
conditioning because the dose of alkylating agents or TBI is reduced by at least 30%. 
Most often these regimens combine fludarabine with an alkylating agent, melphalan, 
busulfan, in reduced doses, or fludarabine with reduced dose TBI (31).  
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There is no standard choice of preparative regimen for HSCT and clinical practice 
varies across countries and institutions. Usually, a decision regarding preparative 
regimen is based upon clinical judgement, taking into account details regarding the 
recipient comorbidities, underlying condition and disease status, donor and graft source 
(32). All of the preparative regimens have short and long term side effects in addition to 
myelotoxicity. Common toxicities include mucositis, nausea and vomiting, alopecia, 
diarrhea, rash, peripheral neuropathy, infertility, interstitial lung disease and sinusoidal 
obstructive syndrome. Long-term complications following TBI also include 
asymptomatic alterations in pulmonary function, cataracts, an autoimmune disease 
(sicca or Sjogren syndrome) and thyroid dysfunction (32). 
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4 
EBV INFECTION AFTER HEMATOPOIETIC STEM CELL 
TRANSPLANTATION 
 
Patients who receive transplant are at risk of a number of short- and long- term 
complications and require long-term follow up (25). Recipients of both allogeneic and 
autologous transplant have risks of infection during the period of hematopoietic and 
immune reconstitution as well as early- and long- term complications from toxicities 
due to the conditioning regimen (e.g. myelodysplasia/secondary leukemia, secondary 
solid tumors, cardiac and pulmonary toxicity) (23,25). Allograft recipients are also at 
risk of graft failure and acute and chronic GvHD (occurring < 100 and > 100 days after 
transplant, respectively) because of the genetic disparity between donor and recipient.  
 
Infections cause up to 7% and to 17% of deaths after auto- and allo-HSCT (26). An 
international group of experts in infectious diseases, HSCT and Public Health worked 
together to compile guidelines for preventing infectious complications among HSCT 
recipients; the document summarizes the current available data in the field (32). The 
risk of infection, particularly of opportunistic infection, is largely determined by three 
factors: 1) the patient's net state of immunosuppression (type, degree and duration); 2) 
the patient’s epidemiologic exposures; and 3) the presence of tissue and/or organ 
damage (e.g. mucositis, renal failure, lung damage) and/or consequences of the invasive 
procedures to which the patient is subjected to (33). The type of infections tend to occur 
at relatively specific times during the post-transplant period and can be divided in three 
periods, based upon the amount of time elapsed from transplant (Figure 9). Specifically: 
1) pre-engraftment phase (I): < 15-45 days after HSCT; 2) early post-engraftment phase 
(II): 30-100 days after HSCT and 3) late post-engraftment phase (III): > 100 days after 
HSCT (34).  
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Figure 9: Timeline and risk factors of opportunistic infection in allo-HSCT recipients. 
(from Tomblyn M et al. Biol Blood Marrow Transplant 2009;15:1143-1238).  
 
EBV: Epstein-Barr virus; HHV6: human herpesvirus 6; PTLD: post-transplant lymphoproliferative disorders. 
  
During phase I, prolonged neutropenia and breaks in the mucocutaneous barrier result in 
substantial risk for bacteremia and fungal infections involving Candida spp and, as 
neutropenia continues, Aspergillus spp. Additionally, herpes simplex virus reactivation 
occurs during this phase. During phase II, infections relate primarily to impaired cell-
mediated immunity. The scope and impact of this defect is determined by the extent of 
GvHD and immunosuppressive therapy for it. Herpesviruses are common infectious 
agents during this period. Other dominant pathogens during this phase include 
Pneumocystis jiroveci and Aspergillus spp. During phase III, persons with chronic 
GvHD and recipients of alternative donor allogeneic transplants remain most at risk for 
infection. Common pathogens include CMV, varicella-zoster virus and infections with 
encapsulated bacteria (e.g. Streptococcus pneumoniae). The relative risk for these 
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infections is approximately proportional to the severity of the patient’s GvHD during 
phases II and III. For recipients of NMA grafts, substantial differences may be observed 
during phase I, but the susceptibility to infections during phases II and III are largely 
similar and driven primarily by the status of the underlying disease, a history of GvHD 
and/or the need for ongoing immunosuppression. The risk of disease from community-
acquired respiratory viruses is elevated during all 3 phases (34).  
Therefore, the risk of infection is primarily determined by the time from transplant and 
the presence or absence of GvHD. Other factors include donor/host histocompatibility, 
disease status, graft type, graft contents, conditioning intensity, and neutrophil 
engraftment. The factors affecting risk of infection are reported in Table 1 (34). 
 
Table 1: Factors affecting risk of infection following HSCT (Adapted from Tomblyn M 
et al. Biol Blood Marrow Transplant 2009;15:1143-1238). 
 
FACTOR RISK OF INFECTION 
 
Type of transplant 
Higher risk with allogeneic, lower risk with autologous or syngeneic 
depending on graft manipulation and clinical setting, including previous 
therapies 
Time from transplant Lower risk with more time elapsed from transplant 
Pre-transplant 
factors 
Higher risk with extensive pre-transplant immunosuppressive, prolonged 
pre-transplant neutropenia or pre-transplant infection 
GvHD Higher risk with grade III-IV acute GvHD or extensive chronic GvHD 
HLA match Higher risk with HLA-mismatched donors, particularly with 
haploidentical donors 
Underline disease 
status 
Higher risk with more advanced disease at the time of transplant 
Donor type Higher risk with unrelated donor than with a fully matching sibling donor 
 
Graft type 
Highest risk with cord blood, intermediate risk with bone marrow and 
lowest risk with mobilized peripheral blood cells.  
Higher risk with T cell-depleted grafts (depending upon method used) 
Immunosuppression 
after transplant 
Higher with immunosuppressive drugs, in particular with corticosteroids, 
antithymocyte globulin, alemtuzumab 
Conditioning  
intensity 
Lower risk in the first 1-3 months post-transplant with low-dose 
chemo/radiotherapy 
Neutrophil 
engraftment 
Higher risk with delayed engraftment/nonengraftment 
GvHD: graft-versus-host-disease; HLA: human leukocyte antigen. 
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As one can observe in Figure 9, the EBV infection occurs commonly from early post-
engraftment period onwards. Although fever and mononucleosis can occur in primary 
EBV infection, the most significant clinical syndrome associated with EBV replication 
in HSCT recipients is post-transplant lymphoproliferative disorders (PTLD) (34). Since 
its discovery as the first human tumor virus, EBV has been implicated in the 
development of a wide range of B-cell lymphoproliferative disorders (35). Specifically, 
the EBV-associated lymphoproliferative disorders include benign, gray and malignant 
disorders. In particular, IM lymphadenitis and EBV-positive mucocutaneous ulcer are 
included in the benign disorders; while CAEBV disease B-cell type and HHV8- and 
EBV-associated germinotropic lymphoproliferative disorder in the gray ones. Finally, 
diffuse large B-cell lymphoma of the elderly, diffuse large B-cell lymphoma associated 
with chronic inflammation, plasmablastic lymphoma, primary effusion lymphoma, 
lymphomatoid granulomatosis, BL, classical HL and PTLD are included in the 
malignant disorders (7). Furthermore, EBV has been associated with other human 
cancers including NPC, gastric carcinoma and T-cell lymphoproliferative disorders such 
as peripheral T-cell lymphomas, angioimmunoblastic T-cell lymphoma, extranodal 
nasal type NK/T-cell lymphoma and other rare histotypes (2,35).  
In Table 2, particular EBV-driven lymphoproliferative disorders with specific latency 
patterns are showed (7). 
 
Table 2: Patterns of EBV latent gene expression in EBV-driven lymphoproliferative 
disorders. (from Ok CY et al. Experimental & Molecular Medicine 2015;47, e132).  
 
Latency Gene products Disease 
I EBER, EBNA-1 BL, PBL, PEL 
II EBER, EBNA-1,  
LMP-1, LMP-2A, LMP-2B 
CHL, EBV+ DLBCL of the elderly,  
PBL (subset), PTLD (subset) 
III EBER, EBNA-1,  
LMP-1, LMP-2A, LMP-2B, 
EBNA-2, EBNA-3A, -3B, -3C 
IM, DLBCL with CI, LyG, PTLD,  EBV+ DLBCL 
of the elderly (subset) 
 
EBER: Epstein-Barr virus encoded small RNA; EBNA: Epstein-Barr virus nuclear antigen; LMP: latent 
membrane protein; BL: Burkitt lymphoma; PBL: plasmablastic lymphoma; PEL: primary effusion 
lymphoma; CHL: classical Hodgkin lymphoma; DLBCL: diffuse large B-cell lymphoma; LyG, 
lymphomatoid granulomatosis; PTLD: post-transplant lymphoproliferative disorder; IM: infectious 
mononucleosis; DLBCL with CI: diffuse large B-cell lymphoma associated with chronic inflammation. 
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5 
EBV-RELATED PTLD 
 
PTLD is increasingly recognized as an important cause of morbidity and mortality in 
both solid organ transplant and HSCT recipients. In solid organ transplant patients, the 
cells giving rise to PTLD are usually of recipient origin, suggesting a role of 
endogenous EBV reactivation in these patients. Conversely, in allo-HSCT, PTLD is 
donor-derived as a consequence of the complete eradication of the host lymphoid 
system by conditioning regimens (36). A revised classification was published in 2008 
by the World Health Organization (WHO) and uses morphologic, immunophenotypic, 
genetic, and clinical features to define four main categories of PTLD such as early 
lesions, polymorphic, monomorphic and CHL-type PTLD (37). All types are associated 
with EBV (38). Fever, generalized lymphadenopathy, respiratory compromise and 
rising liver transaminase levels are typical and have usually been associated with a 
rapidly progressive multi-organ failure and death. Lesions are nodal and extra-nodal, 
frequently involving Waldeyer’s ring, the gastrointestinal tract, the liver, and the central 
nervous system. PTLD that arise later after transplantation (>1 year, late EBV-PTLD) 
are more commonly localized and often have an indolent course. On the contrary, 
patients with EBV infection usually asymptomatic initially (39). Risk factors for 
development of PTLD include type of donor, T-cell depletion, use of ATG, 
splenectomy and EBV serology mismatch between donor and recipient (40). In a recent 
large, multi-center and retrospective analysis, the overall EBV-related PTLD frequency 
observed was of 3.22%, ranging from 1.16% for matched-family donor to 11.24% in 
mismatched unrelated donor recipients (41). EBV-PTLD incidence varies markedly 
with the time after transplantation, with particularly high rates occurring during the first 
5 months, followed by a steep decline in incidence between 6 and 12 months post-
transplant (early PTLD < 1 year). A significantly increased risk of PTLD continues 
among longer term survivors, although the rate is greatly diminished. The high 
incidence of PTLD during the first few months after transplant is consistent with 
clinical investigations of the temporal pattern of immune reconstitution in HSCT 
recipients (42). In fact, the incidence decreases due to the increase in EBV-specific T 
cell (43). Late PTLD after HSCT (> 1 year) differ in their risk factors, pathology and 
Part I 
_______________ 
25 
 
EBV association. These tumors are sometimes of T cell origin rather than B cell origin, 
and at times are not EBV associated (39).  In fact, the EBV genome is found in more 
than 90% of B-cell PTLD occurring during the first year after transplantation (in the 
early phase), while up to 45% of late onset PTLD may be EBV negative (36). The 
diagnosis of EBV-PLTD requires biopsy with in situ hybridization or immunochemistry 
to define viral association. EBV-encoded RNA in situ hybridization is the most 
sensitive tool for detecting virus in tumor. LMP-1 staining is also available in most 
pathology laboratories but is negative in the subset of tumors that do not express the 
viral antigen. Immunohistochemistry for EBNA-1 could also be broadly applicable (39). 
One year post-transplant, chronic GvHD, an established correlate of immune 
dysregulation in long-term survivors, has been identified as a strong risk factor for late-
onset PTLD. Thus, it is likely that risk factors associated with altered immunity and T-
cell regulatory mechanisms might be predictors of both early and late onset PTLD (44). 
 
MECHANISMS FOR EBV-DRIVEN PTLD    
EBV is associated with both B cell and epithelial cell malignancies. As previously 
described, EBV has both latent and lytic programs in its life-cycle. Since lytic EBV 
replication triggers the death of infected cells, tumors require the expression of latent 
programs. Among the EBV latent proteins, LMP-1 is the main oncogenic one and is 
essential for EBV-driven tumorigenesis (45). As previously reported, this protein 
activates several downstream signaling pathways, which contribute to the expression of 
anti-apoptotic proteins and cytokines by acting like CD40. Like most cancers, EBV-
associated malignancies require induction of telomerase activity. Telomerase, a 
ribonucleoprotein complex containing an internal RNA template and a catalytic protein 
with telomere reverse transcriptase (TERT) activity, extends the telomeres at the ends of 
eukaryotic chromosomes, thus preventing cell senescence and apoptosis. The internal 
RNA template is constitutively present in normal and tumor cells, while TERT is the 
rate-limiting component of the telomerase complex and its expression correlates with 
telomerase activity. TERT activity is repressed in somatic tissues, but both TERT 
expression and telomerase activity are elevated in most human tumors. In EBV-infected 
primary B lymphocytes, activation of TERT occurs concomitantly with the induction of 
latent EBV proteins and down-regulation of EBV lytic gene expression. LMP-1 is the 
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main driver of EBV-induced immortalization since it activates TERT. In turn, TERT 
expression negatively affects the expression of BZLF-1, the master regulator of the viral 
lytic cycle, thereby favoring the induction and maintenance of EBV latency, a 
prerequisite for EBV-driven transformation. In contrast, TERT silencing induces the 
expression of BZLF-1, EA-D and gp350 EBV lytic proteins and triggers a complete 
lytic cycle. Although latency programs predominate in EBV-driven tumors, some recent 
data have suggested that the uncontrolled viral lytic cycle has some pathogenic 
importance, at least in the early phase of transformation. In fact, lymphoblastoid B cell 
lines obtained with lytic-defective EBV strains have been shown to be less effective in 
inducing EBV-positive lymphoproliferations in severe combined immunodeficiency 
mice, an effect due to the lower production of the B-cell growth promoting factors IL-6, 
cIL-10 and vIL-10, dependent on BZLF-1, the main EBV lytic transactivator. 
Moreover, several EBV lytic proteins have also been shown to favor immune evasion 
by inhibiting the synthesis of IFN-γ and suppressing CD8 cytotoxic T cells and to 
contribute to tumorigenesis by promoting angiogenesis. Besides immune depression, 
persistent immune activation/chronic inflammation may also play a key role in PTLD 
development. Studies have identified parallels between cancer and infectious disease. 
Indeed, in cancer as in infectious diseases, the release of microbial pathogen-associated 
molecular patterns (PAMPs - such as lipopolysaccharide, 16S ribosomal DNA and CpG 
DNA) and endogenous damage-associated molecular patterns (DAMPs - such as 
mitochondrial DNA) by engaging the extra- or intracellular domain of Toll-like 
receptors may initiate a complex signal transduction cascade which ultimately leads to 
the release of pro-inflammatory cytokines, such as IL-6, IL-10, IFN-α and tumor 
necrosis factor, causing chronic inflammation. This chronic stimulation may activate 
EBV replication and/or contribute to the polyclonal expansion of EBV positive cells. 
Chronic B-cell hyperactivation is driven by overproduction of B-cell stimulatory 
cytokines, such as IL-6, IL-10, IFN-α and tumor necrosis factor (45). 
In Figure 10 a schematic depict of the pathogenetic mechanisms of early onset EBV-
PTLD is reported (45). Briefly, PAMPs and DAMPs, through Toll-like receptors, 
promote the release of pro-inflammatory cytokines, which in turn activate EBV lytic 
cycle. At early stage of disease, EBV lytic replication leads to increased number of 
infected cells. Moreover, B-cell activation, due to persistent inflammation/immune 
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activation, may also favor expansion of EBV-infected B cells, a crucial step for PTLD 
development. Along with infection, the oncogenic LMP-1 viral protein transcriptionally 
activates TERT which in turn blocks lytic viral replication. EBV-infected B cells 
expressing LMP-1 and cellular TERT protein are prone to transformation (45). 
 
Figure 10: Pathogenetic mechanisms of early onset EBV-PTLD. (from Petrara MR et 
al. Cancer Letters 2015; 369:37-44). 
 
 
DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns; IL: interleukin; 
INF: interferon; TNF: tumor necrosis factor; TERT: telomere reverse transcriptase; miRNA: microRNA 
 
 
STRATEGIES FOR TREATMENT OF EBV-DRIVEN PTLD 
There is no consensus treatment model for the optimal management of PTLD due to its 
clinico-pathologic heterogeneity. Strategies to prevent EBV-associated PTLD usually 
aim at partially recovering immune surveillance and involve reduction of immune 
suppression to allow restoration of specific immunity and control of EBV-infected 
proliferating cells (45). Strategies for treatment of EBV-driven PTLD include:  
• Reduction of immunosuppressive therapy, if possible. It appears to be effective in 
23-50% of cases, although the difference in response seems to be related to the degree 
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of reduction of immunosuppression or to the time of disease onset. Patients with early-
onset disease have better outcomes with reduced immunosuppression than those with 
late-onset PTLD (46). 
• Anti-CD20 monoclonal antibody rituximab 375 mg/m2, weekly doses - the number 
of doses are assessed locally on the basis of changes in EBV DNA load. It is the first 
line of treatment for patients who do not respond to reduction or discontinuation of 
immunosuppression (45). In several studies, rituximab administered for treatment 
purposes yielded a 40-68% response rate (47-49). In the preemptive setting, it has been 
demonstrated that the anti-CD20 antibody can prevent EBV-associated PTLD in about 
90% of cases (50). 
• EBV-specific cytotoxic T cells infusion, if available. The most brilliant results were 
obtained in the pre-emptive setting, whereas the clinical benefit in patients with overt 
PTLD is still unsatisfactory in a proportion of cases (45). 
• Antiviral agents. The limited data available on antiviral agents in patients with EBV 
reactivation and PTLD following allo-HSCT does not support their use. The main cause 
of PTLD is the proliferation of the latently infected EBV-positive B cells - and not lytic 
replication - which is why antiviral pharmacotherapy is not expected to be effective in 
this setting (39). At this regard, there is increasing interest in developing strategies 
potentially able to efficiently reactivate EBV lytic gene expression in latently infected 
tumor cells to treat overt EBV-associated malignancies, as lytic infection promotes the 
death of EBV- positive tumor cells both in vitro and in vivo. Combination of antivirals 
with lytic cycle inducers is emerging as a highly promising strategy in treating EBV-
driven tumors. In view of the role of TERT in regulating the switch from latent to lytic 
infection, a strategy aimed at inhibiting TERT in combination with antiviral drugs 
appears particularly attractive (45). 
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6 
MANAGEMENT OF EBV INFECTION: STATE OF THE ART  
 
Prompt diagnosis is surely necessary due to the rapid and often disseminated nature of 
PTLD in HSCT recipients (51). Several studies have clearly shown that the 
development of PTLD is in most cases, both after solid organ and stem cell transplant, 
accompanied by a significant increase in EBV DNA level in peripheral blood (52-57). 
Increasing EBV DNA levels rather than a stable-elevated EBV DNA load seems to be a 
more reliable marker of PTLD (58). Therefore, serial monitoring is important for 
identification of patients at risk of disease, distinguishing patients with a stable-elevated 
EBV DNA load from those with increasing EBV DNA levels (39). While it is accepted 
that EBV DNA levels in the blood of patients with EBV-related PTLD are significantly 
higher than those in transplant recipients without PTLD (52-57), to date the choice of 
optimal clinical specimen - whole blood (WB), plasma or PBMCs - for the monitoring 
of EBV infection in transplanted patients is a matter of debate (59-62). Different assays 
use WB, plasma or PBMCs, all requiring different interpretation. The choice of unit of 
measurement also remains controversial (63).  In general, assays using PBMCs are able 
to predict EBV disease at the earliest stage. Elevated EBV DNA in PBMCs may reflect 
both EBV in normal B cells (a population that may be expanded in immunosuppressed 
patients) and EBV in transformed cells. EBV DNA in plasma might reflect virus 
shedding, which occurs intermittently from lytically infected B cells, as well as virus 
released from necrotic cells. EBV load in WB reflects the combination of all sources 
(63). Several studies comparing EBV DNA determination in PBMCs, WB, and plasma 
using real-time PCR assays showed higher analytical sensitivity for PBMCs and WB 
(38,59,64-66). In addition, there is no international consensus on what is the EBV DNA 
threshold level predictive for developing PTLD and then for the need of pre-emptive 
therapy. In fact, various data about this issue have been reported and have been related 
to local experiences (50, 67-72).  
Clinically, the presence of high or increasing levels of EBV DNA in peripheral blood 
has been used as a parameter to modulate the immunosuppressive therapy and to start 
pre-emptive or antitumor therapy (73). Nevertheless, the detection of increased EBV 
load alone is not always predictive of impending PTLD (45). In fact, studies have 
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demonstrated that the outcome of virus infections depends on the efficacy of specific T 
cell responses (74). Numerous studies have focused on immune monitoring of human 
cytomegalovirus (CMV) in transplant recipients, while monitoring of EBV-specific T 
cell responses and their association with EBV-related complications after transplant 
remain largely unexplored (74). Furthermore, it should be note that in recent years there 
has been a growing interest in the development of immune monitoring approaches that 
may allow the identification of infectious risk in transplant recipients and, eventually, 
the modulation of immunosuppressive strategies by using non pathogen-specific assays 
(i.e. quantification of cytokines and chemokines, enumeration of T-cell subsets and 
ImmuKnow assay) (74).  
 
At this regard, in our Centre at St. Orsola-Malpighi University Hospital, before the 
launch of this project involving HSCT recipients, we studied the potential additive value 
of immunological assays, both pathogen-specific and non pathogen-specific, in the post-
transplant setting of solid organ transplant recipients. Specifically, we assessed i) the 
utility of measuring CMV-specific cell-mediated immunity (CMI) by Enzyme-linked 
ImmunoSPOT assay in bowel/multivisceral transplant recipients to provide additional 
information on the risk of infection and development of CMV disease (75); ii) the 
clinical benefits of adjusting immunosuppressive therapy in liver transplant recipients  
based on a non-pathogen- specific immune function assay results such as ImmuKnowTM 
assay (Interventional group) compared to a group managed with the standard clinical 
practice (Control group). Among the primary outcomes, the incidence of infection 
between the two groups was compared in order to establish if ImmuKnowTM assay 
provides a useful biomarker which enables optimizing immunosuppression to improve 
patient outcomes by preventing infections (76) (See the two papers in Part VII - 
Annexes). Finally, we performed the monitoring of CMV-specific CD8+ T cell 
responses using the QuantiFERON®-CMV assay in heart transplant recipients. 
Specifically, the pattern of CMV-specific CMI reconstitution after heart transplant was 
evaluated and the clinical utility of the assay for the management of post-transplant 
CMV infection was assessed (“Monitoring of CMV-specific cell-mediated immunity in 
heart transplant recipients: clinical utility of the QuantiFERON®-CMV assay for the 
management of CMV infection”; submitted manuscript - J Clin Virol). 
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To date, the diagnosis and monitoring of EBV infection are based on direct evaluation 
of viral burden by quantitative molecular methods such as real-time PCR assay. 
However, these tests do not provide information regarding the host immunological 
response against the EBV replication, thus often failing in the prediction of infection 
progression to overt disease.  
 
The general objective of the PhD research was to assess the utility of measuring EBV 
blood replication combined with the specific viral cellular immunity in allo-HSCT 
recipients to monitor the risk of development of EBV-PTLD. Moreover, the kinetics of 
EBV DNA in two different blood compartments - WB and PBMCs - were studied. 
 
In particular the PhD project, that involved both adult and paediatric allo-HSCT 
recipients, was focused on the following specific topics: 
 
1. The incidence of EBV infection and the potential risk factors for the development of 
active EBV infection. 
 
2. Suitability of WB as clinical specimen to monitor the risk of developing EBV-PTLD.  
 
3. Combined virological-immunological monitoring of EBV infection as a possible 
predictive marker of EBV-related complications. 
 
4. The management of EBV infection and EBV-PTLD prevention. 
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Consecutive adult and paediatric patients who underwent allo-HSCT during the period 
2014 - 2015, respectively at the Institute of Hematology and Medical Oncology “L. and 
A. Seràgnoli” and at the Operative Unit of Paediatrics - Oncology, Haematology, and 
Stem Cell Transplantation Program - of the St. Orsola-Malpighi University Hospital of 
Bologna were enrolled. The study was approved by the St. Orsola-Malpighi University 
Hospital Research Ethics Committee (VIRO-13 Study; 41/2013/U/Tess - see the related 
documents in Part VII - Annexes) and all patients provided informed consent. As a 
starting point, the EBV serostatus in paired Donor/Recipients (D/R) was determined to 
identify EBV risk groups: D-/R- and D+/R- (EBV primary infection); D-/R+ and D+/R+ 
(EBV reactivation/reinfection). For all patients, routine virological monitoring of EBV 
infection was performed on WB samples by a quantitative real-time PCR. Virological 
monitoring was performed every week during the first 100 days post-transplant and 
every 2 weeks until 180 days post-transplant. Afterwards, blood samples were 
processed if clinically indicated. Since EBV DNA is typically harbored within latently 
infected B-lymphocytes, very low EBV DNA levels may be present in WB samples in 
the setting of latent infection. Therefore, we established that an active EBV infection 
was defined as the detection of EBV DNA greater than 500 copies/mL WB in at least 
two consecutive samples. After the first EBV DNA positivity in WB samples > 500 
copies/mL, EBV DNA load in PBMCs will be also prospectively monitored starting 
from the next visit. Furthermore, in the case of EBV DNAemia, monitoring was 
performed weekly for at least 1 month. Immunological monitoring of EBV infection 
was carried out using Enzyme-linked ImmunoSPOT (EliSpot) assay that enumerates 
Interferon-gamma-secreting EBV-specific T cells (both CD4+ and CD8+ cells), at a 
single cell level, upon in vitro stimulation with latent and lytic viral antigens. EliSpot 
assay was performed on patients’ blood samples at days 60, 100, 180 and 360 after allo-
HSCT. Moreover, for the patients at higher risk of developing EBV-PTLD, i.e. patients 
who showed high viral load, EliSpot assay was performed during the next visit. 
Specifically, based on previous studies (77,78) and on the GITMO guidelines for the 
diagnosis and treatment of EBV-PTLD in HSCT recipients, any values of EBV DNA > 
10,000 copies/mL WB and > 1,000 copies/1x105 PBMCs were defined as high viral 
load. In addition, all patients were monitored for CMV infection during the post-
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transplantation period. CMV real-time PCR was performed weekly during the first three 
months and then monthly until the sixth month. Afterwards, blood samples were 
processed if clinically indicated.  
 
Patients underwent virological-immunological and clinical monitoring for at least one 
year post-transplant. 
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1 
THE INCIDENCE OF EBV INFECTION AND THE POTENTIAL 
RISK FACTORS FOR ITS DEVELOPMENT  
 
 
INCIDENCE OF EBV INFECTION 
 
The overall incidence of post-transplant active EBV infection in adult and paediatric 
patients was equal to 45.5% and 61.1%, respectively. Specifically, in the adult study 
population the incidence of post-transplant primary EBV infection and EBV 
reactivation/reinfection was equal to 3% and 42.4%, respectively. No paediatric patients 
were EBV-seronegative at the time of transplant. 
 
ADULT STUDY POPULATION 
Thirty-seven adult allo-HSCT recipients were enrolled. Four patients (10.8%) were 
excluded from the study because they died in the immediate early post-transplant period 
(median time 7 days post-transplant; range, 5 - 42). For all the four patients the source 
of stem cells was CB and the donor type was a MUD; the causes of death were relapse 
of the original disease (n = 2; LAM) and respiratory failure (n = 1). Among the 33 
evaluable patients, 21 were males and 12 females with a mean age of 40 years (range, 
18 - 59). The study population’s transplant characteristics are reported in Tables 3 
(patients with active EBV infection; n = 15) and 4 (patients not actively EBV infected; n 
= 18).  
 
 
  
 
 
Table 3: Characteristics of 15 adult patients who developed an active post-transplant EBV infection and results of virological monitoring.  
Patients were disposed in the Table on the basis of the viral load detected during the follow-up of EBV infection: from highest to lowest EBV DNAemia 
values.  
 
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; HL, Hodgkin lymphoma; CML, chronic myeloid leukemia; ALCL, anaplastic large cell lymphoma; Pt, patient; M, 
male; F, female; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow; CB, cord blood; D, donor; R, recipient; TBI, total body irradiation; RIC, reduced- 
intensity conditioning; CyA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; GvHD, graft-versus-host disease. 
 
Pt Age years Sex
Primary 
disease
Donor
type
Graft 
origin
EBV 
serology Conditioning regimen
T-cell 
depletion
GvHD 
prophylaxis
EBV DNAemia
whole blood
copies/mL
9 40 M ALL MUD BM D?/ R+ TBI-based myeloablative regimen in vivo CyA  + MTX min-max522 – 119,039
21 41 F AML MUD CB D?/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MMF Min-max 1837 – 74,374 
7 34 F HL MUD PBSC D+/ R+ RIC regimen in vivo CyA  + MTX min-max4650 – 55,769
17 35 F AML RELATED Sibling PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max1433 – 15,820
18 33 M AML MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max517 – 10,966
6 49 F AML RELATED Sibling PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX min-max623 – 10,521
16 57 M CML MUD PBSC D?/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max564 – 7,279
5 59 M AML MUD PBSC D+/ R+ RIC regimen in vivo CyA  + MTX min-max678 – 3,386
2 18 M ALL MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX min- max510 – 3,147
27 22 M CML MUD PBSC D-/R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX min-max537 – 3,035
12 53 F AML MUD BM D+/ R+ Busulfan-based myeloablative regimen in vivo Only MTX min-max603 – 2,657
19 55 F ALL MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX min-max686 – 1,769
34 43 F ALCL RELATED Sibling PBSC D-/R+ RIC regimen in vivo CyA + MTX min-max631 – 1,703
23 35 M AML MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX min-max720 – 1,611
4 20 M ALL RELATED Sibling PBSC D+/ R- Busulfan-based myeloablative regimen in vivo CyA  + MTX min-max514 – 1,038
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Table 4: Characteristics of 18 adult patients who resulted negative for EBV DNA over the entire follow-up. 
 
AML, acute myeloid leukemia; MM, multiple myeloma; DLBLC, diffuse large B-cell lymphoma; ALL, acute lymphoblastic leukemia; MS, myeloid sarcoma; CML, chronic myeloid 
leukemia; MDS, myelodysplastic syndrome; Pt, patient; M, male; F, female; MUD, matched unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow; CB, cord blood;  
D, donor; R, recipient; RIC, reduced-intensity conditioning; CyA, cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; GvHD, graft-versus-host disease. 
Pt Age years Sex
Primary 
disease
Donor
type
Graft 
origin
EBV 
serology Conditioning regimen
T-cell 
depletion
GvHD 
prophylaxis
EBV DNAemia
whole blood
copies/mL
1 51 M AML MUD PBSC D?/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
3 24 M AML MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
8 43 M AML MUD BM D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
10 42 M AML MUD BM D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
11 45 F AML MUD CB D?/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MMF Negative
14 25 F AML MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo Only CyA Negative
20 34 M MM MUD CB D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
22 50 M DLBCL MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
24 37 M ALL MUD PBSC D-/R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
25 22 M ALL RELATED Sibling PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
26 21 M ALL MUD BM D+/ R+ Busulfan-based myeloablative regimen in vivo CyA  + MTX Negative
28 39 F MS RELATED Sibling BM D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
29 38 M AML MUD BM D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
30 43 F CML MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
31 51 M MDS MUD BM D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
32 56 M AML MUD PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
33 46 M MM RELATED Sibling PBSC D+/ R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
35 47 F MDS MUD PBSC D-/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
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Most patients (48.5%) underwent transplant for AML. The donor type was a MUD for 
26 allo-HSCT (78.8%) and a related donor type for 7 (21.2%) patients; in all transplants 
the donor was HLA-identical sibling. The source of stem cells was PB in 66.7% of 
transplants (22/33 patients). At the time of transplant, the EBV serostatus of D/R were: 
D+/R+ in 23/33 patients (69.7%), D+/R- in 1/33 patients (3%) and D-/R+ in 4/33 
patients (12.1%). The serology of the donor was not available in 5 cases (15.2%); all the 
respective recipients were EBV-seropositive. The conditioning regimen was of reduced 
intensity for 3 patients and MA for 30 patients. All 33 patients underwent in vivo T-cell 
depletion to reduce rejection and GvHD. On the basis of the patient-related and 
transplant related characteristics, ATG rabbit (GRAFELON formerly ATG-Fresenius; 
Neovii Biotech GmbH, Graefelfing, Germany), in a total dose ranging from 15 - 30 
mg/kg, was administered over 5 days, from day -6 to -2. In most cases, GvHD 
prophylaxis consisted of an association of cyclosporine A and methotrexate (n = 29). 
 
The 33 adult allo-HSCT recipients were monitored for EBV infection for a median time 
of 12 months post-transplant (range, 5 - 17). For 18 out of 33 patients (54.5%), WB 
samples tested negative for EBV DNA over the entire follow-up. Fifteen patients 
(45.5%) developed an active post-transplant EBV infection: 11 patients who underwent 
allo-HSCT from MUD (42.3%, 11/26 patients) and 4 patients transplanted from related 
donor (57.1%, 4/7 patients). One out of 15 patients (6.7%) developed primary EBV 
infection and 14/15 (93.3%) patients developed EBV reactivation/reinfection. Among 
the 15 patients with an active post-transplant EBV infection, 9 patients (60%) showed 
low values of EBV DNAemia (< 10,000 copies/mL WB), whereas 6 patients (40%) 
showed values of EBV DNAemia equal or greater than 10,000 copies/mL WB. Two out 
of 15 (13.3%) actively EBV infected patients developed EBV-related complications 
such as mononucleosis-like syndrome - fever and pharyngitis - (patient number 21) and 
EBV-PTLD (patient number 9). The results of the virological follow-up are reported in 
Figure 11. 
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Figure 11: Results of the virological follow-up - Adult patients.  
 
 
 
The median peak of viral load in patients with low and high values of EBV DNAemia 
was 2,657 copies/mL (range, 1,038 - 7,279 copies/mL) and 35,794 copies/mL (range, 
10,521 - 119,039 copies/mL), respectively. The median time at which EBV DNAemia 
was first detected was 52 days (range, 20 - 474) post-transplant. The results obtained by 
virological monitoring, along with the range of EBV DNAemia values detected per 
patient, are reported in Table 3.  
 
PAEDIATRIC STUDY POPULATION 
Twenty-one paediatric allo-HSCT recipients were enrolled. Among the 21 patients, 3 
patients (14.3%) died approximately two months post-transplant (median time 66 days 
post-transplant; range, 57-67). Two of them received a HSCT from a related donor and 
died of multi-organ failure - BM and combined BM-CB were the sources of stem cell; 
the remaining patient underwent allo-HSCT from MUD, BM was the source of stem 
cells and the cause of death was relapse of the original disease (AML). Then, the 
paediatric study population included 18 evaluable patients. The mean age was 9 years 
(range, 9 months - 20 years) and the male/female ratio was of 13/5. Study population’s 
transplant characteristics are reported in Tables 5 (patients with active EBV infection; n 
= 11) and 6 (patients not actively EBV infected; n = 7). 
  
 
 
Table 5: Characteristics of 11 paediatric patients who developed an active post-transplant EBV infection and results of virological 
monitoring.  
Patients were disposed in the Table on the basis of the viral load detected during the follow-up of EBV infection: from highest to lowest EBV DNAemia 
values. 
 
SAA, severe aplastic anemia; ALL, acute lymphoblastic leukemia; β-TM, beta-thalassemia major; AML, acute myeloid leukemia; Pt, patient; M, male; F, female; MUD, matched 
unrelated donor; PBSC, peripheral blood stem cell; BM, bone marrow; D, donor; R, recipient; RIC, reduced-intensity conditioning; CyA, cyclosporine A; MTX, methotrexate; GvHD, 
graft-versus-host disease.  
 
 
Pt Age years Sex
Primary
disease
Donor
type
Graft 
origin
EBV 
serology Conditioning regimen
T-cell
depletion
GvHD 
prophylaxis
EBV DNAemia
whole blood
copies/mL
21 15 M SAA RELATED Sibling PBSC D+/R+ RIC regimen in vivo CyA + MTX min- max872 – 2,011,688
17 4 M ALL MUD BM D+/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min- max631 – 683,294
4 10 M ALL MUD PBSC D+/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max1120 – 89,724
20 6 M β-TM MUD BM D?/R+ RIC regimen in vivo CyA + MTX min- max2813 – 45,548
18 1 M AML RELATED Sibling BM D+/R+ Busulfan-based myeloablative regimen NO Only CyA min-max1,289 – 15,312
8 8 M ALL RELATED Sibling BM D-/R+ Treosulfan-based myeloablative regimen NO Only CyA min- max522 – 14,787
3 14 M AML MUD BM D+/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max820 – 12,395
2 8 M ALL MUD BM D?/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max560 – 10,763
1 8 M ALL MUD BM D+/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX min-max513 – 3,412
19 9 M β-TM RELATED Sibling BM D+/R+ RIC regimen in vivo Only CyA min- max546 – 2,727
7 13 F AML RELATED Sibling BM D?/R+ Busulfan-based myeloablative regimen NO Only CyA min-max509 – 1,033
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Table 6: Characteristics of 7 paediatric patients who resulted negative for EBV DNA over the entire follow-up. 
 
 
AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; Pt, patient; M, male; F, female; MUD, matched unrelated donor; BM, bone marrow; D, donor; R, recipient; CyA, 
cyclosporine A; MTX, methotrexate; MMF, mycophenolate mofetil; GvHD, graft-versus-host disease. 
Pt Age years Sex
Primary
disease
Donor
type
Graft 
origin
EBV 
serology Conditioning regimen
T-cell
depletion
GvHD 
prophylaxis
EBV DNAemia
whole blood
copies/mL
5 9 F AML RELATED Sibling BM D?/R+ Busulfan-based myeloablative regimen NO Only CyA Negative
9 4 M ALL MUD BM D-/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
10 11 M AML MUD BM D?/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
12 12 F ALL MUD BM D+/R+ Busulfan-based myeloablative regimen in vivo CyA + MMF Negative
13 5 M AML MUD BM D+/R+ Busulfan-based myeloablative regimen in vivo CyA + MTX Negative
15 20 F ALL RELATED Sibling BM D+/R+ Busulfan-based myeloablative regimen NO Only CyA Negative
16 1 F ALL RELATED Sibling BM D-/R+ Busulfan-based myeloablative regimen NO Only CyA Negative
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Half of all patients (50%) underwent transplant for ALL. The donor type was a MUD 
for 10 allo-HSCT (55.6%) and a related donor type for 8 (44.4%) patients; in all 
transplants the donor was HLA-identical sibling. The source of stem cells was BM in 
88.9% of transplants (16/18 patients). At the time of transplant, the EBV serostatus of 
D/R were: D+/R+ in 12/18 patients (66.6%) and D-/R+ in 3/18 patients (16.7%). The 
serology of the donor was not available in 3 cases (16.7%); all the respective recipients 
were EBV-seropositive. The conditioning regimen was of reduced intensity for 3 
patients and MA for 15 patients. A total of 12 patients (66.7%) underwent in vivo T-cell 
depletion: all 10 MUD transplants and 2 out of 8 HLA-identical sibling transplants. On 
the basis of the patient-related and transplant-related characteristics, ATG rabbit 
(Thymoglobuline®, Genzyme, Cambridge, Massachusetts, USA) was administered in a 
total dose ranging from 6 to 9 mg/kg over 3 days, from day -4 to -2.  In most cases, 
GvHD prophylaxis consisted of an association of cyclosporine A and methotrexate (n = 
10). 
  
The 18 paediatric allo-HSCT recipients were monitored for EBV infection for a median 
time of 12 months post-transplant (range, 2 - 13). All patients were EBV-seropositive at 
the time of transplantation. For 7 out of 18 patients (38.9%), WB samples tested 
negative for EBV DNA over the entire follow-up. Eleven patients (61.1%) developed a 
post-transplant EBV reactivation/reinfection: 6 patients who underwent allo-HSCT 
from MUD (60%, 6/10 patients) and 5 patients transplanted from related donor (62.5%, 
5/8 patients). Among the 11 patients with an active post-transplant EBV infection, 3 
patients (27.3%) showed low values of EBV DNAemia (< 10,000 copies/mL WB), 
whereas 8 patients (72.7%) showed values of EBV DNAemia equal or greater than 
10,000 copies/mL WB. One out of 11 actively EBV infected patients (9.1%) developed 
an EBV-PTLD. The results of the virological follow-up are reported in Figure 12. 
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Figure 12: Results of the virological follow-up - Paediatric patients.  
 
 
 
The median peak of viral load in patients with low and high values of EBV DNAemia 
was 2,727 copies/mL (range, 1,033 - 3,412 copies/mL) and 30,430 copies/mL (range, 
10,763 - 2,011,688 copies/mL), respectively. The median time at which EBV DNAemia 
was first detected was 48 days (range, 25 - 143) post-transplant. The results obtained by 
virological monitoring, along with the range of EBV DNAemia values detected per 
patient, are reported in Table 5.  
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RISK FACTORS FOR DEVELOPING OF EBV INFECTION 
 
Comparisons between patient-related and transplant-related characteristics and 
development of EBV infection were evaluated using chi-square test of independence. 
Patients who developed active post-transplant EBV infection were compared with not 
infected patients. In the analysis, adult and paediatric patients were considered as a 
unique population. P-values < 0.05 were considered statistically significant.  
 
ADULT AND PAEDIATRIC STUDY POPULATION 
RIC regimen in combination with in vivo T-cell depletion has been shown to be a risk 
factor for the developing of EBV infection rather than the primary disease; donor type; 
graft origin; in vivo T-cell depletion with ATG; acute GvHD and chronic GvHD. The analysis 
was reported in Table 7. 
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Table 7: Patient characteristics and risk factors for EBV infection - Adult and paediatric 
patients.   Bold P-values are statistically significant 
  Total 
EBV DNAemia 
 
NEGATIVE 
EBV DNAemia 
 
POSITIVE 
P value 
Number of patients (%) 51 (100) 25 (49) 26 (51)    
Primary disease 
ALL 16 (31.4) 7 (43.7) 9 (56.3) 
0.873 AML  21 (41.1) 11 (52.4) 10 (47.6) CML 3 (5.9) 1 (33.3) 2 (66.7) 
Other * 11 (21.6) 6 (55.5) 5 (45.5) 
Donor type     
Unrelated (MUD) 36 (70.6) 19 (52.8) 17 (47.2) 0.406 Related (Sibling) 15 (29.4) 6 (40) 9 (60) 
Graft origin     
Bone marrow  24 (88.9) 13 (54.2) 11 (45.8) 
0.563 Cord blood  3 (9.1) 2 (66.7) 1 (33.3) 
Peripheral blood  24 (11.1) 10 (41.7) 14 (58.3) 
Conditioning regimen 
Myeloablative# 45 (88.2) 25 (55.6) 20 (44.4) 0.011 Reduced-intensity  6 (11.8) 0 6 (100) 
In vivo T-cell depletion  with ATG 
Yes  45 (88.2) 22 (48.9) 23 (51.1) 0.959 No  6 (11.8) 3 (50)  3 (50) 
Association - Conditioning regimen and ATG 
Myeloablative + ATG 39 (76.4) 22 (56.4) 17 (43.6) 
0.036 Reduced-intensity + ATG 6 (11.8) 0 6 (100) 
Myeloablative Only 6 (11.8) 3 (50) 3 (50) 
CMV infection 
Yes 29 (56.9) 13 (44.8) 16 (55.2) 0.492 No  22 (43.1) 12 (54.5) 10 (45.5) 
Acute GvHD ( < 100 days post-transplant) grading 
Absent  20 (39.2) 10 (50) 10 (50) 
0.986 I  10 (19.6) 5 (50) 5 (50) 
> II 21 (41.2) 10 (47.6) 11 (52.4) 
Chronic GvHD (> 100  days post-transplant) grading    Data available for 50 patients  
Absent  41 (82) 21 (51.2) 20 (48.8) 0.331 Mild to severe 9 (18) 3 (33.3) 6 (66.7) 
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; CML: chronic myeloid leukemia; MUD: 
matched-unrelated donor; ATG: antithymocyte immunoglobulin; CMV: cytomegalovirus; GvHD: graft-versus-host 
disease. 
 
* severe aplastic anemia (n=1); beta-thalassemia major (n=2); Hodgkin lymphoma (n=1); anaplastic large 
cell lymphoma (n=1); multiple myeloma (n=2); diffuse large B-cell lymphoma (n=1); myeloid sarcoma 
(n=1); myelodysplastic syndrome (n=2). 
#Myeloablative conditioning regimen includes both busulfan-based myeloablative regimen and total body 
irradiation-based myeloablative regimen. 
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2 
SUITABILITY OF WHOLE BLOOD AS CLINICAL SPECIMEN TO 
MONITOR THE RISK OF DEVELOPING EBV-PTLD 
 
Real-time PCR for EBV DNA quantification (EBV ELITe MGBTM kit, ELITech Group, 
Turin, Italy) was performed on WB and PBMC samples, following the manufacturer’s 
instructions.  
Technical information 
Blood samples were collected in ethylenediaminetetraacetic acid (EDTA)-
anticoagulated tubes. DNA was extracted from 200 µL of WB using the 
QIASymphonysp instrument (Qiagen GmbH, Hilden, Germany), eluted in 90 µL of 
Elution Buffer and 20 μl were processed for EBV DNA quantification. DNA was 
extracted from 2x105 PBMCs using the NucliSens easyMAG System (bioMerieux, 
Marcy l’Etoile, France) according to the manufacturer’s instructions; half of the eluated 
volume corresponding to 1x105 PBMCs was used as input DNA in each real-time PCR. 
Amplification, detection and analysis were performed using the ABI PRISM 7300 
platform (Life Technologies, Foster City, California, United States). The PCR assay 
targets a region of the EBNA-1p gene of EBV. The analytical sensitivity of the assay is 
10 copies of target DNA per amplification reaction. The LLQ of the assay is 225 
copies/mL WB and 11 copies/1x105 PBMCs. EBV DNA load was reported as quantities 
of copies/mL and copies/1x105 PBMCs.  
 
The correlation between Log10 copies of EBV DNA in WB and PBMC samples was 
obtained using weighted Pearson correlation to take into account the different number of 
subjects’ repeated measures. 
 
ADULT STUDY POPULATION 
A total of 809 WB samples and 252 paired WB and PBMC samples were processed; the 
median number of paired WB and PBMC samples analyzed per patient was 18 (range, 3 
- 33). Forty-nine out of 252 samples (19.5%) were negative and 178 samples (70.6%) 
were positive for EBV DNA both in WB and PBMC samples; 25 (9.9%) samples were 
discordant. Among the 178 positive samples: 50 samples (28.1%) were positive with a 
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quantitative result; 104 samples (58.4%) tested positive but below the LLQ of the PCR 
assay and 24 samples (13.5%) were positive with a quantitative result in WB and 
positive, but below the LLQ of the PCR assay in PBMC samples. The 50 samples that 
resulted positive with a quantitative result in both the two blood compartments were 
taken into consideration for the correlation analysis. The correlation coefficient obtained 
was r = 0.787 (P < 0.001) (Figure 13).  
 
Figure 13: Correlation between EBV DNA levels in 50 WB and PBMC samples 
collected from adult allo-HSCT recipients.  
 
Pt: patient 
 
 
 
 
 
 
EBV DNA kinetics in WB and PBMC samples were analyzed in all the 15 actively 
EBV infected patients. Representative EBV DNA kinetics in the two blood 
compartments of four out of 15 patients are reported in Figure 14. 
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Figure 14: Representative EBV DNA kinetics in WB and PBMC samples of four adult 
allo-HSCT recipients with active EBV infection.  
 
The line ( ) indicates the LLQ of the real-time PCR assay for WB samples. The line ( ) 
indicates the LLQ of the real-time PCR assay for PBMC samples. Log10 EBV DNA levels in 
WB and in PBMC samples were represented with open and filled circles, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PAEDIATRIC STUDY POPULATION 
A total of 250 WB and 168 paired WB and PBMC samples were processed; the median 
number of paired WB and PBMC samples analyzed per patient was 13 (range, 3-31). 
Fifty out of 168 samples (29.8%) were negative and 105 samples (62.5%) were positive 
for EBV DNA both in whole blood and PBMC samples; 13 (7.7%) samples were 
discordant. Among the 105 positive samples: 36 samples (34.3%) were positive with a 
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quantitative result; 43 samples (41%) tested positive but below the LLQ of the PCR 
assay and 26 samples (24.7%) were positive with a quantitative result in WB and 
positive but below the LLQ of the PCR assay in PBMC samples. The 36 samples that 
resulted positive with a quantitative result in both the two blood compartments were 
taken into consideration for the correlation analysis. The correlation coefficient obtained 
was r = 0.976 (P < 0.001) (Figure 15).  
 
Figure 15: Correlation between EBV DNA levels in 36 WB and PBMC samples 
collected from paediatric allo-HSCT recipients.  
 
Pt: patient 
 
 
 
 
EBV DNA kinetics in WB and PBMC samples were analyzed in all eleven patients. 
Representative EBV DNA kinetics in the two blood compartments of four out of 11 
patients are reported in Figure 16. 
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3 
 
COMBINED VIROLOGICAL-IMMUNOLOGICAL MONITORING 
OF EBV INFECTION AS A POSSIBLE PREDICTIVE MARKER OF 
EBV-RELATED COMPLICATIONS  
 
The immunological monitoring was carried out using EliSpot assay (EliSpot Interferon-
γ Basis Kit; GenID GmbH, Strasburg, Germany).  
 Technical information 
Blood samples were collected in sodium citrate-treated tubes. PBMCs were isolated by 
density gradient centrifugation using Ficoll Hypaque (GE Healthcare Bio-Sciences AB, 
Uppsala, Sweden). An aliquot of 2x105 PBMCs was stimulated separately with 
phytohemagglutinin (PHA-P) at 5 µg/ml, with latent and lytic viral antigens at 5 µg/ml 
or culture medium only (negative control), for 20-24 hours in a CO2 incubator. Two 
commercially available latent and lytic EBV-specific peptide mix were used (GenID 
GmbH, Strasburg, Germany). In particular, peptide pools derived from Epstein-Barr 
nuclear antigens (EBNApp) such as EBNA3App (amino acid (AA) 158-166, 325-333, 
379-387, 458-466, 603-611) and EBNA3Cpp (AA 258-266, 281-290), latent membrane 
protein 2-derived single peptide (LMP2p, AA 426-434), BRLF1pp (AA 148-156, 134-
143, 28-37), BMLF1pp (AA 259-267, 280-288) and BZLF1p (AA 190-197) were used. 
In response to the antigen, T cells specifically release INF-γ, which is then bound by the 
antibody coated to the well. Cytokine release is visualized by an enzyme-labelled 
detection antibody. The end results are blue spots, each of which represents the area of 
one cell secreting several molecules of INF-γ. Coloured spots were counted using a 
computer-assisted image analysis system (AID EliSpot Reader System, Strassberg, 
Germany). The EliSpot results were interpreted as reported in Table 8.  
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Table 8: Interpretation of EliSpot results. 
PHA: phytohemagglutinin; SFCs: spot forming cells; CMI: cell-mediated immunity. 
 
The mitogen stimulation and the negative control were included to determine general T-
cell responsiveness (PHA-P > 50 spot forming cells (SFCs)/2x105 PBMCs) and 
background (< 10 SFCs/2x105 PBMCs), respectively. Cellular immunity to EBV in 
healthy EBV-seropositive individuals was also evaluated to check each assay run.  
 
According to the study design, EliSpot assay was performed at four fixed points after 
transplant (+60, +100, +180, +360 day) for all patients and when the patients exceeded 
10,000 copies/mL WB at the next visit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EBV LYTIC or/and 
LATENT ANTIGENS 
minus NEGATIVE 
CONTROL 
(SFCs/2x105  PBMCs) 
MITOGEN (PHA-P) 
minus NEGATIVE 
CONTROL 
(SFCs/2x105  PBMCs) 
 
EliSpot 
RESULT 
 
 
INTERPRETATION 
OF RESULTS 
<  5  < 50 Indeterminate CMI NOT DETECTED 
<  5 > 50 Negative EBV-specific CMI NOT DETECTED 
> 5 > 50 Positive EBV- specific CMI DETECTED 
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ADULT STUDY POPULATION 
EliSpot results were correlated with the incidence of EBV infection (Figure 17). 
 
Figure 17: EliSpot results and incidence of EBV infection - Adult patients. 
T1 (+60 day), T2 (+100 day), T3 (+180 day) and T4 (+360 day).  
 
 
 
 
Moreover, the results of immunological monitoring obtained in patients with active 
EBV infection were analyzed; the patients were grouped on the basis of the viral load 
detected (< 10,000 copies/mL WB and > 10,000 copies/mL WB) (Figure 18). 
 
 
 
 
 
 
 
 
  
Figure 18: Results of the immunologi
outcome - Adult patients.
 
The EliSpot results obtained during 
infection were taken into account.
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PAEDIATRIC STUDY POPULATION 
The results of combined virological-immunological monitoring of EBV infection in 
paediatric patients were analyzed in a fashion similar to the adult study population 
(Figures 20-22). 
 
Figure 20: EliSpot results and incidence of EBV infection - Paediatric patients. 
T1 (+60 day), T2 (+100 day), T3 (+180 day) and T4 (+360 day).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 21: Results of the immunological monitoring of EBV
outcome - Paediatric patients.
 
The EliSpot results obtained during active EBV infection or at the time
infection were taken into account.
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infection of two paediatric patients.
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indicates the LLQ of the real
WB and in PBMC samples were represented with open and filled circles, respectively. The line 
(  ) indicates the EliSpot assay cut
calculated using the formula “sample 
The bar (  ) indicates the EliSpot result.
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ASSOCIATION OF EBV-SPECIFIC T-CELL RESPONSES WITH PEAK VIRAL LOAD  
 
The association between EBV-specific CMI and EBV DNAemia peak were evaluated 
using Mann-Whitney test. Among patients who developed an active EBV infection, 
patients who had a positive EBV-EliSpot result - i.e. patients with detectable EBV-
specific CMI - were compared with patients who resulted EBV-EliSpot negative - i.e. 
patients without EBV-specific CMI. In the analysis, adult and paediatric patients were 
considered as a unique population. P-values < 0.05 were considered statistically 
significant.  
 
ADULT AND PAEDIATRIC STUDY POPULATION 
Median peak levels of EBV DNAemia were significantly higher for patients with 
negative EBV-EliSpot result (6 adult and 5 paediatric patients) than for patients with 
positive EBV-EliSpot result (9 adult and 6 paediatric patients) during active or at time-
point after the onset of EBV infection (P = 0.013) (Table 9). 
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Table 9: Association of EBV-specific CMI with peak viral load. 
 
EBV-EliSpot 
  
POSITIVE 
 
EBV-EliSpot 
 
NEGATIVE 
 
Peak viral load - copies/mL WB Peak viral load - copies/mL WB 
3,035 1,703 
3,174 3,386 
1,038 1,769 
2,657 55,769 
7,279 119,039 
1,611 74,374 
3,412 12,395 
1,033 89,724 
2,727 683,294 
10,521 45,548 
15,820 2,011,688 
10,966 
10,763 
14,787 
15,312 
 
n = 15; Median = 3,412 
 
n = 11; Median = 55,769 
 
 
Mann-Whitney test: z = 2.465 
                                    P = 0.013 
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4 
THE MANAGEMENT OF EBV INFECTION AND PTLD 
PREVENTION 
 
The management of EBV infection for patients with any value of EBV DNAemia > 
10,000 copies/mL was defined at individual patient level. Proven EBV-PTLD was 
defined according to the European Conference on Infections in Leukemia (ECIL) 
guidelines (37). Furthermore, cases of proven EBV-PTLD were classified according to 
the WHO criteria (34).  
 
ADULT STUDY POPULATION 
Among the six patients with high viral load, the three patients with detectable EBV-
specific CMI (patients number 17, 18 and 6) controlled EBV replication spontaneously 
and were all completely asymptomatic, while the three patients without EBV-specific 
CMI (patients number 7, 9 and 21) received anti-CD20 monoclonal antibody rituximab 
(2-4 administrations, at dose of 375 mg/m2/week) and 2 of them (2/3; 66.7%) developed 
EBV-related complications such as mononucleosis-like syndrome (fever and 
pharyngitis) at +474 day (patient n. 21) and EBV-PTLD with nodal involvement at +65 
day (patient n. 9) post-transplant. For all patients, the first dose of anti-CD20 therapy 
was administered at the peak of EBV DNA levels in WB. For two out of 3 patients, the 
peak of EBV DNA levels were reached simultaneously in both the two blood 
compartments; the median EBV DNA levels was equal to 74,374 copies/mL WB and to 
902 copies/1x105 PBMCs. For the remaining patient (patient number 21), the peak of 
viral load (74,374 copies/mL) was coincident with the first positivity; then the 
respective EBV DNA levels in PBMCs was not available. During the treatment, a 
decrease of EBV DNA levels in both blood compartments was observed in all patients 
who achieved negativity at the end of the anti-CD20 therapy. Nevertheless, in one 
patient (33.3%; patient number 9), despite pre-emptive anti-CD20 monoclonal antibody 
administration, the progression of EBV infection to overt disease was observed. The 
successful management of EBV-PTLD in this patient by virological-immunological 
monitoring of EBV infection, prompt diagnosis and early treatment is described in 
detail in a published Brief Communication (Transpl Immunol. 2016;34:60-64) that is 
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provided in Part VII - Annexes. In all the nine patients who maintained viral loads < 
10,000 copies/mL WB, EBV clearance occurred spontaneously and the EBV infection 
was asymptomatic. It is recalled that the majority of the patients (6/9; 66.7%) presented 
EBV-specific cellular immune responses during active EBV infection or at the first 
time-point after EBV DNAemia and 3 out of 9 patients (33.3%) presented general T-cell 
responsiveness.  
 
Virological, immunological and clinical data of adult patients with active EBV infection 
are summarized in Table 10. 
  
 
 
Table 10: Fifteen adult patients with active EBV infection - Virological, immunological and clinical data. 
Pt 
EBV 
serostatus 
D/R 
Onset of EBV 
infection 
Days post-TX 
EBV DNAemia 
Peak copies/mL 
WB 
EBV EliSpot 
result 
Management of EBV 
infection 
EBV-related complications Outcome 
9 D?/R+ 40 119,039 Negative Anti-CD20 therapy Nodal polymorphic and monomorphic 
DLBCL-like 
Alive 
21 D?/R+ 474 74,374 Negative Anti-CD20 therapy Mononucleosis-like syndrome  
(fever and pharyngitis) 
Alive 
7 D+/R+ 62 55,769 Negative Anti-CD20 therapy NO Alive 
17 D+/R+ 52 15,820 Positive Spontaneous Clearance NO Alive 
18 D+/R+ 20 10,966 Positive Spontaneous Clearance NO Dead 
Relapse of the original disease 
6 D+/R+ 42 10,521 Positive Spontaneous Clearance NO Alive 
16 D?/R+ 87 7,279 Positive Spontaneous Clearance NO Dead 
Relapse of the original disease 
5 D+/R+ 53 3,386 Negative Spontaneous Clearance NO Alive 
2 D+/R+ 35 3,147 Positive Spontaneous Clearance NO Alive 
27 D-/R+ 85 3,035 Positive Spontaneous Clearance NO Alive 
12 D+/R+ 47 2,657 Positive Spontaneous Clearance NO Alive 
19 D+/R+ 35 1,769 Negative Spontaneous Clearance NO Alive 
34 D-/R+ 95 1,703 Negative Spontaneous Clearance NO Alive 
23 D+/R+ 55 1,611 Positive Spontaneous Clearance NO Alive 
4 D+/R- 40 1,038 Positive Spontaneous Clearance NO Dead 
Relapse of the original disease 
Pt, patient; D, donor; R, recipient; TX, transplant; DLBCL: diffuse large B-cell lymphoma. 
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PAEDIATRIC STUDY POPULATION 
The 3 patients with EBV DNA load > 10,000 copies/mL WB and with detectable EBV-
specific CMI controlled EBV replication spontaneously and were all completely 
asymptomatic. Among the five patients without EBV-specific CMI, 2 (40%; patient 
number 3 and 20) cleared spontaneously EBV infection and had an asymptomatic 
infection; while 3 (60%; patient number 4, 17 and 21) received anti-CD20 monoclonal 
antibody rituximab (1-2 administrations, at dose of 375 mg/m2/week). Among the latter 
3 patients, for 2 patients (66.7%; patient number 4 and 17) the first dose of anti-CD20 
therapy was administered at the peak of EBV DNA levels that were reached 
simultaneously in both the two blood compartments; the median EBV DNA levels was 
equal to 386,509 copies/mL WB and to 1,678 copies/1x105 PBMCs. A decrease of EBV 
DNA levels in both blood compartments was observed during the treatment and at the 
end of the therapy they achieved EBV DNA negativity. Regarding the remaining patient 
(33.3%; patient number 21), he developed an EBV-PTLD with both nodal and extra-
nodal involvement, i.e. gastrointestinal tract (stomach and large bowel), at 45 days post-
transplant. In particular, a sudden increase in EBV DNA levels in both WB and PBMCs 
samples was observed during the weekly virological monitoring and anti-CD20 
monoclonal antibody rituximab was immediately administrated due to high viral load 
values (65,881 copies/mL WB and 1,021 copies/1x105 PBMCs), but the patient had 
clinically overt PTLD. During the treatment - after 2 rituximab administrations - PCR 
assay revealed an increase in EBV DNA up to a peak of viral load of 2,011,688 
copies/mL WB and 33,263 copies/1x105 PBMCs (+59 day post-transplant) and the 
patient showed persistence of symptoms and signs of PTLD. Furthermore, the patient’s 
clinical condition rapidly worsened, until reaching renal and respiratory failures. The 
patient died of multi-organ failure at +61 days post-transplant.  
In all the three patients who maintained viral loads < 10,000 copies/mL WB, a positive 
response to EBV was detected by EliSpot assay, EBV clearance occurred spontaneously 
and the EBV infection was asymptomatic.  
Virological, immunological and clinical data of paediatric patients with active EBV 
infection are summarized in Table 11. 
  
 
Table 11: Eleven paediatric patients with active EBV infection - Virological, immunological and clinical data. 
 
Pt 
EBV 
serostatus 
D/R 
Onset of EBV 
infection 
Days post-TX 
EBV DNAemia Peak 
copies/mL WB 
EBV EliSpot 
result 
Management of EBV 
infection 
EBV-related complications Outcome 
21 D+/R+ 33 2,011,688 Positive Anti-CD20 therapy 
- Nodal monomorphic DLBCL-like 
- Extra-nodal PTLD involving stomach 
and large bowel 
Dead 
Multi-organ failure 
17 D+/R+ 44 683,294 Negative Anti-CD20 therapy NO Alive 
4 D+/R+ 28 89,724 Negative Anti-CD20 therapy NO Alive 
20 D?/R+ 76 45,548 Negative Spontaneous Clearance NO Alive 
18 D+/R+ 25 15.312 Positive Spontaneous Clearance NO Alive 
8 D-/R+ 158 14,787 Positive Spontaneous Clearance NO Alive 
3 D+/R+ 56 12,395 Negative Spontaneous Clearance NO 
Dead 
Renal and respiratory failure 
2 D?/R+ 143 10,763 Positive Spontaneous Clearance NO Alive 
1 D+/R+ 85 3,412 Positive Spontaneous Clearance NO Alive 
19 D+/R+ 48 2,727 Positive Spontaneous Clearance NO Alive 
7 D+/R+ 40 1,033 Positive Spontaneous Clearance NO 
Dead 
Pneumonia 
       Pt, patient; D, donor; R, recipient; TX, transplant; DLBCL: diffuse large B-cell lymphoma. 
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CLINICAL OUTCOME - ADULT AND PAEDIATRIC STUDY POPULATION 
Survival of patients who underwent transplant was defined as the time (months) from 
transplantation to either death or last observation. In particular, the median clinical 
follow-up was of 15 months after allo-HSCT (range, 2-24). Survival estimates were 
obtained using the Kaplan-Meier approach. Comparison between groups - actively EBV 
infected versus EBV not infected patients - was performed using the log-rank test 
(Figure 23). 
 
Figure 23: Kaplan-Meier survival curves of transplanted patients by EBV reactivation. 
 
The dotted line represents patients who developed active EBV infection. The solid line 
represents patients not EBV infected. 
 
 
The 2-year survival estimate was 0.694 in actively EBV infected patients and 0.768 in 
not infected patients (log-rank test: chi2=1.40, p = 0.237) 
 
 
In our cohort, a total of 9 patients died (17.3%; 9/52). Specifically, 6 out of 33 (18.2%) 
adult patients died at a median time of 7 months (range, 5-11) after allo-HSCT; the 
causes of death were relapse of the original disease (n = 4), sepsis (n = 1) and bacterial 
pneumonia (imaging diagnosis; n = 1). Three out of 18 paediatric patients (16.7%) died 
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at a median time of 6.4 months (range, 2-15) after allo-HSCT; the causes of death were 
multi-organ failure (n=1), renal and respiratory failure (n = 1) and bacterial pneumonia 
(imaging diagnosis; n = 1).  
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 EBV-PTLD is an uncommon, but frequently fatal, complication after allo-HSCT and 
prompt diagnosis is necessary due to the rapid and often disseminated nature of the 
disease (40,49,77). EBV-PTLD may present with a diverse spectrum of clinical 
symptoms and signs, underscoring the need for a high index of suspicion in making the 
diagnosis (79). In the past, mortality rates due to EBV-driven disease was greater than 
90%. In fact, its treatment was limited to reduction of immunosuppression, 
chemotherapy or unselected donor lymphocytes infusion. Current treatment strategies, 
such as anti-CD20 monoclonal antibody rituximab and EBV-specific cytotoxic T 
lymphocytes therapy, have significantly reduced the risk of death in established EBV-
PTLD after stem cell transplant (80). Therefore, because the clinical presentation of 
PTLD is rather non-specific and because early diagnosis and treatment result in better 
outcome, there is great interest in developing tests to predict the development of the 
disease (79). In the present PhD project, 51 allo-HSCT recipients - 33 adult and 18 
paediatric - underwent combined virological-immunological monitoring for EBV 
infection during post-transplant period. Virological monitoring of EBV infection was 
performed for all patients by processing WB samples using a quantitative real-time 
PCR. EBV DNA quantification in both WB and in PBMC samples was adopted for 
patients who developed an active EBV infection. Immunological monitoring was 
carried out with INF-γ EliSpot that is an increasingly diffused clinical laboratory 
technique for monitoring the cellular immune responses to infections - with IFN-γ 
production by T cells having been shown to correlate with functional immunity (81). 
As reported in previous studies (67,68), we observed that active EBV infection is a 
frequent event after transplant: the overall incidence of EBV infection in our cohort was 
equal to 51% (45.5% in adult and 61.1% in paediatric recipients). Moreover, EBV 
infection with high viral load was observed in 53.8% of the actively infected patients (in 
40% of the adult and in 72.7% of paediatric recipients). As expected, the onset of EBV 
infection was observed during the early post-engraftment phase; in particular at a 
median time of 52 and 48 days post-transplant in adult and paediatric patients, 
respectively. Nevertheless, EBV DNAemia was first detected after 1 year post-
transplant in 1 adult patient (unrelated CB transplant), who developed a symptomatic 
EBV infection at +474 day (patient number 21). The finding of late-onset EBV 
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infection underlines the need to continue virological monitoring for patients who may 
be at high risk, e.g. as long as GVHD prophylaxis or treatments are administered.  
We identified that RIC HSCT in combination with selective depletion of recipient T 
cells with ATG relative to B-cells, was associated with higher frequencies of EBV 
infection, pointing to the same result recognized by other studies (82,83), including one 
of our previous studies entitled “Prospective Epstein-Barr virus-related post-transplant 
lymphoproliferative disorder prevention program in paediatric allogeneic hematopoietic 
stem cell transplant: virological monitoring and first-line treatment” (84) (Transpl Infect 
Dis. 2016;18:44-54; see paper in Part VII - Annexes). This probably reflects the 
profound immunosuppression following RIC HSCT, together with the incomplete 
ablation of recipient-derived B-cells. In our cohort of patients, we were not able to 
evaluate the contribution of EBV serology mismatch between donor and recipient to 
developing of post-transplant EBV infection because donor EBV serology was available 
for 42 out of 51 EBV seropositive patients (n = 7 D-/R+ and 35 D+/R+). The recipients’ 
EBV serostatus at the time of transplant was also not taken into consideration for the 
analysis, because only one patient resulted EBV-seronegative (D+/R-; adult patient 
number 4). Finally, none of the patients underwent splenectomy, therefore comparison 
between this clinical parameter and EBV infection could not be evaluated. 
Measurement of EBV DNA load by quantitative real-time PCR assays can be a 
sensitive aid to PTLD diagnosis, but unfortunately it is not always specific for disease 
onset (73). In general, assays using PBMCs are the most sensitive and predict EBV 
disease at the earliest time, but owing to technical aspects, it would be preferable to test 
EBV DNA load in WB samples (73, 85). In agreement with previous studies (84,86,87), 
in both the adult and paediatric study populations, we obtained a significant correlation 
between EBV DNA levels in WB and PBMC samples (r = 0.787 and r = 0.976, P < 
0.001, respectively). Moreover, a similar kinetics of EBV DNA load in the two different 
blood compartments of the patients was observed: peak DNA levels were reached 
simultaneously and the times of DNA clearance were comparable. In addition, both 
specimen types appeared to be equally informative to assess the risk of patients to 
develop PLTD in the clinical setting. In fact, in the patients, EBV infection was 
managed with the use of anti-CD20 monoclonal antibody rituximab at the peak of DNA 
levels or when the EBV DNA levels exceed the EBV DNA threshold levels for 
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preemptive therapy defined in GITMO guidelines (i.e. 10,000 copies/mL WB and > 
1,000 copies/1x105 PBMCs) that was occurred simultaneously in both the blood 
compartments. Therefore, among the study population on the basis of EBV DNA levels 
detected in WB samples, we were able to identify 5 patients (19.2%) eligible for pre-
emptive therapy. In the 80% of cases (4/5 patients), the first-line treatment for EBV-
related disease was effective in controlling viral proliferation and avoiding progression 
into EBV-PTLD. The remaining patient, despite the administration of pre-emptive anti-
CD20 therapy developed an EBV-PTLD with nodal involvement. However, the early 
use of the anti-CD20 monoclonal antibody has proven to be a safe and effective 
treatment strategy for proven EBV-PTLD. In fact, a decrease in EBV-DNA load of 2 
log of magnitude in the first two weeks of treatment was observed and EBV infection 
was cleared at the end of the therapy. A complete disease remission, two months after 
the EBV-PTLD diagnosis and four doses of anti-CD20 monoclonal antibody was 
observed and both the blood compartments tested negative for EBV DNA. EBV-PTLD 
persists in remission 10 months following the initial diagnosis. Another case of EBV-
PTLD in the early post-transplant period was observed, but with an aggressive clinical 
course. In particular, this paediatric patient showed early viral reactivation followed by 
rapid progression to full-blown PTLD: before preemptive therapy could be started, the 
aforementioned patient already had clinical signs of overt PTLD. The patient developed 
an EBV-PTLD with both nodal and extra-nodal involvement at 45 days post-transplant, 
no response ensued to rituximab administrations and the patient died 15 days after 
EBV-PTLD diagnosis. These findings are in agreement with the literature data. In fact, 
in a recent comprehensive review of reported cases regarding the outcome of treatment 
of EBV-PTLD in HSCT recipients, the successful prevention of PTLD was reported in 
89.7% of the patients receiving rituximab as preemptive therapy (50). Furthermore, in 
several studies, rituximab administered for treatment purposes yielded a 40-68% 
response rate (47-49). Finally, the occurrence of rapid progression to lethal PTLD was 
also reported by other investigators (78). Accordingly, the overall frequency of biopsy-
proven EBV-PTLD in our cohort was 3.9% (2/51 patients), which is in line with other 
recent reports (41, 88). 
The pattern of general and EBV-specific T-cell reconstitution in our cohort was 
analyzed. We observed that the higher number of indeterminate results was present 
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during the early post-transplant period, that over time the immune response became 
more sustained and that concurrently the percentage of patients with active EBV 
infection clearly decreased. Furthermore, as observed by other authors (89), compared 
to adult recipients, paediatric had faster CMI reconstitution. In fact, all paediatric 
patients developed general CMI within 100 days post-transplant versus 360 days post-
transplant of the adult recipients. In our cohort, the 42.4% of the adult and the 44.4% of 
the paediatric patients showed EBV-specific CMI at 60 days post-transplant and it may 
be due to the rate of EBV infection occurred during the first two months post-transplant. 
In fact, it has been suggested that the occurrence of EBV DNA positivity may 
implement the responsiveness of the patient’s immune system (81); in our cohort, the 
33% and 50% of adult and paediatric patients developed respectively an active EBV 
infection within 60 days post-transplant. Moreover, as reported by other studies (81,90), 
we observed that EBV-specific T-cell responses were not constant; 29.4% of the adult 
patients with a positive EBV-EliSpot result subsequently had a negative result.  
EliSpot responses to latent and lytic EBV-specific peptide mix were evaluated for each 
patient. In healthy individuals the hierarchy of T-cell responses against the different 
latent and lytic EBV antigens is well established (91), whereas the analysis of the EBV-
specific T-cell responses in patients after transplant remains largely unexplored (74). In 
our cohort, we did not observe a distinct pattern of distribution of EBV-specific T-cell 
responses to lytic and latent antigens (data not shown). A similar result was obtained in 
a solid organ transplant setting, where the authors reported that the distribution of EBV-
specific T-cell responses observed in transplant recipients was altered compared to that 
observed in healthy individuals (92). The correlation between EBV-specific T-cell 
responses and EBV infection, specifically in relation to viral load and clinical course 
was also studied. The lack of EBV-specific T-cell immune responses during the active 
EBV infection or at the time-point after the onset of infection was associated with a 
significantly higher median peak level of EBV DNA in blood and a greater severity of 
EBV infection. In fact, the 54.5% of the patients without detectable EBV-specific CMI 
needed anti-CD20 therapy because they had not been able to control EBV replication 
spontaneously and the 27.2% developed EBV-related complications including, as 
previously reported, a lethal PTLD. On the contrary, all patients who had a detectable 
EBV-specific CMI controlled EBV replication spontaneously and were all completely 
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asymptomatic. As reported by other studies (89,93), these findings suggest that post-
transplant EBV-specific CMI is a critical determinant controlling the EBV infection and 
consequently the virus-related complications.  
In our cohort, the majority cause of death was the relapse of the original disease, 
accounting for the 44.4% of cases. As other authors, we did not observe detrimental 
effect of EBV active infection on survival patient (69,94). 
 
In conclusion, the present study suggests that a close EBV DNAemia monitoring may 
be a useful strategy to control EBV-related PTLD in high risk patients. In fact, WB 
proved to be a suitable clinical specimen to monitor EBV DNA load after allo-HSCT 
for the management of post-transplant EBV infection and PTLD prevention. Moreover, 
this study confirms that RIC in combination with in vivo T-cell depletion is a 
particularly important risk factor for the developing of EBV infection. Finally, our data 
showed the potential usefulness of measuring EBV blood replication combined with the 
specific viral cellular-immunity in allo-HSCT recipients in order to identify the patients 
at higher risk for EBV-PTLD who would benefit from appropriate pre-emptive 
interventions. 
 
In the light of the results obtained, we propose in our Centre at St. Orsola-Malpighi 
University Hospital, the following combined virological-immunological monitoring 
schedule in order to improve the management of EBV infection in those patients at 
higher risk of developing EBV-related complications. When EBV-DNA load is over 
10,000 copies/mL WB and in the absence of EBV-related signs or symptoms, the EBV-
EliSpot assay could be required to evaluate EBV-specific T-cell recovery kinetics. 
EBV-EliSpot result should be an important second parameter for identifying patients 
who may cleared spontaneously EBV DNA load (positive EBV-EliSpot result) or who 
will benefit most from pre-emptive interventions (negative EBV-EliSpot result). In the 
latter case, a closer virological monitoring should be performed and the immunological 
assay should be repeated a month later in order to detect the reconstitution or not of 
EBV-specific CMI. Such a strategy requires confirmation into the routine clinical 
practice where it will be applied during the next years in order to obtain further 
evidence regarding the usefulness of this new tool in the transplant settings. 
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Tonitoring Cytomegalovirus T-Cell Immunity in Small
owel/Multivisceral Transplant Recipients
. Chiereghin, L. Gabrielli, C. Zanfi, E. Petrisli, A. Lauro, G. Piccirilli, F. Baccolini, A. Dazzi, M. Cescon,
.C. Morelli, A.D. Pinna, M.P. Landini, and T. Lazzarotto
ABSTRACT
Background. Cytomegalovirus (CMV) is a major cause of graft failure and posttrans-
plantation mortality in intestinal/multivisceral transplantation. CMV infection exhibits a
wide range of clinical manifestations from asymptomatic infection to severe CMV disease.
Study’s Purpose. The purposes of this study were to assess the utility of measuring
CMV-specific cellular immunity in bowel/multivisceral transplant recipients and to provide
additional information on the risk of infection and development of CMV disease.
Methods. We studied 10 bowel/multivisceral transplant recipients to investigate the
kinetics of CMV infection using real-time polymerase chain reaction (on blood and biopsy
tissue samples) and CMV-specific T-cell reconstitution by Enzyme-linked ImmunoSPOT
Assay (ELISPOT) that enumerates Interferon-–secreting CMV-specific T cells upon in
vitro stimulation with viral antigens (pp65 and IE-1).
Results. All patients were seropositive for CMV. According to the pattern of T-cell
reconstitution occurring either within the first month after transplantation or later,
patients were classified as early (n  7) or late responders (n  3). Clinically, early
responder patients (3/7; 43%) experienced asymptomatic or mild CMV infections, whereas
all late responders (3/3; 100%) developed moderate or severe CMV disease. A reduction
in mean and peak CMV viral load was observed in early responders, whereas the onset
time of infection did not differ significantly between early and late CMV responders.
Conclusions. A good and early reconstitution of CMV-specific T-cell immune responses
after transplantation is a critical determinant in controlling CMV infections. Simultaneous
monitoring of CMV infection and CMV-specific T-cell immunity predicts T-cell–mediated
control of CMV infection.
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Betaherpesvirinae, is one of the most common op-
ortunistic pathogens complicating the care of transplant
ecipients, and a major cause of posttransplantation mor-
idity and mortality.1 CMV infections in solid-organ trans-
lant recipients give rise to a broad spectrum of clinical
anifestations from asymptomatic infection to severe dis-
ase.2 Prevention strategies have included preemptive and
rophylactic approaches that have significantly decreased
he burden of CMV disease following organ transplanta-
ion.3
CMV replication is largely controlled by cellular immu-
ity.4 Over the past decade, conceptual and technical
dvances have substantially improved T-cell assays; it is now gna, Italy. E-mail: tiziana.lazzarotto@aosp.bo.it
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70 CHIEREGHIN, GABRIELLI, ZANFI ET ALossible to functionally characterize viral- specific T-cell
mmunity.5 Several studies have analyzed the correlation
etween CMV-specific T-cell responses and CMV infec-
ions by evaluating CD4 and CD8 T cell immune
esponses in recipients of kidney, liver, lung, hematopoietic
tem cell or heart transplants. The results have demon-
trated the importance of CMV-specific CD4 and CD8
-cell responses in the control of CMV infections after
ransplantation.3,6–19 The aim of our study was to assess the
tility of monitoring CMV-specific cellular immunity in
owel/multivisceral transplant recipients to evaluate the
isk of the development of severe CMV infection.
ETHODS
election and Description of Participants
rom March 2005 to January 2009, we enrolled 10 patients
ndergoing intestinal small bowel/multivisceral transplantation.
he study population comprised recipients of 8 isolated intestinal
nd 2 multivisceral transplants (without liver). All patients were
dults, with a male/female ratio of 7:3 and a mean age of 34 years.
ll transplant recipients and their respective donors were seropos-
tive for CMV at the time of transplantation (D/R).
echnical Information
ll patients received prophylaxis with intravenous ganciclovir (5
g/kg per dose twice a day) and intravenous CMV immune
lobulin (3500 U every other day) for 2 weeks, followed by oral
alganciclovir (450 mg/d) until the twelfth month after transplan-
ation.
The immunosuppressive regimen was based on induction ther-
py with alemtuzumab (Campath, Genzyme Europe BV-NL) and
ow-dose tacrolimus (Prograf, Astellas Pharma US, Deerfield, Ill,
SA) maintenance treatment. Alemtuzumab was administered in
doses of 0.3 mg/kg after graft reperfusion and on day 3.
acrolimus, initially intravenous then oral, was administered at a
ose of 0.075 mg/kg twice daily with target tacrolimus trough blood
evels of 8–12 ng/mL. Steroids were added in cases of acute cellular
ejection episodes.
Routine follow-up of CMV infection was performed on blood
amples using CMV pp65 antigenemia assay as previously de-
cribed in detail20 and on intestinal biopsy specimens using real-
ime polymerase chain reaction (PCR; Q-CMV Real Time Com-
lete Kit, Nanogen Advanced Diagnostics SRL, Turin Italy).
Blood samples were collected every week during the first 3
onths, every 2 weeks until the sixth month, and monthly from
hen onward. Intestinal biopsies were performed during routine
leoscopy to check rejection status. Additional blood and biopsy
amples were taken if clinically indicated. Pre-emptive CMV
herapy was started when the antigenemia count was 1 positive
ell/200,000 polymorphonuclear leukocytes in peripheral blood
PMNLs) or when a positive CMV tissue load was 100 copies/g
NA. The findings were correlated with suspicious histology
nd/or clinical indications. Retrospectively, we performed virolog-
cal and immunological monitoring on blood samples collected
uring the first 4 months posttransplantation. Virological surveil-
ance was performed using CMV quantitative real-time PCR
Q-CMV Real Time Complete Kit, Nanogen Advanced Diagnos-
ics SRL) at the time of transplantation and then weekly; we
xamined 140 blood samples. The immunological surveillance was
arried out using Enzyme-linked ImmunoSPOT assay (ELISPOT; eliSpot Interferon- Basis Kit; Nanogen Advanced Diagnostics
RL) on blood samples collected at the time of transplantation and
hen monthly; we examined 50 samples.
MV Quantitative Real-Time PCR
NA was extracted from 100 L of ethylenediaminetetraacetic
cid (EDTA)-anticoagulated whole blood using the NucliSens
asyMAG System (bioMerieux, Marcy l’Etoile, France) according
o the manufacturer’s instructions. An aliquot of 5 L of these
xtracted DNA samples was used for the CMV quantitative
eal-time PCR on the ABI Prism 7300 Real Time PCR System (PE
pplied Biosystem, Foster City, Calif, United States). Primers and
robes are located in the highly conserved major immediate early
ntigen (MIEA) region of the CMV genome. The limit of assay
etection was 500 copies/mL of blood; CMV load was reported as
umber of copies/mL.
LISPOT Assay
his assay enumerates interferon--secreting CMV-specific T cells
pon in vitro stimulation with viral antigens. ELISPOT assays
rovided CMV-specific quantitation of both CD4 and CD8
ells. Blood samples were collected in sodium citrate–treated tubes.
eripheral blood leukocites (PBLs) were isolated by density gradi-
nt centrifugation using Ficoll-Hypaque (GE Healthcare Bio-
ciences AB, Uppsala, Sweden). An aliquot of 2 105 T cells were
ncubated in the anti–INF- antibody coated wells together with
MV-specific antigens (IE1 and pp65-UL83) for 20–24 hours in a
O2 incubator. In response to the antigen, T cells specifically
elease INF-, which is then bound by the antibody coated to the
ell. Cytokine release is visualized by an enzyme-labeled detection
ntibody. The end results are blue spots, each of which represents
he area of one cell secreting several molecules of INF-.21 Colored
pots were counted using a computer-assisted image analysis
ystem (AID EliSpot Reader System, Strassberg, Germany). Neg-
tive and positive controls were included to check each sample as
ell as the whole assay. Cells incubated with medium alone and
ith phytohemagglutinin (PHA-P) mitogen were used as negative
nd positive controls, respectively.
A response was considered positive when the number of spot-
orming cells (SFCs) in the wells stimulated with peptides was 5.
he CMV T-cell immune response was considered weak when the
umber of SFCs was between 5 and 20, good between 20 and 100,
nd very good 100. The assay could only be performed if there
as a sufficient quantity of isolated lymphocytes (2  106 cells) in
he collected blood (20 mL).
tatistical Techniques
wo-group comparisons of mean values were statistically assessed
sing Student t test for independent samples. P  .05 was consid-
red significant.
ESULTS
ccording to the pattern of T-cell reconstitution posttrans-
lantation, there were 10 recipients classified as having
ither an early or a late CMV-specific T-cell response. Early
nd late CMV responders showed reconstitution of CMV-
pecific T-cell responses within and after 1 month posttrans-
lantation, respectively. Seven of the 10 transplant recipi-
nts (70%) displayed early CMV-specific T-cell responses,
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CMV T-CELL IMMUNITY 71hereas 3 (30%) had late CMV-specific T-cell responses, as
etected using the ELISPOT assay (Table 1).
The virological tests showed CMV infections in 6 of the
0 recipients (60%). Specifically, 3 of the 7 early CMV
esponders (43%) developed CMV infections; whereas all
3/3; 100%) late CMV-specific response patients developed
MV infections (Table 1).
Clinically, 2 of the 3 infected patients in the group of
arly CMV responders were asymptomatic and 1 suffered
rom a mild CMV infection (fever). All late CMV respond-
rs developed symptomatic CMV infections: 1 mild (fever)
nd 2 severe. One of these 2 patients underwent graftectomy
or CMV enteritis with rejection. The patient died due to
epsis on day 69 posttransplantation. The other patient with
evere symptomatic infection developed CMV pneumonia
nd died on day 125 after transplantation from sepsis.
The early responder patient with CMV infection died
ue to fungal sepsis at 150 days after transplantation. (The
ungus was not identified.) The mortality rate among CMV-
nfected patients was 50% (3/6 patients) and the causes of
eath were sepsis in all cases. No patients without CMV
nfection died.
Focusing our attention on patients with CMV infection
e observed that the time to when CMV DNA was first
etected after transplantation did not differ significantly
etween early and late responders (mean, 82 days vs 62
ays, respectively; Table 1). In contrast, mean and peak
evels of CMV DNA in blood were significantly higher for
ate than for early responders (Table 2).
Figure 1 shows a patient with good reconstitution of
MV-specific T-cell responses in the first month posttrans-
lantation (early CMV responder). The CMV-specific T-
ell response was also good/very good over the following 4
onths. Monitoring of CMV infection in the first 4 months
osttransplantation disclosed no infection (viral load in the
Table 1. Association of Early Vs. Late CMV-Specific T-Cell
Response With Infection and Onset of Infection
T-Cell
Response
No. of
Patients
No. of
CMV-Infected
Patients (percentage)
Onset of Infection
Days Posttransplantation
Mean
Early 7 3 (43%) 82
Late 3 3 (100%) 62
Total 10 6
P 0.549* (64.99–104.99)†
*Student test.
†95% confidence interval of the difference between the means.
Table 2. Association of Early Vs. Late CMV-Specific T-Cell Resp
T-Cell Response No. of Patients with CMV Infection
Early 3
Late 3
Total 6
P*Student’s test.
†95% confidence interval of the difference between the means.lood was  500 copies/mL). This patient has had a good
linical outcome to date (3 years posttransplantation).
Figure 2 reports an example of a patient who did not
econstitute CMV-specific T-cell responses within the first
onth after transplantation (as late CMV responder). A
eak response (5  SFCs  20) was also present over the
ollowing weeks. At 3 months posttransplantation the
atient developed a CMV infection with a high viral load
n the blood (peak viral load, 152,300 copies/mL), although
he patient was receiving prophylaxis treatment. Clinically,
his patient experienced a severe symptomatic CMV infec-
ion presenting as CMV pneumonia, which was unsuccess-
ully treated with intravenous ganciclovir, and died due to
epsis on day 125 posttransplantation.
ISCUSSION
y virtue of its unique immunological, physiological, and
acteriological nature, the intestine remains the most diffi-
ult abdominal organ to transplant.22 The vigorous rejec-
ion caused by the particularly high immunogenicity of the
ymphocyte-rich intestinal allograft and the unique capacity
f the intestine to mount a graft-versus-host disease
GVHD) demand greater degrees of immunosuppression
n intestinal than recipients of other transplanted or-
ans.22,23 Advances in immunosuppressive therapy have
engthened the survival of intestinal transplant recipients,
ut the strong immunosuppressive protocols have been
ssociated with an increased risk of developing tissue-
nvasive infections.24 Among viral infections, CMV is a
ajor cause of graft failure and posttransplantation mor-
With Viral Blood Load in the First 4 Months Posttransplantation
lood Load Copies/mL
Mean
Peak Viral Blood Load Copies/mL
Mean
2,500 4,900
37,000 118,000
2* (69324–324)† 0.029* (207676–18523)†
ig 1. Early CMV responder. Kinetics of CMV-specific T-cell
econstitution and CMV infection during the first 4 months
osttransplantation. Abbrevations: VGCV, valganciclovir; SFC,
pot-forming cells.onse
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72 CHIEREGHIN, GABRIELLI, ZANFI ET ALality in intestinal/multivisceral transplantation, playing a
ajor role in the first 6 months after transplantation.25,26
We monitored 10 small bowel/multivisceral transplant
ecipients, observing that the total prevalence of CMV
nfection in the first 4 months after transplantation was 60%
espite prophylactic therapy. All of these patients were
MV-seropositive. Studying the correlation between CMV-
pecific T-cell responses and CMV infections, we observed
hat CMV infections occurred in 3 of the 7 early CMV
esponders (43%) and in all 3 late CMV responders
100%). Moreover, moderate and severe CMV infections
ere strongly associated with late CMV responders (1/3
nd 2/3 patients, respectively); however, early responders
eveloped asymptomatic (2/3 patients) or mild (1/3 pa-
ients) CMV infections. Therefore, a CMV-specific T-cell
mmune response in the first month after transplantation
as associated with a lower rate and lesser severity of CMV
nfection. In addition, the CMV-specific T-cell immune
esponse in the first month after transplantation was asso-
iated with a reduced mean and peak CMV viral load in the
lood. This observation suggests that early reconstitution of
MV-specific cellular immunity posttransplantation is a
ritical determinant controlling CMV infection, although
he onset of infection did not differ significantly between
arly and late CMV responders.
In addition, all of our transplant recipients received
rolonged valgancyclovir prophylaxis. Only 3 of 10 patients
ailed to reconstitute CMV T-cell responses within the early
eriod, which may suggest that the prolonged prophylaxis
id not influence the evolution of the T-cell response.
As already implemented in other organ transplants, we
elieve that immunologic monitoring in addition to virolog-
cal monitoring is needed in the highly susceptible intes-
inal transplant recipients to ensure the best manage-
ent of CMV infection. Immunological surveillance
fter transplantation may serve to select a subgroup of
atients at high-risk of CMV-related disease requiring
loser viral monitoring and more careful follow-up. Be-
ause prolonged prophylaxis increases the cost of drugs
ig 2. Late CMV responder. Kinetics of CMV-specific T-cell
econstitution and CMV infection during the first 4 months
osttransplantation. Abbrevations: VGCV, valganciclovir; SFC,
pot-forming cells.nd may give rise to antiviral resistance and toxicity,
p
sreatment could be tailored to the individual patient,
aintaining prophylaxis in high-risk patients and sus-
ending therapy earlier in those at lowest risk. Addi-
ional prospective studies are required to guide safe
hanges in anti-CMV prophylaxis.
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OriginalClinicalScienceçLiverImmunosuppression Modifications Based on an
Immune Response Assay: Results of a
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Background.An immune function assay showspromise for identifying solid organ recipients at risk for infection or rejection. The
following randomized prospective study was designed to assess the clinical benefits of adjusting immunosuppressive therapy in
liver recipients based on immune function assay results.Methods. Adult liver recipients were randomized to standard practice
(control group; n = 102) or serial immune function testing (interventional group; n = 100) performed with a commercially available in
vitro diagnostic assay (ImmuKnow; Viracor-IBT Laboratories, Lee's Summit, MO) before transplantation, immediately after surgery
and at day 1, weeks 1 to 4, 6, and 8, andmonths 3 to 6, 9, and 12. The assay was repeated within 7 days of suspected/confirmed
rejection/infection and within 1 week after event resolution. Results. Based on immune function values, tacrolimus doses were
reduced 25% when values were less than 130 ng/mL adenosine triphosphate (low immune cell response) and increased 25%
when values were greater than 450 ng/mL adenosine triphosphate (strong immune cell response). The 1-year patient survival
was significantly higher in the interventional arm (95% vs 82%; P < 0.01) and the incidence of infections longer than 14 days after
transplantation was significantly lower among patients in the interventional arm (42.0% vs. 54.9%, P < 0.05). The difference in in-
fection rates was because of lower bacterial (32% vs 46%; P < 0.05) and fungal infection (2% vs 11%; P < 0.05). Among recipients
without adverse events, the study group had lower tacrolimus dosages and blood levels.Conclusions. Immune function testing
provided additional data which helped optimize immunosuppression and improve patient outcomes.
(Transplantation 2015;99: 1625–1632)Most solid organ transplant recipients require lifelongtreatment with potent immunosuppressant medica-
tions which reduce the risk of allograft rejection but increase
patient morbidity and mortality after long-term use. Com-
monly reported adverse events associated with immunosup-
pressive therapy include hypertension (77%), hyperlipidemia
(66%), renal toxicity (50%), obesity (40%), cancer (26%),
and diabetes mellitus (22%).1 During the immediate postop-
erative period, overimmunosuppression is associated with a
greater incidence of infection and sepsis. Optimal immuno-
suppressive therapy balances the risk of rejection caused byReceived 1 July 2014. Revision requested 7 November 2014.
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Copyright © 2015 Wolters Kluwer Han inadequately suppressed immune system and the risk
of infection, cancer, and drug toxicity caused by over-
immunosuppression. Drug therapymust be carefully tailored
to each transplant recipient because of the differences in race,
sex, metabolism, multiple drug regimens, and type of allo-
graft transplant.
An immune function assay has been cleared by the U.S.
Food and Drug Administration for measuring changes in
cell-mediated immunity in solid organ transplant recipients
undergoing immunosuppressive therapy (ImmuKnow; Viracor-
IBT Laboratories, Lee's Summit, MO).2 Numerous retro-
spective and prospective studies have demonstrated the
ability of this immune function assay—when used withcontributed new reagents and analytic tools. V.B. participated in data analysis. P.
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1626 Transplantation ■ August 2015 ■ Volume 99 ■ Number 8 www.transplantjournal.comother biomarkers—to identify patients at risk of organ
rejection3–7 and infection5,8–15 across a range of organs.
The assay can also distinguish between rejection and recur-
rent hepatitis C infection,16 facilitate conversion from one
immunosuppressant to another,17,18 and may be useful for
identifying patients with increased risk of short-term mortal-
ity,19 predicting posttransplant recurrence of hepatocellular
carcinoma (HCC)12 and evaluating immune status of pa-
tients with de novo malignancy.20
Previously, the role of this immune function test was retro-
spectively assessed for monitoring and adjustment of immu-
nosuppression in patients after orthotopic liver transplant.21
Based on those promising results, a prospective randomized
study was designed to assess the clinical benefit of adjusting
immunosuppressive therapy based on immune function as-
say results compared to a group managed with the standard
clinical practice. The outcome data of this analysis are re-
ported here.
MATERIALS AND METHODS
Study Design
This was a prospective, randomized, parallel, blinded, in-
terventional trial comparing the outcomes of adult liver
transplant recipients whose immunosuppressive therapy is
managed by previous standard practice (control group) or
by adjusting therapy based on cell-mediated immune re-
sponses determined by the immune function assay (inter-
ventional group). Outcomes were assessed 12 months after
transplantation among liver recipients enrolled between
July 2008 and March 2013. This study was approved by
the local hospital ethics committee.
Patients
Consecutive adult liver transplant recipients not partici-
pating in other studies and who provided informed consent
were enrolled. There were no exclusions pertaining to the
cause of end-stage liver disease (ESLD). To ensure treatment
groups were balanced, enrolled patients were randomized
1:1 based on the cause of ESLD,model for end-stage liver dis-
ease (MELD) score, the presence of HCC, and sex. A signifi-
cant number of liver recipients with ESLD secondary to
hepatitis C virus (HCV) infection were not included because
of a parallel study.
Immune Function Testing
Immune function testing was performed with a commer-
cially available in vitro diagnostic assay cleared by the U.S.
Food and Drug Administration that uses whole blood sam-
ples collected in sodium heparin vacuum tubes (ImmuKnow;
Cylex, Inc., now part of ViraCor-IBT Laboratories, Inc.,
Lee's Summit, MO). The assay is designed to detect cell-
mediated immunity by measuring the concentration of ATP
from CD4+ cells after stimulation and was performed
as directed by the manufacturer.2 Values of 225 ng/mL
or lower ATP suggest a low immune cell response and values
of 525 ng/mL or higher ATP suggest a strong immune
cell response.22
To prospectively evaluate the management of immunosup-
pression based on their immune function assay values, all pa-
tients were tested with the assay before liver transplantation,
immediately after surgery, and at each clinic visit occurring at
approximately day 1, weeks 1 to 4, 6 and 8, and months 3 toCopyright © 2015 Wolters Kluwer6, 9, and 12.2 The assay was repeated within 7 days of a
suspected or confirmed rejection or infection and again
within 1 week after resolution of the event.
Intervention
Immunosuppressive therapy consisted of tacrolimus and a
steroid taper according to standard practice at our center.
The steroid tapering was planned as follows: 1 g methylpred-
nisolone before liver reperfusion, 200mg at day 1, 160mg at
day 2, 120 mg at day 3, 80 mg at day 4, and 40 mg at day 5.
Subsequently, oral prednisone 25 mg was administered daily
and gradually stopped during the next 6 months.
The target tacrolimus plasma levels were 8 to 12 ng/mL at
4 months and 6 to 10 ng/mL after 4 months.23 Steroids were
not tapered in patients transplanted for primary biliary cir-
rhosis, autoimmune cirrhosis, or primary sclerosing cholangitis.
In cases of renal impairment (defined as plasma creatinine >
1.5 mg/dL), tacrolimus levels were reduced to 4 to 6 ng/mL
and mycophenolic acid or a mechanistic target of rapamycin
(mTOR) inhibitor was added.
Based on immune function assay values and our clinical
experience, the following was used to adjust therapy in the
Interventional group: the tacrolimus dose was reduced by
25%when immune function valueswere less than 130ng/mL
ATP (low immune response) and increased by 25%when as-
say values were greater than 450 ng/mL ATP (strong immune
response). Tacrolimus dosage changes were made until the
assay values stabilized between 130 and 450 ng/mL ATP.
These values were previously documented as thresholds for
risks of infection and rejection, respectively, with a value of
280 ng/mL corresponding with the greatest negative predic-
tive value for either event.7 Treating physicians in the control
group were blinded to the immune assay results, and immu-
nosuppression was adjusted according to standard practice.
Adverse Events
Rejection was diagnosed by biopsy and graded as indeter-
minate, mild, moderate, or severe according to the Banff
schema.24 Infection was defined as a microbial phenomenon
characterized by an inflammatory response (pain, heat, red-
ness, swelling)25 to the presence of microorganisms and were
classified according to standardized criteria.26 In this sense,
bacterial, viral, parasitic, andmycotic infectionswere included.
Systemic inflammatory response syndrome was defined as
a systemic inflammatory response to a variety of severe clin-
ical insults, and it was considered to be manifested by the
presence of 2 or more of the following conditions: (1) body
temperature greater than 38 °C or less than 36 °C; (2) heart
rate greater than 90 beats/min; (3) respiratory rate greater
than 20/min or PaCO2 less than 32 mm Hg; (4) white blood
count greater than 12,000/mm3 or less than 4000/mm3. Sep-
sis was defined as a systemic response to infectionmanifested
by systemic inflammatory response syndrome,27 and it was
deemed severe in presence of organ dysfunction or when re-
quiring hospitalization. Cytomegalovirus (CMV) viral syn-
drome was defined when CMV-DNA or CMV-antigen
positivitywasassociatedwith fevergreater than38°C for2days
of unexplained origin, leucopenia, myalgia, or arthralgia.28
Infectious Screening Protocol
The CMV-DNAwas routinely measured once weekly dur-
ing the hospital stay, aswell as hepatitis B surface antigen and
hepatitis B surface antibody in patients who underwent liver Health, Inc. All rights reserved.
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received a graft from a HBcAb donor. After discharge, pa-
tients were followed in a dedicated outpatient clinic. Com-
plete blood count, renal and hepatic function, urinalysis,
andCMV-DNAweremeasured at every visit. Hepatitis B sur-
face antigen, hepatitis B surface antibody, HBV-DNA, and
HCV-RNA were also measured if clinically indicated (ie,
HBV-positive patients, HCV-positive patients, and recipients
of HBcAb-positive graft). Blood, urine, ascites, and broncho-
alveolar cultures were performed any time there was clinical
suspicion of infection but surveillance cultures were not rou-
tinely performed.More specific microbiological tests, such as
galactomannan Ag determination and interferon- γ release
assay for latent tuberculosis infection, were performed as
second-line tests. Chest roentgenograms were performed
any time there was the clinical suspicion of pulmonary infec-
tion. Computed tomography (CT) was the second-line test if
the roentgenogram was dubious. Abdominal ultrasound or
CT scan was performed any time there was a clinical suspi-
cion of intra-abdominal infections and to rule out arterial/
biliary graft complications.
Infection Prophylaxis Protocol
The followingmedications were administrated as infection
prophylaxis:
• Trimethoprim/sulfamethoxazole tablets 60 mg/800 mg, 3
times weekly for 12 months after liver transplantation as
Pneumocystis carinii prophylaxis,
• Nystatin oral suspension 100,000 IU/mL, 5 mL 4 times daily
until steroid treatment interruption as candidiasis prophylaxis,
• Intravenous ganciclovir at a dose based on creatinine clear-
ance until postoperative day 7 in cases of donor/recipient
CMV serology mismatch (donor IgG+/recipient IgG−); subse-
quently, oral valganciclovir at a dose based on creatinine
clearance for 12 months after liver transplantation. No
CMV infection prophylaxis is routinely administered to
IgG+ recipients.
Infection Treatments
An empiric antimicrobial therapy was started in case of
clinical suspicion of infection. Blood and urine cultures were
performedwhen clinically indicated and ascites and broncho-
alveolar lavage cultures were performed when available.
More specific microbiological tests were performed as sec-
ond line tests (galactomannan Ag culture; QuantiFERON,
Cellestis LTD, Chadstone, Australia). Radiological tests (chest
X-ray, abdominal CT scan) were used to identify infection
sites. If the cultures were positive, the antimicrobial treatment
was modified according to the antibiograms.
Outcomes
The primary study outcome was a comparison of patient
survival, infections, allograft rejection, and graft loss between
the control and interventional groups. Secondary outcomes
were differences in the dose of primary immunosuppressants
among patients without adverse events, posttransplant renal
failure (considering dialysis, plasma creatinine level and
glomerular filtration rate according to the formula: GFR
(mL/min/1.73 m2) = 175  (Scr)−1.154  (Age)−0.203  (0.742
if female) (1.212 if African American), diabetes (treatment
with insulin or oral antidiabetic agents), HCC recurrence,Copyright © 2015 Wolters Kluwer Hand the addition of adjunctive immunosuppressants, such
as an antiproliferative, mTOR, or steroid.
Statistical Analysis
Published data of a 20% incidence of rejection29,30 and
30% to 65% incidence of bacterial and CMV infections31,32
were used to calculate the required number of enrolled pa-
tients. We hypothesized that immune function testing may
lower the risk of these events by 30%. Using Fisher exact test
with an α of 0.05 and β of 0.80, a sample size of 103 patients
was required for each group. Univariate analysis was per-
formed using Student t test for continuous variables and
Fisher exact test for categorical variables. For 2-tailed calcu-
lations, differences were considered significant for P less
than 0.05.
The patient survival after liver transplantation was calcu-
lated by the Kaplan-Meier method starting from the day of
LT to the day of death or to the most recent follow-up visit.
Differences were compared by the log-rank test, and vari-
ables were evaluated in the multivariate analysis using Cox
proportional hazard model (Figure 1).
Ethics
The study was conducted in accordance with the declara-
tion of Helsinki and followed the Good Clinical Practice
guidelines of the International Conference on Harmoniza-
tion. The protocol used in this study was approved by the
Independent Ethics Committee at Sant'Orsola-Malpighi
Hospital of the Università di Bologna. ClinicalTrials.gov
Identifier: NCT01764581.RESULTS
Patient Characteristics and Allocation
A total of 202 de novo liver transplant patients 18 years or
older received a deceased or extended criteria donor liver be-
tween July 2008 andMarch 2013. Patients were randomized
1:1 to the control (standard practice) group (n = 102) and the
interventional (immune function testing) group (n = 100).
There were no statistical differences between the groups with
respect to group allocation, posttransplantation follow-up,
and analysis.
The demographics, cause of ESLD, and surgical proce-
dures of the enrolled patients are summarized in Table 1.
There were no significant differences with respect to age,
sex, race, MELD score, donor MELD (D-MELD) score,33
or reason for liver transplantation. All donors were deceased,
and no differences were seen between standard or extended
criteria donors.
Notably, therewas an inverse correlation between immune
function assay values andMELD scores prior to transplanta-
tion. Patients withMELD scores greater than 20 had statisti-
cally lower immune function values than patients with lower
MELD scores (median 58 ng/mL adenosine triphosphate
[ATP] vs. 114 ng/mL ATP; P < 0.05).
Patient Survival
The actuarial survival rate of patients was 89% in the in-
terventional group compared to 78.4% in the control group
(P < 0.05) and 1-year patient survival was significantly higher
in the interventional group (95% vs 82%, P < 0.01), as re-
ported in Figure 2.ealth, Inc. All rights reserved.
FIGURE 1.
TABLE 1.
Demographics and clinical features of the study populations
All patients
(N = 202)
Intervention
group
(n = 100)
Control
group
(n = 102) P
Recipients
Mean age (SD), y 54 (11) 55 (11) 53 (12) n.s.
Male sex, n (%) 127 (62.9) 66 (66) 61 (59.8) n.s.
Viral hepatitis, n (%)
HCV-positive 53 (26.2) 25 (25) 28 (27.5) n.s.
HBV-positive 81 (40) 39 (39) 42 (41.2) n.s.
Virus negative 68 (33.7) 36 (36) 32 (31.4) n.s.
HCC, n (%) 70 (34.7) 32 (33)a 38 (37.3)b n.s.
Mean MELD score (SD) 20 (10) 19 (9) 21 (10) n.s.
MELD > 20, n (%)c 99 (49) 44 (44) 55 (53.9) n.s.
Mean BMI (SD), kg/m2 25.5 (4.6) 25.4 (4.5) 25.5 (4.7) n.s.
Donors
Mean age (SD), y 54.54 (20.3) 53.22 (19.3) 55.7 (21.3) n.s.
Male sex, n (%) 106 (52.5) 57 (57) 49 (48) n.s.
Cause of death, n (%)
Cerebrovascular accident 132 (65.3) 63 (63) 69 (67.6) n.s.
Trauma 39 (19.3) 21 (21) 18 (17.6) n.s.
Other 31 (15.3) 16 (16) 15 (14.7) n.s.
Mean BMI (SD), kg/m2 26.1 (5.2) 25.9 (5.1) 26.5 (5.3) n.s.
Mean ischemia time (SD), min 396 (102) 400 (127) 383 (69) n.s.
D-MELD score (SD) 1162 (708) 1090 (705) 1234 (706) n.s.
D-MELD >1600, n (%) 54 (27.1) 22 (22.2) 32 (32) n.s.
a (T1 = 13, T2 = 11; T3 = 8).
b (T1 = 17, T2 = 12, T3,=9).
c MELD score was measured 1 day before liver transplantation.
BMI, body mass index.
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tional group (33%) and 22 were in the control group (67%).
Eleven patients died from infections (33.3%), 9 patients from
multiorgan failure (27.3%), 6 from recurrent HCC or de
novo tumor (18.2%), 4 from surgical complication (12.1%),
and 3 from recurrent HCV hepatitis (9.1%).
One patient in the control group and 2 patients in the inter-
ventional group were retransplanted because primary graft
nonfunction.
The univariate analysis showed a statistical correlation
with a lower patient survival at 1 year for the cases with
D-MELD greater than 1600 (81.5% vs. 91%, P < 0.05)
andwith infection events (82.6% vs 96%, P < 0.01), whereas
the presence of HCC or HCV-positive, acute rejection, or
other recipient and donor features did not demonstrate any
correlation with the patient survival.
The multivariate analysis, including the D-MELD greater
than 1600 and the study groups, showed that the inter-
ventional arm was independently associated with a higher
1-year patient survival (P < 0.01; 95% confidence interval,
1.3–9.5).
Adverse Events
The numbers of adverse events in the 2 study groups are
shown in Table 2. There was no statistical difference between
cohorts with respect to acute rejection events, which were
mild in most cases according to Banff scores with no occur-
rence of steroid-resistant or chronic rejection.
The infection events after the first 2 weeks posttransplant
were significantly lower in the interventional group (42%
vs. 54.9%, P < 0.05) corresponding with improved patientCopyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
FIGURE 2. Patients survival 1 year after transplantation for interven-
tion and control groups. The patient survival after liver transplantation
was calculated by the Kaplan-Meier method starting from the day of
LT to the day of death or to themost recent follow-up visit. The 1-year
patient survival was significantly higher in the Interventional group
(95% vs. 82%, P < 0.01).
© 2015 Wolters Kluwer Ravaioli et al 1629survival in that group. This difference was further increased
when selecting the recipients with MELD scores greater than
20 (Table 2).
Among the laboratory-confirmed infectious episodes that
occurred after postoperative day 14, bacterial infections were
responsible for most cases (57.1%), specifically, bacteremia
(n = 45), pneumonia (n = 15), biliary tree infections (n = 6),
urinary tract infections (n = 5), and ascites infection (n = 6).
Viral infections were involved in 33.3% of cases including
herpes simplex (n = 3), varicella zoster (n = 2), human herpes
virus 6 (n = 1), human herpes virus 1 (n = 2), human herpes
virus 8 (n = 2), West Nile virus (n = 1), and CMV (N = 33).
Fungal infections were responsible for the remaining cases
(9.6%):Aspergillus pneumonia (n = 3), cerebralAspergillosis
(n = 1), and candidemia (n = 9).
Overall, patients in the control group experienced a higher
incidence of infections. Among patients with bacterial infec-
tions (N = 77; 57.1%), 47 (46.1%) occurred in the con-
trol group versus 32 (32%) in the interventional groupTABLE 2.
Comparison of outcomes at 12 months of follow-up
All patients (N = 202) Inter
Patient survival, % 170 (84.2)
Event-free recipients, % 83 (58.9)
Infectious episodes >14 d
after transplantation, %
98 (48.5)
Acute rejections, % 33 (16.3)
Recipients with >3 infection, % 21 (10.4)
Bacterial infections, % 77 (57.1)
Fungal infections, % 13 (9.6)
Viral infections, % 45 (33.3)
All patients, MELD >20 (N = 99) Interventio
Patient survival, % 81 (81.8)
Infectious episodes >14 d
after transplantation, %
60 (60.6)
a Cause of 11 deaths: multiple organ failure (n = 2, 18%), infections (n = 3, 27%), recurrent HCV hepati
b Cause of 22 deaths: multiple organ failure (n = 7, 32%), infections (n = 8, 36%), recurrent HCV hepatitis
were measured the day before liver transplantation.
Copyright © 2015 Wolters Kluwer H(P < 0.05). Similarly, among patients with fungal infections
(n = 13; 9.6%), 11 (10.8%) occurred on the control group
versus 2 (2%) in the interventional group (P < 0.05). There
was no significant difference in the number of patients with
viral infections in the control and intervention groups
(23 vs 22, respectively). Patients in the control group were
twice as likely to be hospitalized for infections with longer
stays compared to patients in the interventional group (rela-
tive risk = 2.1).Immunosuppression Adjustment: Patient Example
An example case of immunosuppression adjustment based
on immune function assay values and clinical condition is de-
scribed in an immune monitoring profile. This 54-year-old
manwas transplanted in June 2009 for cryptogenic cirrhosis.
His immunosuppressive therapy was managed according to
immune function testing as described above. Immune func-
tion values increased from 23 to 137 ng/mL ATP during the
first posttransplant week and by week 2 had reached
285 ng/mL ATP. During this time, his immunosuppression
therapy followed routine practice as these values did not per-
sist below 130 ng/mL or exceed 450 ng/mLATP. His immune
function assay values decreased to 32 ng/mL ATP between
days 14 and 50 and his tacrolimus (Prograf; Astellas Pharma
S.p.A., Carugate, IT) was reduced from 12 mg per day (6 mg
twice per day) to 9 mg per day (5 mg in the morning, 4 mg in
the evening). As a result, his immune function value increased
to 166 ng/mL ATP at 3 months. His immune function assay
value decreased to 106 ng/mL at his 6-month clinic visit,
and his tacrolimus was further adjusted to 4 mg per day
(2 mg twice per day). At 9 months after transplantation, he
was diagnosed with chronic renal failure and at 12 months
his immune function assay value was 65 ng/mL ATP. Tacroli-
mus was further reduced to 2 mg per day and then to 1 mg
per day and mycophenolate mofetil (CellCept; Roche Regis-
tration Limited, Welwyn Garden City, UK) was added at a
dose of 1000 mg per day (500 mg twice per day). No infec-
tions or rejections occurred during the course of this patient's
first posttransplant year.vention group (n = 100) Control group (n = 102) P
89 (89.0)a 80 (78.4)b <0.05
41 (41.0) 42 (41.2) n.s.
42 (42.0) 56 (54.9) <0.05
19 (19.0) 14 (13.7) n.s.
11 (11.0) 10 (9.8) n.s.
32 (32.0) 47 (46.1) <0.05
2 (2.0) 11 (10.8) <0.05
22 (22.0) 23 (22.5) n.s.
n group, MELD >20 (n = 44) Control group, MELD >20 (n = 55)
41 (93.2) 40 (72.7) <0.01
22 (50.0) 38 (69.1) <0.05
tis (n = 1, 9.1%), surgical complication (n = 2, 18%), and tumor-related causes (n = 3, 27%).
(n = 2, 9.1%), technical reasons (n = 2, 9.1%), and tumor-related causes (n = 3; 14%). MELD scores
ealth, Inc. All rights reserved.
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and Infections
Among recipients without adverse events during the first
3 months after transplantation, patients in the interventional
group had significantly lower median tacrolimus doses
(6 mg vs 8 mg, P < 0.01) and tacrolimus trough levels
(8 mg/dL vs 9 mg/dL, P < 0.01). At 6 and 12 months after
transplantation, the median tacrolimus level were 7 and
6 mg/dL, respectively, in the interventional group compared
to 8 and 7 mg/dL in the control group (for each, P < 0.05).
At postoperative day 30, the number of infection events
was statistically correlated with lower level of immune func-
tion assay values (median, 83 vs 178 ng/dL ATP; P < 0.001),
aswell as the tacrolimus daily dosage (median, 5 vs 4mg/day,
P < 0.01) and tacrolimus level (median, 7 vs 8 ng/mL;
P < 0.05), which were lower in the infection group and there-
fore not effective to prevent them.
Dividing the patients according to the presence or the
absence of infection, we found a correlation with a lower
immune function assay at each timepoint during the
6-month posttransplant period, whereas the tacrolimus
level showed a correlation only in the first month after
transplantation (Figure 3).
The patients with rejection had a higher level of immune
function assay values without reaching statistical difference
(median, 211 vs 163 ng/dL; P = 0.09), while they had a signif-
icantly higher tacrolimus daily dosage and plasma level (me-
dian 8 vs 5 mg/day, P < 0.001 and median 9 vs 8 ng/mL;
P < 0.001). Conversely, the tacrolimus dosage and levels were
higher in the patients with rejection.
There were no between-group differences in the use of
antiproliferatives (mycophenolic acid, mycophenolate mofe-
til, or azathioprine (GlaxoSmithKline S.p.A., Verona, IT), ste-
roids or mTOR inhibitors.DISCUSSION
The present randomized trial demonstrated the benefit of
managing immunosuppression in adult liver transplant recip-
ients using the ImmuKnow immune function assay. The
ImmuKnow assay measures the ability of CD4+ cells to re-
spond to mitogenic stimulation by phytohemagglutinin-L
in vitro by quantifying the amount of ATP produced in
CD4+ cells after stimulation.22 The most commonly used
immunosuppressive medications, such as cyclosporine andFIGURE 3. Plasma ImmuKnow and Tacrolimus values among with and
cantly higher (Stronger immune response) among patients without infecti
tacrolimus trough levels were significantly higher among patients without
Copyright © 2015 Wolters Kluwertacrolimus, inhibit lymphocytes and especially T lympho-
cytes such as CD4+ cells.2 As the proliferation of CD8+ cells
and other components of the cell-mediated immune response
are largely under the control of CD4+ cells, the measurement
of CD4+ activation is a more accurate reflection of global
cell-mediated immune function. By combining sequential im-
mune assay values with other routine tests, the treating trans-
plant physician has a more complete immunological picture
helpful in making more pondered decisions regarding ther-
apy adjustments.
Similar to other reports, we found bacterial infections to be
themost common type of infections26; however, using the im-
mune function assay, the patients in the interventional arm of
the study had a reduced number of bacterial and fungal infec-
tion events and improved the patient survival during the first
year after transplantation.
These results are in agreement with other studies that dem-
onstrated a correlation between low assay values and the in-
cidence of recurrent hepatitis C viral infections,7,10,21,29
human immunodeficiency virus/HCV-coinfected patients,30
bacterial infections,31 and invasive fungal infections32 among
liver transplant recipients. In 1 observational study, liver re-
cipients with an immune function value less than 130 ng/mL
ATP were 12 times more likely to develop an infection
(P < 0.001),9 and the results of a largemeta-analysis concluded
that the immune function test is a valid tool for determining
the risk of further infection in adult liver transplant recipients.8
Similar to several previous studies, the immune function
test values did not correlate with episodes of rejection in liver
recipients34 although some investigators have reported it to
be useful for monitoring rejection.6,31 The results of a recent
study suggest the predictive power of the immune function
assay may be improved by combining it with the CD4+ T
lymphocyte count and CD4+/CD8+ ratio.35
The multivariate analysis including the variable D-MELD
score, which summarizes the donor and recipient features,
confirmed that the interventional arm had an independently
higher survival (19% improvement) at the first year after
transplantation compared to the control group with conven-
tional postoperative management.
Early during the study, it was observed that patients with
pretransplant MELD scores greater than 20 had signifi-
cantly lower ImmuKnow values. This demonstrates that
many patients are highly immunosuppressed before receiving
any immunosuppressive therapy. As a result of this finding,without infections. Left, Median ImmuKnow assay values were signifi-
ons at each time period after transplantation. *P < 0.01. Right, Median
infections during the first month following transplantation. *P < 0.01.
 Health, Inc. All rights reserved.
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given to patients during transplant surgery by combining
ImmuKnow values with MELD scores. These very sick
patients, transplanted earlier with an allocation system
based on MELD score,36–38 are at higher risk of mortality
due to infection,39 demanding a strategy to reduce their
immunosuppression.
Utilization of the ImmuKnow test results to optimize im-
munosuppression yielded improved patient survival and re-
duced infectious episodes in the interventional group as
shown in Table 2. These findings were even more striking
for the recipients with MELD scores greater than 20 in the
interventional group who had a patient survival nearly
20% higher than that in the control group with the same
MELD score.
Drug levels are often used to guide immunotherapy; how-
ever, this approach often results in drug toxicity, infection, or
graft rejection.40We showed that the measurement of plasma
tacrolimus levels is not sufficient to prevent infection as dem-
onstrated in Figure 3. After the first month posttransplant,
patients with or without infection had the same tacrolimus
level, whereas the ImmuKnow values were significantly
lower in the cases with infections. On the other hand, the im-
mune assay should not be considered an alternative to the ta-
crolimus level, but it should be a piece of a complex puzzle of
the immunosuppression of a transplant recipient. By using
this assay, wewere able to reduce the daily tacrolimus dosage
and the trough level in the interventional group. This was
demonstrated among the patients without adverse events be-
cause patients with infection were managed by reducing im-
munosuppression while increasing immunosuppression in
patients with rejection. Therefore, if 1 group had higher rates
of infection, an analysis of tacrolimus dose and plasma level
would have suggested reducing immunosuppression in pa-
tients with infection.
The analysis of tacrolimus dosage and plasma levels was
focused on recipients without adverse events to limit biases
that may be caused from treating patients with various
adverse events (increased immunosuppression for apparent
rejections and decreased immunosuppression for diagnosed
infections). The lower exposure to tacrolimus will likely im-
prove the long-term renal function of patients whenmanaged
by ImmuKnow,41 even if our data did not show any statisti-
cal significant difference of creatinine level and glomerular
filtration rate at 6 and 12 month after transplantation (data
not reported).
Because the use of steroids and other immunosuppressants
were not subject to change based on ImmuKnow values,
there were no differences in the amount of these agents used
between the 2 groups.
There was higher patient survival among HCV-positive
patients and those with HCC in the Interventional group
(data not reported). These patients are supposed to benefit
from lower immunosuppression to prevent viral and tumor
recurrence of disease, but there were no statistical differences,
and the number of cases was insufficient for any conclusive
subanalysis.
It may be suggested that the same lower levels of immuno-
suppression among patients in the interventional group with-
out adverse events can be achieved without using the
ImmuKnow assay42 and that the assay was less effective
in preventing rejection events compared to infections.Copyright © 2015 Wolters Kluwer HPerforming another randomized study in which immuno-
suppression is minimized by using conventional criteria
of clinical practice may provide additional data. Al-
though the literature does not provide any suggestions
for implementing this strategy,47,48 the results of our
study offers an effective tool to minimize immunosup-
pression, especially in patients with high MELD scores.
Our results showed a significant difference in patient sur-
vival and significantly lower bacterial and fungal infection
rates between the study groups, which were otherwise com-
parable according to the donor and recipient features and
the multivariate analysis confirmed this important data. Fur-
thermore, the sample size and the statistical power of the
study prevented any statistical bias.
In conclusion, the present prospective, interventional, con-
trolled, and randomized study demonstrates that ImmuKnow
provides a useful biomarker which enables optimizing immu-
nosuppression to improve patient outcomes by preventing
bacterial and fungal infections, reducing immunosuppressant
drug use and improving 1-year patient survival after liver
transplantation. These results are even more compelling in
cases with MELD scores greater than 20.
ACKNOWLEDGMENTS
The authors acknowledge the editorial assistance of Dr. Carl
Hornfeldt during the preparation of this manuscript.REFERENCES
1. Mells GNeuberger J. Long-term care of the liver allograft recipient. Semin
Liver Dis. 2009;29:102–120.
2. ImmuKnow® Immune Cell Function Assay. Product Insert 2007. Cylex™
Inc., Columbia, MD.
3. He J, Li Y, Zhang H, et al. Immune function assay (ImmuKnow) as a
predictor of allograft rejection and infection in kidney transplantation.
Clin Transplant. 2013;27:E351–E358.
4. Heikal NM, Bader FM, Martins TB, et al. Immune function surveillance:
association with rejection, infection and cardiac allograft vasculopathy.
Transplant Proc. 2013;45:376–382.
5. Zhou H, Wu Z, Ma L, et al. Assessing immunologic function through
CD4 T-lymphocyte adenosine triphosphate levels by ImmuKnow assay
in Chinese patients following renal transplantation. Transplant Proc.
2011;43:2574–2578.
6. Dong JY, Yin H, Li RD, et al. The relationship between adenosine
triphosphate within CD4(+) T lymphocytes and acute rejection after liver
transplantation. Clin Transplant. 2011;25:E292–E296.
7. Hashimoto K, Miller C, Hirose K, et al. Measurement of CD4+ T-cell
function in predicting allograft rejection and recurrent hepatitis C after
liver transplantation. Clin Transplant. 2010;24:701–708.
8. Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow as a diagnostic
tool for predicting infection and acute rejection in adult liver transplant
recipients: a systematic review and meta-analysis. Liver Transplant.
2012;18:1245–1253.
9. Xue F, Zhang J, Han L, et al. Immune cell functional assay in monitoring of
adult liver transplantation recipients with infection. Transplantation.
2010;89:620–626.
10. Hashimoto K, Miller CM, Quintini C, et al. Impact of Cylex (R) immune cell
function assay in predicting acute cellular rejection and recurrence of HCV
in liver transplantation. Am J Transplant. 2008;8:612–613.
11. López-Hoyos M, Rodrigo E, Arias M. The usefulness of intracellular
adenosine-5'-triphosphate measurement in CD4+ cells in renal transplant.
Nefrologia. 2013;33:381–388.
12. Kobashigawa JA, Kiyosaki KK, Patel JK, et al. Benefit of immune
monitoring in heart transplant patients using ATP production in activated
lymphocytes. J Heart Lung Transplant. 2010;29:504–508.
13. Serban G, Whittaker V, Fan J, et al. Significance of immune cell function
monitoring in renal transplantation after thymoglobulin induction therapy.
Hum Immunol. 2009;70:882–890.ealth, Inc. All rights reserved.
1632 Transplantation ■ August 2015 ■ Volume 99 ■ Number 8 www.transplantjournal.com14. Thai NL, Blisard D, Tom K, et al. Pancreas transplantation under
alemtuzumab (Campath-1H) and tacrolimus: Correlation between low
T-cell responses and infection. Transplantation. 2006;82:1649–1652.
15. Gautam A, Fischer SA, Yango AF, Gohh RY, Morrissey PE, Monaco AP.
Cell mediated immunity (CMI) and post-transplant viral infections—role
of a functional immune assay to titrate immunosuppression. Int
Immunopharmacol. 2006;6:2023–2026.
16. Cabrera R, Ararat M, Soldevila-Pico C, et al. Using an mmune functional
assay to differentiate acute cellular rejection from recurrent hepatitis C in
liver transplant patients. Liver Transpl. 2009;15:216–222.
17. Tanaka T, Takatsuki M, Soyama A, et al. Evaluation of immune function
under conversion from Prograf to Advagraf in living donor liver
transplantation. Ann Transplant. 2013;18:293–298.
18. San Segundo D, Fernández-Fresnedo G, Gago M, et al. Number
of peripheral blood regulatory T cells and lymphocyte activation at
3 months after conversion to mTOR inhibitor therapy. Transplant Proc.
2010;42:2871–2873.
19. Berglund D, Bengtsson M, Biglarnia A, et al. Screening of mortality in
transplant patients using an assay for immune function. Transpl
Immunol. 2011;24:246–250.
20. Uemura T, Riley TR, Khan A, et al. Immune functional assay for
immunosuppressive management in post-transplant malignancy. Clin
Transplant. 2011;25:E32–E37.
21. Te HS, Dasgupta KA, Cao D, et al. Use of immune function test in
monitoring immunosuppression in liver transplant recipients. Clin
Transplant. 2012;26:826–832.
22. Kowalski R, Post D, Schneider MC, et al. Immune cell function testing: an
adjunct to therapeutic drug monitoring in transplant patient management.
Clin Transplant. 2003;17:77–88.
23. de Simone P, Beckebaum S, Koneru B, Fung J, Saliba F. Everolimus
with reduced tacrolimus in liver transplantation. Am J Transplant.
2013;13:1373–1374.
24. Lee RG, Tsamandas AC, Demetris AJ. Large cell change (liver cell
dysplasia) and hepatocellular carcinoma in cirrhosis: matched case-
control study, pathological analysis, and pathogenetic hypothesis.
Hepatology. 1997;26:1415–1422.
25. Signore A. About inflammation and infection. EJNMMI Research.
2013;3:8.
26. Humar A, Michaels M, AST ID. Working Group on Infectious Disease
Monitoring. American Society of Transplantation recommendations for
screening, monitoring and reporting of infectious complications in
immunosuppression trials in recipients of organ transplantation. Am J
Transplant. 2006;6:262–274.
27. Bone RC. Sepsis and coagulation. An important link. Chest. 1992;
101:594–596.Copyright © 2015 Wolters Kluwer28. Razonable RR. Cytomegalovirus infection after liver transplantation:
current concepts and challenges. World J Gastroenterol. 2008;14:
4849–4860.
29. Mendler M, Kwok H, Franco E, Baron P, Weissman J, Ojogho O.
Monitoring peripheral blood CD4+ adenosine triphosphate activity in a
liver transplant cohort: insight into the interplay between hepatitis C virus
infection and cellular immunity. Liver Transpl. 2008;14:1313–1322.
30. Natsuda K, Soyama A, Takatsuki M, et al. The efficacy of the ImmuKnow
assay for evaluating the immune status in human immunodeficiency virus
and hepatitis C virus-coinfected patients. Transplant Proc. 2014;46:733–735.
31. Mizuno S,Muraki Y, Nakatani K, et al. Immunological aspects in late phase
of living donor liver transplant patients: usefulness of monitoring peripheral
blood CD4+ adenosine triphosphate activity. Clin Dev Immunol. 2013;
2013:982163.
32. Zhou T, Xue F, Han LZ, et al. Invasive fungal infection after liver
transplantation: risk factors and significance of immune cell function
monitoring. J Dig Dis. 2011;12:467–475.
33. Ikegami T, Imai D, Wang H, et al. D-MELD as a predictor of early graft
mortality in adult-to-adult living-donor liver transplantation. Transplantation.
2014;97:457–462.
34. Hwang S, Kim KH, Song GW, et al. Peritransplant monitoring of immune
cell function in adult living donor liver transplantation. Transplant Proc.
2010;42:2567–2571.
35. Li RD, Sun Z, Dong JY, et al. A quantitative assessment model of T-cell
immune function for predicting risks of infection and rejection during the
early stage after liver transplantation. Clin Transplant. 2013;27:666–672.
36. Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the Meld
system: a prospective study from a single European center. Am J
Transplant. 2006;6:1572–1577.
37. RoayaieK, FengS. Allocationpolicy for hepatocellular carcinoma in theMELD
era: room for improvement? Liver Transpl. 2007;13(11 Suppl 2):S36–S43.
38. Agopian VG, Petrowsky H, Kaldas FM, et al. The evolution of liver
transplantation during 3 decades: analysis of 5347 consecutive liver
transplants at a single center. Ann Surg. 2013;258:409–421.
39. Silberhumer GR, Hetz H, Rasoul-Rockenschaub S, et al. Is MELD score
sufficient to predict not only death on waiting list, but also post-
transplant survival? Transpl Int. 2006;19:275–281.
40. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med.
2007;357:2601–2614.
41. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work
Group. KDIGO clinical practice guidelines for the care of kidney
transplant recipients. Am J Transplant. 2009;9(Suppl 3):S1–S155.
42. Lerut JMJ, Verbaandert C, Talpe S, et al. Tacrolimus monotherapy in liver
transplantation: one-year results of a prospective, randomized, double-
blind, placebo-controlled study. Ann Surg. 2008;248:956–967. Health, Inc. All rights reserved.






Transplant Immunology 34 (2016) 60–64
Contents lists available at ScienceDirect
Transplant Immunology
j ourna l homepage: www.e lsev ie r .com/ locate / t r imBrief communicationSuccessful management of EBV-PTLD in allogeneic bone marrow
transplant recipient by virological–immunological monitoring of EBV
infection, prompt diagnosis and early treatmentAngela Chiereghin a, Clara Bertuzzi b, Giulia Piccirilli a, Liliana Gabrielli a, Diego Squarzoni a, Gabriele Turello a,
Martina Ferioli c, Mariarosaria Sessa c, Francesca Bonifazi c, Lucia Zanoni d,
Elena Sabattini b, Tiziana Lazzarotto e,⁎
a Operative Unit of Clinical Microbiology, Laboratory of Virology, St. Orsola-Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
b Department of Specialised, Experimental, and Diagnostic Medicine, Hematopathology Section, St. Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna,
Italy
c Institute of Hematology and Medical Oncology, “L. and A. Seràgnoli”, St. Orsola-Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
d Department of Specialised, Experimental, and Diagnostic Medicine, Operative Unit of Nuclear Medicine, St. Orsola-Malpighi University Hospital, University of Bologna, Via Massarenti
9, 40138 Bologna, Italy
e Department of Specialised, Experimental, and Diagnostic Medicine, Operative Unit of Clinical Microbiology, Laboratory of Virology, St. Orsola-Malpighi University Hospital, University
of Bologna, Via Massarenti 9, 40138 Bologna, ItalyAbbreviations:EBV-PTLD, Epstein–Barr virus-relatedp
tive disorder; DLBCL, diffuse large B-cell lymphoma; allo-
stem cell transplant; ATG, antithymocyte globulin; GVH
EliSpot, Enzyme-linked ImmunoSPOT; 18F-FDG PET/CT, 18
emission tomography-computed tomography.
⁎ Corresponding author.
E-mail addresses: angela.chiereghin@gmail.com (A. Ch
clarabertuzzi@gmail.com (C. Bertuzzi), giulia.piccirilli@yah
liliana.gabrielli@aosp.bo.it (L. Gabrielli), diegosquarzoni@y
turellogabriele@gmail.com (G. Turello), ferioli.martina@al
sessamariarosaria@gmail.com (M. Sessa), francesca.bonifa
luciaironic@hotmail.it (L. Zanoni), elena.sabattini@aosp.bo
tiziana.lazzarotto@unibo.it (T. Lazzarotto).
http://dx.doi.org/10.1016/j.trim.2015.12.002
0966-3274/© 2015 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 7 August 2015
Received in revised form 12 November 2015
Accepted 11 December 2015
Available online 12 December 2015Epstein–Barr virus-related post-transplant lymphoproliferative disorder (EBV-PTLD) is an uncommon, but
frequently fatal, complication after allogeneic hematopoietic stem cell transplant. Prospective post-transplant
virological and immunological monitoring allowed to successfully manage a patient who developed both poly-
morphic and monomorphic, “diffuse large B-cell lymphoma like”, as an EBV-PTLD, 65 days after allogeneic
bone marrow transplant. Early detection of signiﬁcant increase in EBV DNA level in patient's peripheral blood
(peak of viral load equal to 119,039 copies/mL whole blood, +56 day after transplant) led to administration of
pre-emptive anti-CD20monoclonal antibody (rituximab) and close clinical monitoring. After oneweek, physical
exam revealed laterocervical adenopathy. Histopathologic features, immunohistochemical characterization and
in situ hybridization study allowed to establish a diagnosis of EBV-related PTLD. Immunological monitoring
showed no EBV-speciﬁc T-cell responses during EBV replication, thus potentially explaining the occurrence of
high EBV load with subsequent PTLD development. A total of four doses of anti-CD20 monoclonal antibody
were administered and at the end of the treatment, EBV infection was cleared and imaging technique showed
complete disease remission. In conclusion, the early use of anti-CD20 monoclonal antibody proved to be a safe
and effective treatment strategy for EBV-PTLD. Moreover, combined virological–immunological monitoring of
EBV infection may more accurately assess patients at higher risk for EBV-PTLD.
© 2015 Elsevier B.V. All rights reserved.Keywords:
Allogeneic bone marrow transplant
EBV DNA load
EBV-speciﬁc T-cell responses
EBV-PTLD
Anti-CD20 monoclonal antibody (rituximab)Epstein–Barr virus-related post-transplant lymphoproliferative
disorder (EBV-PTLD) consists of a heterogeneous group of EBV diseasesost-transplant lymphoprolifera-
HSCT, allogeneic hematopoietic
D, graft-versus-host-disease;
F-ﬂuorodeoxyglucose positron
iereghin),
oo.it (G. Piccirilli),
ahoo.it (D. Squarzoni),
ice.it (M. Ferioli),
zi@unibo.it (F. Bonifazi),
.it (E. Sabattini),with neoplastic lymphoproliferation, developing after transplant, and
caused by iatrogenic suppression of T-cell function [1]. After allogeneic
hematopoietic stem cell transplant (allo-HSCT), the incidence of
EBV-PTLD is lower than 2% and may increase to 10–20% in patients
with established risk factors [1,2]. Prospective monitoring of EBV
viremia by quantitative PCR assay is recommended for patients at high
risk of PTLD, since EBV-PTLD is usually accompanied by increased EBV
DNA levels in peripheral blood [1,3–5].
Here we present the successful management of a 40 year-old male
who developed both polymorphic and monomorphic, “diffuse large
B-cell lymphoma (DLBCL) like”, EBV-PTLD, 65 days after receiving
allo-HSCT for acute lymphoblastic leukemia.
In September 2013, in a routine screening, the peripheral blood
showed leukocytosis with lymphocytosis, with atypical features; a
61A. Chiereghin et al. / Transplant Immunology 34 (2016) 60–64bone marrow biopsy was performed and showed the presence of an
Acute pro-B Lymphoblastic Leukemia Ph+. Eight months after the ini-
tial diagnosis, the patient underwent allo-HSCT from an HLA-identical
unrelated donor, at the Institute of Hematology and Medical Oncology
“L. and A. Seràgnoli”, St. Orsola-Malpighi University Hospital of Bologna.
The source of stem cells was bone marrow. The donor was provided
by the German Bone Marrow Donor Registry — DKMS Deutsche
Knochenmarkspenderdatei GmbH. The donor and recipient were both
positive for EBV. The conditioning regimen consisted of cyclophospha-
mide 60 mg/kg/day for 2 consecutive days, followed by single dose –
single fraction total body irradiation, 8 Gy at a dose rate of 7 cGy/min.
Low dose anti-thymocyte globulin (ATG) GRAFELON (formerly ATG-
Fresenius; Neovii Biotech GmbH, Graefelﬁng, Germany), total
30mg/kg, was administered over 5 days, from day−6 to−2. Total nu-
cleated cells at the dose of 2.88 × 108/kg, CD34 positive cells at the dose
of 2.05 × 106/kg and CD3 positive cells at the dose of 28.52 × 106/kg
were infused. Graft-versus-host-disease (GVHD) prophylaxis consisted
of Cyclosporine A and short coursemethotrexate (15mg/m2 at day+1,
10 mg/m2 at days +3 and +6). Cyclosporine A was administered
in order to maintain blood concentration ranging from 150 to
258 ng/mL. The patient did not develop acute GVHD and steroids
were not administered.
Prospective virological and immunological monitoring of EBV infec-
tion was performed during the post-transplant period. Virological
follow-up of EBV infection was performed every week during the ﬁrst
100 days post-transplant and every 2 weeks until 180 days post-
transplant. Afterwards, the patient's blood samples were processed
after each examination. Speciﬁcally, routine virological monitoring
was performed on whole blood samples, by a commercial quantitative
real-time PCR (EBV ELITe MGB™ kit, ELITech Group, Turin, Italy), fol-
lowing the manufacturer's instruction. The PCR assay targets a region
of the EBNA-1p gene of EBV. The analytical sensitivity of the assay is
10 copies of target DNA per ampliﬁcation reaction. The lower limit of
quantiﬁcation (LLQ) of the assay is 225 copies/mL whole blood. PCR
assay on a bioptic sample from the patient's excised lymph node
was also performed. The LLQ of the assay is 10 copies/microgram
DNA. Immunological monitoring was carried out by Enzyme-linked
ImmunoSPOT Assay (EliSpot; EliSpot Interferon-γ Basis Kit; GenID
GmbH, Strasburg, Germany) at days 48, 100, 180, 270 and 365 after
transplant. The assay enumerates Interferon-gamma-secreting EBV-
speciﬁc T cells (both CD4+ and CD8+ cells), at a single cell level,
upon in vitro stimulation with latent and lytic viral antigens. With this
method it is possible to detect one antigen speciﬁc T-cell out of 1000
cells. Two commercially available latent and lytic EBV-speciﬁc peptide
mix were used (GenID GmbH, Strasburg, Germany). In particular,Fig. 1. Results of the virological–immunological monitoring of EBV infectipeptide pools derived from Epstein–Barr nuclear antigens (EBNApp)
such as EBNA3App (amino acid (AA) 158–166, 325–333, 379–387, 458–
466, 603–611) and EBNA3Cpp (AA 258–266, 281–290), latentmembrane
protein 2-derived single peptide (LMP2p, AA 426–434), BRLF1pp (AA
148–156, 134–143, 28–37), BMLF1pp (AA 259–267, 280–288) and
BZLF1p (AA 190–197) were used. Cells were stimulated separately with
latent and lytic viral antigens at 5 μg/mL or phytohemagglutinin (PHA-
P) at 5 μg/mL or culture medium only (negative control). The mitogen
stimulation and the negative controlwere included to determine general
T-cell responsiveness (PHA-P ≥ 50 SFCs/200,000 lymphocytes) and
background (≤10 SFCs/200,000 lymphocytes), respectively. Cellular
immunity to EBV in healthy EBV-seropositive individuals was also
evaluated to check each assay run. The test's procedure was conducted
as described elsewhere [6]. Parafﬁn sections from the pathological
sample were subjected to antigen retrieval and stainedwithmonoclonal
antibodies directed against the following antigens: CD20, CD10, BCL6,
IRF4, and Bcl2. The in situ hybridization was performed using the EBV
(EBER) CISH PNA Probe Y5200 (Dako), according to the manufacturer's
instructions. During the immediate post-transplant period, the patient
did not develop severe complications. The results obtained by virological
and immunological monitoring of EBV infection and the patient's
immune competence were reported in Fig. 1.
The line ( ) indicates the Lower Limit of Quantiﬁcation of the real
time PCR assay for the whole blood samples (225 copies/mL). The line
( ) indicates the EliSpot assay cut-off for positive response to EBV
(≥5 SFCs/200,000 lymphocytes, calculated using the formula “sample−
negative control”). The lines with ﬁlled and open circles represent viro-
logical and immunological monitoring, respectively. In the upper area
of the graph, the total lymphocyte count (103/mmc, reference interval
0.80–4.32) obtained at each virological–immunological time point was
reported.
Thirty-three days post-transplant, the patient resulted positive for
EBV-DNA (375 copies/mL) on routine virological monitoring. At
+40 day after allo-HSTC, EBV DNAemia increased (11,150 copies/mL)
and at the next visit, EBV-speciﬁc T-cell responses by EliSpot assay
were also assessed. In particular, at +48 day after allo-HSTC, the pres-
ence of general T-cell responsiveness (response to mitogen stimulation,
PHA-P ≥ 50 SFCs/200,000 lymphocytes) and lack of speciﬁc T-cell re-
sponses against both EBV latent and lytic antigens (≤5 SFCs/200,000
lymphocytes, “sample− negative control”) were detected by EliSpot
assay; EBV DNAemia was of 28,002 copies/mL. The EBV DNAemia con-
tinued to increase (88,695 copies/mL, +54 day after allo-HSTC)
reaching the peak at +56 day after transplant (119,039 copies/mL).
The patient started with anti-CD20 monoclonal antibody (rituximab)
consisting in 4 administrations, at a dose of 375 mg/m2/week, on dayon and total lymphocyte count during the ﬁrst year post-transplant.
Fig. 2.Histology and immunohistochemistry of the lymph node. A. Polymorphic cell pop-
ulation with diffuse growth pattern, composed by lymphoid cells and plasma cells
(Giemsa). B. Partial immunoreactivity for CD20, probably due to the previous therapy
with anti-CD20monoclonal antibody (rituximab). C. In situ hybridization shows EBV-RNA
integration in the pathologic cell population.
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lymph node enlargement which led to lymph node excision at day
+65. The lymph node structure was affected by an atypical polymor-
phic cell population with diffuse growth pattern, composed by lym-
phoid cells of variable size, with a moderate amount of large elements,
with round nuclei and multiple peripheral nucleoli, as well as plasma
cells (Fig. 2A). At immunohistochemistry the large cells mainly showed
a non-germinal centre B cell phenotype (CD20+, CD10−, BCL6−)with
expression of Bcl2 and IRF4 and some MYC protein positive elements,
while the plasma cells/plasmacytoid elements were CD20−/IRF4+(Fig. 2B). In situ hybridization assay showed EBV-RNA integration in
the pathologic cell population (Fig. 2C).
Upon these immuno-morphologic features, a diagnosis of an EBV-
related PTLD was rendered with polymorphic and monomorphic
DLBCL-like coexisting areas. In themeanwhile, PCR assay of a bioptic sam-
ple of the same lymph node revealed a high level of EBV-DNA (1,113,186
copies/microgram DNA), this result conﬁrmed the EBV pathogenesis of
PTLD. The patient was subjected to whole body 18F-ﬂuorodeoxyglucose
(FDG)-positron emission tomography-computed tomography (PET/CT),
which showed positive uptake in multiple lymph nodes in right and left
laterocervical region together with presacral region (Fig. 3A). During the
treatment, PCR assay revealed a decrease in EBV-DNA and at the end of
the therapy the patient achieved EBV DNA negativity. Two months after
the EBV-PTLD diagnosis and four doses of anti-CD20, 18F-FDG PET/CT
showed a complete disease remission (Fig. 3B).
EliSpot assay showed response to mitogen stimulation and nonre-
sponse to EBV stimulation at all other post-transplant speciﬁc time-
points in which it was performed (+100, +180, +270 and
+365 days after transplant) (Fig. 1). Serum immunoglobulin (Ig)
levels – IgG, IgA and IgM – were determined routinely during
the post-transplant period (data not shown). In occasion of the last
follow-up visit on +365 day after allo-HSCT, the three serum immuno-
globulin concentrations were lower than the reference intervals. Specif-
ically, serum IgG, IgA and IgM levels were equal to 356 ng/mL (reference
interval 700–1600), 48ng/mL (reference interval, 70–400) and25ng/mL
(reference interval, 40–230), respectively.
Here, we have presented a case of successful treatment of EBV-PTLD
with anti-CD20 monoclonal antibody after allogeneic bone marrow
transplant. The patient developed an early EBV-related PTLD (i.e. two
months after allo-HSCT; b1 year post-transplant). This is in accordance
with the published literature, in fact particularly high rates of PTLD dur-
ing the ﬁrst 6months after transplant are observed and the EBV genome
is found in more than 90% of B-cell PTLD occurring during the ﬁrst year
after transplantation [2,7]. Moreover, the patient had two known risk
factors for PTLD, speciﬁcally he had received a graft from an unrelated
donor and antithymocyte globulin during the conditioning regimen.
However the antithymocyte globulin, used at a low dose, has shown
no increase of viral infections – EBV-related PTLD included – in over a
decade of use at our Institution [8]. Prospective virological monitoring
of EBV infection allowed early detection of signiﬁcant increase in EBV
DNA level in the patient's peripheral blood. Patient was closely
monitored for symptoms attributable to EBV disease and pre-emptive
anti-CD20 monoclonal antibody was administered at the peak of viral
load. Nevertheless, after one week, the progression of EBV infection to
overt disease was observed. A total of four doses of anti-CD20 monoclo-
nal antibody were administered. Treatment was well tolerated and no
signiﬁcant adverse events attributed to the drug occurred. A decrease
in EBV-DNA load of 2 log of magnitude in the ﬁrst two weeks of treat-
ment was observed. Furthermore, EBV infection was cleared at the end
of the therapy. The early effects of the treatment were already evident
in immunohistochemistry, in factwe found only a partial CD20 immuno-
reactivity due to the selective effect of anti-CD20 as monoclonal anti-
body. A complete disease remission, two months after the EBV-PTLD
diagnosis and four doses of anti-CD20 monoclonal antibody was ob-
served andwhole blood samples testednegative for EBVDNA. The occur-
rence of high EBV load with subsequent PTLD development could be
explained by the lack of EBV-speciﬁc immune responses observed in
the patient during EBV replication. In fact, several studies have reported
that the risk for EBV-PTLD is correlatedwith lack or delay of EBV-speciﬁc
immune reconstitution after stem cell transplant [9–11]. Furthermore,
immunological monitoring showed no EBV-speciﬁc cellular immune re-
constitution during the remaining post-transplant period. Moreover, a
moderate immunoglobulin deﬁciency – IgG, IgA and IgM –was also ob-
served at one year post-transplant. This result is in accordancewith other
ﬁndings, in particular Bordon et al. [12] observed that in pediatric allo-
HSCT recipients, an adequate immune reconstitution after the use of
Fig. 3. Baseline (at diagnosis) 18F-FDG PET/CT (A) and post-treatment 18F-FDG PET/CT (B). A: 18F-FDG PET/CT shows pathological uptake in laterocervical lymph nodes both right (stations
II–III–IV; SUVmax value 12.9) and left side (stations I–II; SUVmax value 13.5) and in presacral node (SUVmax value 7.4). B: Post-treatment 18F-FDG PET/CT shows a complete metabolic
response (no pathological uptake).
63A. Chiereghin et al. / Transplant Immunology 34 (2016) 60–64anti-CD20 monoclonal antibody (rituximab) early after allo-HSCT can
take years. No other episode of EBV reactivation was observed and
EBV-PTLD persists in remission 10months following the initial diagnosis.
At 9 months post-transplant, the patient developed limited chronic
GVHD that did not require immunosuppression therapy. To date, the pa-
tient is alive and well and regularly seen for follow-up.
In conclusion, the early use of the anti-CD20 monoclonal antibody
(rituximab) has proven to be a safe and effective treatment strategy
for EBV-PTLD, conﬁrming the literature data [13–15]. Furthermore,
our data showed the potential usefulness of measuring EBV blood repli-
cation combined with the speciﬁc viral cellular-immunity in allo-HSCT
recipients in order to identify the patients at higher risk for EBV-PTLD
who would beneﬁt from more appropriate pre-emptive interventions.
Currently, a prospective clinical trial is in progress at our University
Hospital in order to assess the real value of the aforementioned moni-
toring strategy for EBV infection in both adult and pediatric allo-HSCT
transplant recipients.
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treatment
A. Chiereghin, A. Prete, T. Belotti, D. Gibertoni, G. Piccirilli,
L. Gabrielli, A. Pession, T. Lazzarotto. Prospective Epstein–Barr
virus-related post-transplant lymphoproliferative disorder prevention
program in pediatric allogeneic hematopoietic stem cell transplant:
virological monitoring and first-line treatment.
Transpl Infect Dis 2016: 18: 44–54. All rights reserved
Abstract: Background. In 28 pediatric allogeneic hematopoietic
stem cell transplant (allo-HSCT) recipients, we aimed to evaluate: (i)
the impact of routine Epstein–Barr virus (EBV) DNA monitoring on
the development of EBV-related post-transplant lymphoproliferative
disorder (EBV-PTLD); (ii) the incidence of EBV infection and the
potential risk factors; and (iii) the suitability of whole blood (WB) as
clinical specimen tomonitor the risk of patients to developEBV-PTLD.
Methods. Quantitative real-time polymerase chain reaction assay was
performed on WB samples for all patients. EBV DNA quantification
also in peripheral blood mononuclear cells (PBMCs) samples was
adopted for the patients at higher risk of developing EBV-PTLD
(≥10,000 copies/mL WB).
Results. High EBV DNAemia levels were observed in 37.5% of the
actively infected recipients (57.1%). Severe aplastic anemia,
matched-unrelated donor transplant, the reduced-intensity
conditioning regimen and, to a lesser extent, the in vivo T-cell
depletion with anti-thymocyte immunoglobulin were associated with
high viral load. A significant correlation between EBV DNA levels in
WB and PBMC samples was obtained (r = 0.755, P < 0.001). A
similar kinetics of EBV DNA in the 2 blood compartments was
observed. Clinically, both specimen types appeared to be equally
informative to assess the risk of patients to develop PTLD. On the
basis of EBV DNAemia levels, in 3 patients (10.7%)
immunosuppressive therapy was reduced and 1 patient (3.5%)
received early treatment for probable EBV disease. No patients
developed EBV-PTLD.
Conclusion. WB proved to be a suitable clinical specimen to monitor
EBV DNA load after allo-HSCT for the management of EBV
infection and PTLD prevention.
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Epstein–Barr virus (EBV) is a ubiquitous c-herpesvirus
with tropism for B lymphocytes that infects at least 90%
of the population worldwide, in which it establishes a
lifelong asymptomatic infection (1). In recipients of
allogeneic hematopoietic stem cell transplant
(allo-HSCT), EBV infection may progress to onset of
44
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a post-transplant lymphoproliferative disorder (PTLD),
a complication that is the result of the outgrowth of
EBV-infected B cells that, in immunocompetent indi-
viduals, is normally controlled by an effective EBV-
specific cytotoxic T-cell response (2, 3). PTLD typically
occurs within the first 6 months after transplantation
and, in >90% of cases, PTLD is EBV positive (4, 5). Risk
factors for development of this complication include
type of donor, T-cell depletion, use of anti-thymocyte
immunoglobulin (ATG), EBV serology mismatch
between donor and recipient, and splenectomy (6). In
a recent large, multicenter and retrospective analysis,
the overall EBV-related PTLD frequency observed was
of 3.22%, ranging from 1.16% for matched-family donor
recipients to 11.24% in mismatched-unrelated donor
recipients (7). Although several studies have convinc-
ingly demonstrated that the development of EBV-
PTLD, both after solid organ and stem cell transplant
(SCT), is mostly accompanied by a significant increase
of EBV DNA levels in the blood of patients (8–13), to
date, the choice of optimal clinical specimen – whole
blood (WB) or peripheral blood mononuclear cells
(PBMCs) – for the monitoring of EBV infection in
transplanted patients is a matter of debate (14–17). In
addition, no international consensus exists on what
EBV DNA threshold level is predictive for developing
PTLD and then for the need of preemptive therapy. In
fact, various data about this issue have been reported
and have been related to local experiences (6, 18–23).
First-line treatment of PTLD includes: (i) anti-CD20
monoclonal antibody rituximab 375 mg/m2, weekly
doses – the number of doses is assessed locally on
the basis of changes in EBV DNA load; (ii) reduction of
immunosuppressive therapy, if possible; (iii) donor
lymphocytes infusion; and (iv) donor EBV-cytotoxic T-
lymphocytes infusion, if available (6).
The aims of the study were to evaluate: (i) the impact
of routine EBV DNA monitoring and first-line treatment
of PTLD on the development of EBV-related disease in
pediatric allo-HSCT recipients; (ii) the incidence of
EBV infection and the potential risk factors; and (iii)
the kinetics of EBV DNA in 2 different blood compart-
ments –WB and PBMCs – in order to establish if WB is
a suitable clinical specimen to monitor the risk of
developing EBV-PTLD in allo-HSCT recipients.
Materials and methods
Study population and transplant characteristics
The study population included 28 consecutive pediatric
patients who underwent allo-HSCT at the Operative Unit
of Pediatrics, Oncology, Haematology, and Stem Cell
Transplantation Program, of the St. Orsola-Malpighi
University Hospital, Bologna, Italy, betweenMarch 2012
and November 2013. The population was made up of 20
male and 8 female pediatric patients, with a mean age of
9.4 years (range 9 months–18.4 years). The study pop-
ulation’s transplant characteristics are reported in
Table 1. Most patients (42.8%) underwent transplant
for acute lymphoblastic leukemia. The donor type was a
matched-unrelated donor (MUD) for 18 allo-HSCT
(64.3%) and a related-donor type for 10 (35.7%) patients;
in all transplants the donor was human leukocyte
antibody (HLA)-identical sibling. The source of stem
cells was bonemarrow in 85.8% of transplants. At the time
of transplantation, the EBV serostatus of donor/recipi-
ent (D/R) was as follows: D+/R+ in 12/28 patients
(42.8%), D+/R in 1/28 patients (3.6%), andD/R+ in 2/
28 patients (7.1%). The serology of the donor was not
available in 13 cases (46.5%); the respective recipients
were: 10 EBV seropositive and 3 EBV seronegative. The
conditioning regimen was reduced-intensity condition-
ing (RIC) for 11 patients and myeloablative for 17
patients. A total of 20 patients (71.4%) underwent
in vivo T-cell depletion to reduce rejection and graft-
versus-host disease (GvHD): all 18MUD transplants and
2 of 10 HLA-identical sibling transplants. In 17 of 20
patients (Patients number 1, 8, 11, 14–25, 27, 28; Table 1)
rabbit ATG (Thymoglobulin, Pasteur-Merieux Con-
naught, Lyon, France) in a dose ranging from 2–
3.75 mg/kg was used for a different period of time
(range 3–5 days). Three patients received rabbit ATG
(ATG-Fresenius, Fresenius Ag, Gr€afelfing, Germany)
for 3 consecutive days at the dose of 5 mg/kg (Patients
number 4, 7, 26; Table 1). In most cases, GvHD prophy-
laxis consisted of an association of cyclosporine and
methotrexate (n = 18).During the engraftment, analysis
of chimerism was performed by short tandem repeats–
polymerase chain reaction (PCR) method on peripheral
blood samples. Full donor chimerism in peripheral blood
was detected in patients at a median time of 20 days
(range 12–35). Furthermore, from day +30, chimerism
status was also analyzed on bone marrow samples that
were collected every 3–6 months during the first 2 years
post transplant. All the post-transplant days when full
donor chimerism was detected in patients’ peripheral
blood and bonemarrow samples are reported in Table 1.
Study design
Virological monitoring of EBV infection was performed
on WB samples using a commercial quantitative
real-time PCR. Follow-up of EBV infection was
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performed every week during the first 100 days post
transplant and every 2 weeks until 180 days post
transplant. Afterward, blood samples were processed
if clinically indicated. In the case of EBV DNAemia,
monitoring was performed weekly for at least 1 month.
Based on previous studies (24, 25) and on Italian Group
of Bone Marrow Transplantation (GITMO) guidelines
for the diagnosis and treatment of EBV-PTLD in HSCT
recipients, any values of EBV DNAemia ≥10,000
copies/mL were defined as high viral load. For the
patients at higher risk of developing EBV-PTLD, that is,
patients who showed high viral load, EBV DNA load in
PBMC samples was also prospectively monitored
starting from the next visit. In addition, all patients
were monitored for cytomegalovirus (CMV) infection
during the post-transplantation period. CMV real-time
PCR was performed weekly during the first 3 months
and then monthly until the 6th month. Afterward, blood
samples were processed if clinically indicated.
The management of EBV infection for patients with
any value of EBV DNAemia ≥10,000 copies/mL was
defined at individual patient level. The first-line man-
agement of EBV infection consisted of reduction in the
immunosuppressive therapy. Anti-CD20 monoclonal
antibody rituximab (4 administrations, at dose of
375 mg/m2/week) was administered when reducing
immunosuppression alone was not sufficient to control
EBV DNAemia or when symptoms suggested EBV-
related disease. Definitions of probable and proven
EBV disease that were adopted in the study are those
reported in the European Conference on Infections in
Leukemia (ECIL) guidelines (6).
Real-time PCR for EBV DNA quantification
Real-time PCR for EBV DNA quantification was per-
formed (EBV ELITe MGBTM kit, ELITech Group, Turin,
Italy). Blood samples were collected in ethylenedi-
amine-tetraacetic acid-anticoagulated tubes. DNA was
extracted from 200 lL of WB using the QIASym-
phonysp instrument (Qiagen GmbH, Hilden, Germany),
eluted in 90 lL of elution buffer, and 20 lL were
processed for EBV DNA quantification. DNA was
extracted from 2 9 105 PBMCs using the NucliSens
easyMAG System (bioMerieux, Marcy l’Etoile, France)
according to the manufacturer’s instructions; half of the
eluated volume corresponding to 1 9 105 PBMCs was
used as input DNA in each real-time PCR. Amplifica-
tion, detection, and analysis were performed using the
ABI PRISM 7300 platform (Life Technologies, Foster
City, California, USA). The PCR assay targets a region
of the EBNA-1 gene of EBV. The analytical sensitivity of
the assay is 10 copies of target DNA per amplification
reaction. The lower limit of quantification (LLQ) of the
assay is 225 copies/mL WB and 11 copies/1 9 105
PBMCs. EBV DNA load was reported as quantities of
copies/mL and copies/1 9 105 PBMCs.
Statistical analysis
Comparisons between patient-related and transplant-
related characteristics and EBV DNAemia were evalu-
ated using chi-square test of independence. Patients
with low EBV DNA levels (<10,000 copies/mL WB) or
without active EBV infection were compared with
patients who showed infection with high EBV DNA
load (≥10,000 copies/mL WB). P-values <0.05 were
considered statistically significant. The correlation
between log10 copies of EBV DNA in WB and PBMC
samples was obtained using weighted Pearson correla-
tion to take into account the different number of
subjects’ repeated measures.
Results
The 28 pediatric allo-HSCT recipients enrolled were
monitored for EBV infection for a median time of
7.1 months post transplant (range 1–22 months). A
total of 353 WB and 88 PBMC samples were processed;
the median number of paired WB and PBMC samples
analyzed per patient was 15 (range 11–19).
Sixteen of 28 patients (57.1%) developed a post-
transplant EBV infection: 11 patients who underwent
allo-HSCT from MUDs (61.1%, 11/18 patients) and 5
patients transplanted from related donors (50%, 5/10
patients). Three of 16 patients (18.7%) developed
primary EBV infection, and 13/16 (81.3%) patients
developed EBV reactivation/reinfection. Therefore, in
our study population, the overall incidence of post-
transplant primary EBV infection and EBV reactiva-
tion/reinfection was equal to 10.7% and 46.4%, respec-
tively.
For 12 of 28 patients (42.9%), WB samples tested
negative for EBV DNA over the entire follow-up.
Among the 16 patients with an active post-transplant
EBV infection, 10 patients (62.5%) showed low values of
EBV DNAemia (<10,000 copies/mL WB), whereas 6
patients (37.5%) showed values of EBV DNAemia
≥10,000 copies/mL WB. The median peak of viral load
in patients with low and high values of EBV DNAemia
was 1978 copies/mL (range: 471–4237 copies/mL) and
127,639 copies/mL (range: 10,477–896,096 copies/mL),
respectively. The median time at which EBV DNAemia
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was first detected was 47 days (range 13–354 days)
post transplant. The results obtained by virological
monitoring, along with the range of EBV DNAemia
values detected per patient, are reported in Table 1. In
total, 88 paired WB and PBMC samples, collected from
the 6 patients with high EBV DNAemia levels, were
processed. Twenty-seven of 88 samples (30.7%) were
negative and 58 samples (65.9%) were positive for EBV
DNA both in WB and PBMC samples; 3 (3.4%) samples
were discordant. Among the 58 positive samples: 33
samples (56.9%) were positive with a quantitative result;
12 samples (20.7%) tested positive but below the LLQ of
the PCR assay, and 13 samples (22.4%) were positive
with a quantitative result in WB and positive, but below
the LLQ of the PCR assay, in PBMC samples. The 33 of
88 samples that resulted positive with a quantitative
result in both the 2 blood compartments were taken
into consideration for the correlation analysis. The
correlation coefficient obtained was r = 0.755
(P < 0.001) (Fig. 1). EBV DNA kinetics in WB and
PBMC samples were analyzed in all 6 patients. Repre-
sentative EBV DNA kinetics in the 2 blood compart-
ments of 4 of 6 patients are reported in Figure 2.
Chi-square test of independence showed a significant
association between EBV DNAemia levels ≥10,000
copies/mL and both transplants from unrelated donors
and RIC regimen (P = 0.039 and P = 0.013, respec-
tively) (Table 2). Moreover, an association between
viral load and underlying disease was found
(P = 0.027), with patients suffering from severe aplastic
anemia (SAA) showing a significantly higher incidence
of EBV infection with high viral load. A milder
association between the development of EBV infection
with high viral load and in vivo T-cell depletion with
ATG was observed (P = 0.081). No relationship was
observed between the origin of the graft; the develop-
ment of post-transplant CMV infection; the acute
(<100 days post transplant) and chronic GvHD
(≥100 days post transplant; data were available for only
25 patients as 3 of 28 patients died after 100 days post
transplant); the EBV serostatus of the recipients; and
the development of EBV infection with high EBV
DNAemia levels (Table 2). None of the patients under-
went splenectomy; therefore, comparison between this
clinical parameter and EBV DNAemia could not be
evaluated.
Regarding the management of EBV DNAemia and
PTLD prevention, among the 10 patients who main-
tained viral loads <10,000 copies/mL WB, in 9/10
patients (90%) EBV clearance occurred spontaneously
and in 1/10 patients (10%) immunosuppression was
reduced at the peak of viral load (D?/R); the patient
achieved EBV DNA negativity in both the 2 blood
compartments 20 days after reduction of the immuno-
suppressive therapy. Among the 6 patients with EBV
DNA load ≥10,000 copies/mL WB, 5 (83.3%) had no
symptoms nor signs of EBV-PTLD, and 1 had a
probable EBV disease (16.7%), defined as lym-
phadenopathy with high EBV blood load, in the
absence of other etiologic factors or established
diseases (6). In particular, among the 5 asymptomatic
patients, 2 patients (40%) controlled EBV DNAemia
spontaneously, and in 3 patients (60%) the immuno-
suppressive therapy was reduced in the presence of
median EBV DNA levels in WB of 512,905 copies/mL
and of 1100 copies/1 9 105 PBMCs. A decrease in
EBV DNA levels in both blood compartments was
observed in all 3 patients who achieved low EBV DNA
levels at a median time of 9 days after the reduction in
the immunosuppressive therapy. Anti-CD20 mono-
clonal antibody rituximab (4 administrations, at dose
of 375 mg/m2/week) was administrated at day +115
after HSCT to the patient with probable EBV disease.
In the first week of treatment, a decrease in EBV DNA
load at 1-log of magnitude was observed with subse-
quent symptom regression at the end of the therapy.
The reduction in immune suppression and the admin-
istration of anti-CD20 monoclonal antibody rituximab
were carried out at the peak of DNA levels that were
reached simultaneously in both the 2 blood compart-
ments.
Among the 28 patients in the study, 8 patients (28.6%)
died at a median time of 7 months (range 1–11) after
allo-HSCT. The causes of death were relapse of the
original disease (n = 4), cerebral hemorrhage (n = 2),
and pulmonary infection (n = 2). The remaining 20
patients (71.4%) were alive and well.
Fig. 1. Correlation between Epstein–Barr virus (EBV) DNA levels in 33
whole blood and periphal blood stem cells (PBMCs) samples of pediatric
allogeneic hematopoietic stem cell transplant recipients. Pt, patient.
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DNAemia levels in the post-transplant
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assay for PBMC samples. Log10 EBV DNA
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circles, respectively.
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Patient characteristics and risk factors for Epstein–Barr virus (EBV) infection
Total
EBV DNAemia
Negative or
<10,000 copies/mL
Whole blood
EBV DNAemia
≥10,000 copies/mL
Whole blood P-value
Number of patients (%) 28 (100) 22 (78.6) 6 (21.4)
Gender: male/female 20/8 17/5 3/3 0.190
Primary disease
ALL 12 (41.4) 11 (91.7) 1 (8.3) 0.027
SAA 4 (13.8) 1 (25.0) 3 (75.0)
AML 4 (17.2) 4 (100) 0
Other1 8 (27.6) 6 (75.0) 2 (25.0)
Donor type
Unrelated (MUD) 18 (64.3) 12 (66.7) 6 (33.3) 0.039
Related (Sibling) 10 (35.7) 10 (100) 0
Graft origin
Bone marrow 24 (85.7) 18 (75.0) 6 (25.0) 0.529
Peripheral blood 2 (7.1) 2 (100) 0
Cord blood 2 (7.1) 2 (100) 0
Conditioning regimen
Myeloablative2 17 (60.7) 16 (94.1) 1 (5.9) 0.013
Reduced-intensity 11 (39.3) 6 (54.5) 5 (45.5)
In vivo T-cell depletion with ATG
Yes 20 (71.4) 14 (70.0) 6 (30.0) 0.081
No 8 (28.6) 8 (100) 0
CMV infection
Yes 12 (42.8) 9 (75.0) 3 (25.0) 0.690
No 16 (57.1) 13 (81.2) 3 (18.8)
Acute GvHD (<100 days post transplant) grading
Absent 19 (67.9) 15 (79.0) 4 (21.0) 0.846
I 3 (10.7) 2 (66.7) 1 (33.3)
≥II 6 (21.4) 5 (83.3) 1 (16.7)
Chronic GvHD (≥100 days post transplant) grading3
Absent 23 (92) 18 (78.3) 5 (21.7) 0.369
Mild to severe 2 (8) 1 (50.0) 1 (50.0)
EBV serostatus
R+ 24 (85.7) 20 (83.3) 4 (16.7) 0.133
R 4 (14.3) 2 (50.0) 2 (50.0)
Comparisons between patient-related and transplant-related characteristics and EBV DNAemia were evaluated using chi-square test of
independence. Bold P-values are statistically significant.
1Diamond-Blackfan anemia (n = 2); Thalassemia major (n = 2); Langerhans cell histiocytosis (n = 1); Fanconi anemia (n = 1); sickle cell disease
(n = 1); familial hemophagocytic lymphohistiocytosis (n = 1).
2Myeloablative conditioning regimen includes both busulfan-based myeloablative regimen and total body irradiation-based myeloablative regimen.
3Data available for 25 patients.
ALL, acute lymphoblastic leukemia; SAA, severe aplastic anemia; AML, acute myeloid leukemia; MUD, matched-unrelated donor; ATG, anti-
thymocyte immunoglobulin; CMV, cytomegalovirus; GvHD, graft-versus-host disease; R, recipient.
Table 2
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Discussion
EBV-PTLD is an uncommon, but frequently fatal,
complication after allo-HSCT and prompt diagnosis is
necessary owing to the rapid and often disseminated
nature of the disease (25–27). In the past, mortality
rates from EBV-driven disease were >90%. In fact, its
treatment was limited to reduction of immunosuppres-
sion, chemotherapy, or unselected donor lymphocytes
infusion. Current treatment strategies, such as anti-
CD20 monoclonal antibody rituximab and EBV-specific
cytotoxic T-lymphocytes therapy, have significantly
reduced the risk of death in established EBV-PTLD
after SCT (28). In the present study, 28 pediatric allo-
HSCT recipients were monitored for EBV infection
during the post-transplant period. Virological monitor-
ing of EBV infection was performed for all patients by
processing WB samples using a quantitative real-time
PCR. EBV DNA quantification in both WB and in
PBMC samples was adopted for the patients at higher
risk of developing EBV-PTLD (≥10,000 copies/mL
WB).
As reported in previous studies (18, 19), we
observed that active EBV infection is a frequent event
after transplantation: the incidence of EBV DNAemia
in our study population was equal to 57.1%. Moreover,
high EBV DNAemia levels were observed in 37.5% of
the recipients who developed post-transplant EBV
infection. We identified that SAA, unrelated donor,
the RIC regimen and, to a lesser extent, in vivo T-cell
depletion with ATG were associated with higher
frequencies of EBV infection with high viral load,
pointing to the same results recognized by other
investigators (24, 26, 27, 29–32). The duration between
disease diagnosis and type of treatments before
transplant was evaluated (data not shown). In partic-
ular, in patients affected from SAA, immunosuppres-
sive therapy is the only alternative therapeutic
approach to HSCT and it includes the use of ATG
and cyclosporine. Therefore, these patients were
intensively treated before allo-HSCT and this could
be the reason why we observed a higher incidence of
EBV infection with high viral load among these
patients. Moreover, the patients with SAA had other
risk factors such as unrelated donor, RIC regimen,
EBV serology mismatch between donor and recipient,
and in vivo T-cell depletion with ATG. The higher
incidence of high viral load in patients with an
unrelated donor could be related to the use of ATG
in this group of patients; in fact, the use of ATG has
been clearly associated with the risk of both EBV
infection and PTLD development (24, 26, 27, 29).
Finally, as reported in other studies (30–32), EBV
infection with high viral load appears to be significantly
related in children following RIC HSCT, particularly
with selective depletion of recipient T cells with ATG
relative to B cells. This finding probably reflects the
profound immunosuppression following RIC HSCT,
together with the incomplete ablation of recipient-
derived B cells. In our cohort of patients, we were not
able to evaluate the contribution of EBV D/R serology
to EBV DNAemia, because donor EBV serology was
available for 14 of 24 EBV-seropositive patients (n = 2
D/R+ and 12 D+/R+) and for only 1 of 4 EBV-
seronegative patients (D+/R). Furthermore, 1 of the 3
remaining EBV-seronegative patients (D?/R) did not
develop post-transplant EBV infection, leading us to
assume that the respective donor could be EBV-
seronegative. However, it should be noted that all 3
patients with known serological mismatch (D/R+ and
D+/R) developed a post-transplant EBV infection with
high viral load. Therefore, only the recipients’ EBV
serostatus at the time of transplant was taken into
consideration for the analysis and no difference was
found between this variable and the EBV DNAemia
levels. We suppose that the inability to find the EBV
seronegativity of the recipient, associated with an
increased risk of developing EBV infection with high
viral load, may have been a result of the small number
of patients in this group and the lack of information
about the EBV status of the respective donors.
Measurement of EBV DNA load by quantitative real-
time PCR assays can be a sensitive aid to PTLD
diagnosis, but unfortunately it is not always specific for
disease onset (3). In general, assays using PBMCs are
the most sensitive and predict EBV disease at the
earliest time, but owing to technical aspects, it would be
preferable to test EBV DNA load in WB samples (3, 33).
In agreement with previous studies (34, 35), we obtained
a significant correlation between EBVDNA levels inWB
and PBMC samples.
Moreover, a similar kinetics of EBV DNA load in the 2
different blood compartments of the pediatric patients
was observed: peak DNA levels were reached simulta-
neously and the times of DNA clearance were compara-
ble. In addition, both specimen types appeared to be
equally informative to assess the risk of patients to
develop PTLD in the clinical setting. In fact, in all
patients, EBV infection was managed with reduction of
immune suppression or with the use of anti-CD20
monoclonal antibody rituximab, at peak DNA levels that
were reached simultaneously in both the 2 blood
compartments. Therefore, among the study population,
on the basis of EBVDNA levels detected inWB samples,
we were able to identify 3 patients (10.7%) eligible for
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preemptive therapy and 1 patient (3.5%) who needed
early treatment for probableEBVdisease. In patients, the
first-line treatment for EBV-related disease was effective
in controlling viral proliferation and avoiding progres-
sion intoEBV-PTLD. In fact, in our study population none
of the patients developed EBV-PTLD.
In conclusion, the present study suggests that close
EBV DNAemia monitoring may be a useful strategy to
control EBV-related PTLD in high-risk patients. In fact,
WB proved to be a suitable clinical specimen to monitor
EBV DNA load after allo-HSCT for the management of
post-transplant EBV infection and PTLD prevention.
Moreover, this study confirms the clinical parameters
associated with an increased risk of developing EBV
infection with high viral load. The presence of the risk
factors may be useful to identify patients who require
closer virological monitoring.
EBV DNA monitoring is essential for managing EBV
infection, but it does not provide information regarding
a patient’s immunological response against EBV repli-
cation. A prospective immunological monitoring with
EliSpot assay combined with virological monitoring is
in progress to assess if this monitoring strategy could
improve the managing of EBV infection and the clinical
decision-making in allo-HSTC recipients.
Acknowledgments:
Thanks: We would like to thank Cristiana Grandi, Lorena
Mezzofanti, Antonella Maria Paglia, Marinella Plazzi,
and Salustia Pop for their excellent technical assistance.
We would like to thank our Linguistic Consultant, Lucy
Scioscia, for editing the English-language text.
Author contributions: A.C. acquired and analyzed data
as well as drafted the article. A. Pession, A. Prete,
and T.B. clinically managed the patients during the
post-transplant period and provided the respective
clinical information. D.G. performed statistical analysis
of the data. G.P. and L.G. contributed to the acquisition
and analysis of the data. T.L. supervised the project and
performed a critical revision of the article. All authors
discussed the results and commented on the article at
all stages. All of them provided final approval of the
version to be submitted.
Conflict of interest: The authors declare no conflict of
interest.
References
1. Balfour HH Jr, Dunmire SK, Hogquist KA. Infectious
mononucleosis. Clin Transl Immunology 2015; 4 (2): e33.
2. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-
related lymphoproliferative disease after pediatric haploidentical
stem cell transplantation. Am J Transplant 2007; 7 (6): 1648–1655.
3. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009; 114
(19): 4002–4008.
4. Rouce RH, Louis CU, Heslop HE. Epstein-Barr virus
lymphoproliferative disease after hematopoietic stem cell
transplant. Curr Opin Hematol 2014; 21 (6): 476–481.
5. Dolcetti R. B lymphocytes and Epstein-Barr virus: the lesson of
post-transplant lymphoproliferative disorders. Autoimmun Rev
2007; 7 (2): 96–101.
6. Styczynski J, Reusser P, Einsele H, et al. Management of HSV,
VZV and EBV infections in patients with haematological
malignancies and after SCT: guidelines from the Second
European Conference on Infections in Leukemia. Bone Marrow
Transplant 2009; 43 (10): 757–770.
7. Styczynski J, Gil L, Tridello G, et al. Response to rituximab-based
therapy and risk factor analysis in Epstein Barr virus-related
lymphoproliferative disorder after hematopoietic stem cell
transplant in children and adults: a study from the Infectious
Diseases Working Party of the European Group for Blood and
Marrow Transplantation. Clin Infect Dis 2013; 57 (6):
794–802.
8. Riddler SA, Breinig MC, McKnight JL. Increased levels of
circulating Epstein-Barr virus (EBV)-infected lymphocytes and
decreased EBV nuclear antigen antibody responses are
associated with the development of posttransplant
lymphoproliferative disease in solid-organ transplant recipients.
Blood 1994; 84 (3): 972–984.
9. Savoie A, Perpete C, Carpentier L, Joncas J, Alfieri C. Direct
correlation between the load of Epstein-Barr virus-infected
lymphocytes in the peripheral blood of pediatric transplant
patients and risk of lymphoproliferative disease. Blood 1994; 83
(9): 2715–2722.
10. Kenagy DN, Schlesinger Y, Weck K, Ritter JH, Gaudreault-
Keener MM, Storch GA. Epstein-Barr virus DNA in peripheral
blood leukocytes of patients with posttransplant
lymphoproliferative disease. Transplantation 1995; 60 (6):
547–554.
11. G€artner BC, Sch€afer H, Marggraff K, et al. Evaluation of use of
Epstein-Barr viral load in patients after allogeneic stem cell
transplantation to diagnose and monitor posttransplant
lymphoproliferative disease. J Clin Microbiol 2002; 40 (2):
351–358.
12. van Esser JW, van der Holt B, Meijer E, et al. Epstein-Barr virus
(EBV) reactivation is a frequent event after allogeneic stem cell
transplantation (SCT) and quantitatively predicts EBV-
lymphoproliferative disease following T-cell-depleted SCT. Blood
2001; 98 (4): 972–978.
13. Kinch A, Oberg G, Arvidson J, Falk KI, Linde A, Pauksens K.
Post-transplant lymphoproliferative disease and other Epstein-
Barr virus diseases in allogeneic haematopoietic stem cell
transplantation after introduction of monitoring of viral load by
polymerase chain reaction. Scand J Infect Dis 2007; 39 (3):
235–244.
14. Wagner HJ, Wessel M, Jabs W, et al. Patients at risk for
development of post-transplant lymphoproliferative disorder:
plasma versus peripheral blood mononuclear cells as material for
quantification of Epstein-Barr viral load by using real-time
quantitative polymerase chain reaction. Transplantation 2001; 72
(6): 1012–1019.
15. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different
specimen types for Epstein-Barr viral load quantification in
Transplant Infectious Disease 2016: 18: 44–54 53
Chiereghin et al: EBV DNA monitoring after pediatric allo-HSCT
peripheral blood of pediatric patients after heart transplantation
or after allogeneic hematopoietic stem cell transplantation. J Clin
Virol 2012; 53 (3): 186–194.
16. Preiksaitis JK, Pang XL, Fox JD, Fenton JM, Caliendo AM, Miller
GG, American Society of Transplantation Infectious Diseases
Community of Practice. Interlaboratory comparison of Epstein-
Barr virus viral load assays. Am J Transplant 2009; 9 (2): 269–279.
17. Hayden RT, Hokanson KM, Pounds SB, et al. Multicenter
comparison of different real-time PCR assays for quantitative
detection of Epstein-Barr virus. J Clin Microbiol 2008; 46 (1):
157–163.
18. Carpenter B, Haque T, Dimopoulou M, et al. Incidence and
dynamics of Epstein-Barr virus reactivation after alemtuzumab
based conditioning for allogeneic hematopoietic stem cell
transplantation. Transplantation 2010; 90 (5): 564–570.
19. Dominietto A, Tedone E, Soracco B, et al. In vivo B-cell depletion
with rituximab for alternative donor hematopoietic SCT. Bone
Marrow Transplant 2012; 47 (1): 101–106.
20. Peric Z, Cahu X, Chevallier P, et al. Features of Epstein-Barr virus
reactivation after reduced intensity conditioning allogeneic
hematopoietic stem cell transplantation. Leukemia 2011; 25 (6):
932–938.
21. Coppoletta S, Tedone E, Galano B, et al. Rituximab treatment for
Epstein-Barr virus DNAemia after alternative-donor
hematopoietic stem cell transplantation. Biol Blood Marrow
Transplant 2011; 17 (6): 901–907.
22. Faraci M, Caviglia I, Morreale G, et al. Viral-load and B-
lymphocyte monitoring of EBV reactivation after allogeneic
hematopoietic SCT in children. Bone Marrow Transplant 2010; 45
(6): 1052–1055.
23. Ahmad I, Cau NV, Kwan J, et al. Preemptive management of
Epstein-Barr virus reactivation after hematopoietic stem cell
transplantation. Transplantation 2009; 87 (8): 1240–1245.
24. Patriarca F, Medeot M, Isola M, et al. Prognostic factors and
outcome of Epstein-Barr virus DNAemia in high-risk recipients of
allogeneic stem cell transplantation treated with preemptive
rituximab. Transpl Infect Dis 2013; 15 (3): 259–267.
25. Omar H, Agglund H, Gustafsson-Jernberg A, et al. Targeted
monitoring of patients at high risk of posttransplant
lymphoproliferative disease by quantitative Epstein-Barr virus
polymerase chain reaction. Transpl Infect Dis 2009; 11 (5):
393–399.
26. Curtis RE, Travis LB, Rowlings PA, et al. Risk of
lymphoproliferative disorders after bone marrow
transplantation: a multi-institutional study. Blood 1999; 94 (7):
2208–2216.
27. Sundin M, Le Blanc K, Ringden O, et al. The role of HLA
mismatch, splenectomy and recipient Epstein-Barr virus
seronegativity as risk factors in post-transplant
lymphoproliferative disorder following allogeneic hematopoietic
stem cell transplantation. Haematologica 2006; 91 (8): 1059–1067.
28. Fox CP, Burns D, Parker AN, et al. EBV-associated post-
transplant lymphoproliferative disorder following in vivo T-cell-
depleted allogeneic transplantation: clinical features, viral load
correlates and prognostic factors in the rituximab era. Bone
Marrow Transplant 2014; 49 (2): 280–286.
29. Bordon V, Padalko E, Benoit Y, Dhooge C, Laureys G. Incidence,
kinetics, and risk factors of Epstein-Barr virus viremia in pediatric
patients after allogeneic stem cell transplantation. Pediatr
Transplant 2012; 16 (2): 144–150.
30. Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease
following haematopoietic stem cell transplantation with reduced
intensity conditioning. Leuk Lymphoma 2007; 48 (2): 256–269.
31. Cohen J, Gandhi M, Naik P, et al. Increased incidence of EBV-
related disease following paediatric stem cell transplantation with
reduced-intensity conditioning. Br J Haematol 2005; 129 (2):
229–239.
32. Wachowiak J, Grund G. Infectious complications in children
conditioned for allogenic haematopoietic stem cell transplantation
with reduced intensity conditioning or with treosulfan-based
reduced toxicity preparative regiment. Rep Pract Oncol Radiother
2007; 12 (3): 175–179.
33. Dolcetti R. Ruolo del virus di Epstein-Barr nella patogenesi dei
disordini linfoproliferativi post-trapianto. Microbiologia Medica
2003; 18 (4): 256–266.
34. Baldanti F, Gatti M, Furione M, et al. Kinetics of Epstein-Barr
virus DNA load in different blood compartments of pediatric
recipients of T-cell-depleted HLA-haploidentical stem cell
transplantation. J Clin Microbiol 2008; 46 (11): 3672–3677.
35. Fafi-Kremer S, Brengel-Pesce K, Bargues G, et al. Assessment of
automated DNA extraction coupled with real-time PCR for
measuring Epstein-Barr virus load in whole blood, peripheral
mononuclear cells and plasma. J Clin Virol 2004; 30 (2):
157–164.
54 Transplant Infectious Disease 2016: 18: 44–54
Chiereghin et al: EBV DNA monitoring after pediatric allo-HSCT
